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Abstract
Studies of Glucocorticoid Resistance in Chronic Lymphocytic Leukaemia
T Melarangi
Glucocorticoids represent an important component of modern treatment regimens 
for patients with fludarabine-refractory or 77\53-defective chronic lymphocytic 
leukaemia. However, not all patients respond to GC therapy. This in-vitro study 
investigated the molecular mechanisms responsible for GC resistance in a cohort 
of 46 primary CLL samples. As expected, dexamethasone-induced killing was 
more pronounced in cases with genes. Cross resistance was observed
between dexamethasone and other GCs but not fludarabine, implying distinct 
resistance mechanisms. GC resistance was not associated with GC receptor 
defects, altered NF-kB signalling or impaired Bim up-regulation. siRNA 
knockdown experiments confirmed that Bim plays a crucial role in the GC- 
induced killing of CLL cells, while immunoprecipation experiments showed that 
GC resistance was associated with impaired Bax/Bak activation and that Bim was 
bound to Bcl-2. Levels of Bcl-2 were found to be higher in GC-resistant samples, 
and disruption of the Bim/Bcl-2 interaction by ABT-737 sensitised GC-resistant 
CLL cells to GC-induced killing. Taken together, these findings provide 
compelling evidence that GC resistance in CLL cells results from the 
sequestration of up-regulated Bim by high levels of Bcl-2 with consequent failure 
of Bax/Bak activation and apoptosis induction.
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Chapter 1: General Introduction
1.1 Chronic lymphocytic leukaemia
1.1.1 Definition
CLL is defined by the accumulation of circulating clonal CD23+ CD5+ light- 
chain-restricted B cells in the blood to a concentration of >5xl09/L (Gribben 
2010), persisting for over 3 months. CLL lymphocytes also commonly express 
CD 19 and show reduced levels of IgM, IgD, and CD79b (Moreau, Matutes et al. 
1997). It is diagnosed by an absolute increase in lymphocytosis and/or bone 
marrow infiltration, coupled with the characteristic features of morphology and 
immunophenotype. Patients may present with lymphadenopathy, systemic 
symptoms such as tiredness, night sweats and weight loss, or the symptoms of 
anaemia or infection. 70-80% of patients are diagnosed as an incidental finding 
on a routine full blood count.
1.1.2 Epidemiology
CLL has an annual incidence of over 3 per 100,000 (Dores, Anderson et al. 2007), 
rising to 50 per 100,000 per year over the age of 70. CLL is the most prevalent 
cancer of the haematopoietic system in the western world, with high associated 
mortality. In fact, 70% of CLL patients die from causes related to CLL, 
especially in the elderly. Many fatalities in CLL are caused by infection and 
haemorrhage due to pancytopenia or immunosuppressive treatments (Anaissie, 
Kontoyiannis et al. 1998), and secondary cancers. Immunological aberrations 
complicate the management of CLL (Mauro, Foa et al. 2000). Median age at
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diagnosis is approximately 72 years (Dores, Anderson et al. 2007) and median 
survival is 5-10 years. The disease is roughly twice as common in males than 
females (Gribben 2010), and there is evidence of familial clustering in a minority 
of cases (Houlston, Catovsky 2008).
1.1.3 Prognosis and prognostic factors
The clinical course of CLL is highly variable, with some patients remaining 
asymptomatic for many years, whilst others show aggressive progression 
(Gribben 2010). The disease progresses from an indolent lymphocytosis to one of 
generalised lymphatic enlargement with pancytopenia (Anaissie, Kontoyiamiis et 
al. 1998). Dysfunctional haematopoiesis leads to accumulation of 
immunologically inactive lymphocytes in blood, bone marrow, and lymphatic 
tissues, which can cause infection, anaemia, and thrombocytopenia (Zenz, 
Mertens et al. 2010). The disease is currently incurable by conventional 
treatments and so many patients experience a range of treatments during the 
course of the disease.
Due to the toxicity of CLL treatments, predicting good prognosis is of essential 
importance in CLL management. There has been great interest in recent years in 
identifying ways to predict clinical outcome. Initially, clinical staging systems 
were developed to assess the degree of tissue infiltration and marrow suppression. 
The two most widely used systems in CLL are those developed by Rai (Rai, 
Sawitsky et al. 1975) and Binet (Binet, Auquier et al. 1981) (Tables 1.1 A and 1.1 
B), which depend upon measurements of total tumour mass as determined by 
measurements of lymphadenopathy, organomegaly, platelet, and haemoglobulin
16
values (Hamblin 2007). These staging systems are still used to predict prognosis 
as well as to assess disease progression, and to guide decisions over when to begin 
therapy, but they are insensitive to clinical heterogeneity within early CLL and so 
are now supplemented by a range of laboratory prognostic markers. Adding 
parameters such as age, gender, lymphocyte count and serum markers can also 
provide a better prediction of overall survival (Wierda, O'Brien et al. 2007, 
Shanafelt, Jenkins et al. 2009) and time to first treatment in early stage CLL 
(Molica, Mauro et al. 2010, Bulian, Tarnani et al. 2010). Lymphocyte doubling 
time is also still an important prognostic factor in CLL, as patients with birth rates 
>0.35% of the clonal population per day have more active and progressive disease 
(Molica, Alberti 1987, Messmer, Messmer et al. 2005).
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Table 1.1 A and 1.1 B. The Rai and Binet staging systems showing median 
survival as described in the original papers. This demonstrates the marked 
effect that tissue infiltration has on prognosis.
Table 1.1 A - Rai Staging
Stage Clinical Features Average Survival 
(months)
0 Bone marrow and blood lymphocytosis only >150
I Lymphocytosis with enlarged nodes 101
II Lymphocytosis with enlarged spleen or liver 
or both
71
III Lymphocytosis with anaemia (Hb less than
10g)
19
IV Lymphocytosis with thrombocytopenia 
(platelets less than 100,000/mm3)
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Table 1.1 B- Binet Staging
Stage Clinical Features Average Survival 
(months)
A No anaemia, no thrombocytopenia, less than 
three involved areas (e.g. spleen, liver, 
lymph nodes)
Same as controls
B No anaemia, no thrombocytopenia, three or 
more involved areas
84
C Anaemia and/or thrombocytopenia 24
Identification of poor prognosis is a key area of research in CLL. Overall, 
(unmutated) UM-/G//K genes, use of the IGHV~3~21 gene, deletion of llq and a 
raised serum B2 microglobulin correlate with reduced PFS (progression-free 
survival) and OS (overall survival) in clinical trials of alkylating agent and purine 
analogue treatment. IGHV mutation status, and CD38 and Zap-70 expression are 
routinely assessed to aid in identifying poor prognosis patients (Hamblin 2007). 
IGHV status segregates the disease into more benign and more malignant versions 
(Hamblin 2007), and is by far the most useful indicator of disease progression for
18
newly diagnosed patients. To determine IGHV status CLL cells are studied by 
gene sequencing. Comparison of the sequence obtained with that of germline is 
then performed and the percentage deviation from the germline sequence 
calculated. Clones are described as either mutated (M) or unmutated (UM) 
depending on whether they exhibit £2% or <2% deviation from germline. These 
sub-groups have markedly different median survivals of around 24 and 8 years, 
respectively (Hamblin, Davis et al. 1999). A search for surrogate markers for this 
difficult assay led to a flow cytometric assay for CD38 (Hamblin 2007). CD38 is 
a hydrolase ectoenzyme expressed on the surface of B, T, and NK cells, which 
plays a role in adhesion and signal transduction (Matrai 2005). The original cut­
off for CD38 positivity was 30%, and this is still upheld, though it is not 
uncontested (Matrai 2005). A flow cytometric assay is also available to measure 
ZAP-70 expresssion, as poor prognosis also correlates with the expression of this 
protein tyrosine kinase of CLL cells (Matrai 2005). Generally, patients 
harbouring few or no IGHV mutations and with many CD38+ or Zap-70+ cells 
have a particularly aggressive course, whilst observations to the contrary predict 
indolent disease (Chiorazzi, Rai et al. 2005).
The karyotype of CLL cells can be assessed by performing fluorescence in situ 
hybridisation (FISH) on mononuclear cells obtained from peripheral blood 
samples. This enables chromosomal abnormalities to be detected. None of these 
offer any diagnostic benefit, but several abnormalities carry prognostic 
significance. Approximately 80% of CLL cases show aberrations in a small 
group of chromosomal regions (Dohner, Stilgenbauer et al. 2000). There are five 
common chromosomal abnormalities in CLL. 13ql4 deletions are the most
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common in CLL and occur in around 50% of patients (Fitchett, Griffiths et al. 
1987): Patients with this isolated deletion of 13ql4 have a good prognosis 
(Hamblin 2007). The other commonly occurring chromosomal abnormalities in 
CLL are deletions at 17pl3 (TP53), Ilq22-q23 (ATM), and 6q21 (17p and llq 
being the most severe), as well as Trisomy 12 (Hamblin 2007). Deletions of 17p 
are found in approximately 10% of CLL patients and the region deleted always 
includes the TP53 gene that encodes p53 protein (Zenz, Mertens et al. 2010). p53 
is an essential mediator of chemotherapy-induced apoptosis that will be 
considered in more detail in Section 1.3.2. Up to 25% of patients with advanced 
disease have deletions around llq23, which is the region containing the ATM 
gene (Zenz, Mertens et al. 2010). The ATM gene is involved in mediating cellular 
responses to DNA damage. Trisomy 12 has little effect on clinical outcome 
(Zenz, Mertens et al. 2010), but it is detectable in up to 25% of cases (Oscier, 
Matutes et al. 1997). Of these chromosomal abnormalities, only loss of TP53 
provides reliable prognostic information. However, both TP53 dysfunction and 
short telomere length do correlate with shorter time to first treatment in early 
stage CLL (Furman 2010). Although it is possible to classify patients as being at 
low, intermediate or high risk of disease progression, there is not yet sufficient 
evidence that these genetic aberrations should influence the timing of initial 
therapy in individual patients. Despite a lack of unifying mutations in early CLL, 
patients have been shown to develop genetic lesions over time (Shanafelt, Witzig 
et al. 2006), thus increasing their importance in the clinical course of CLL.
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1.2 CLL cell development
1.2.1 Natural history
CLL cells are considered to be activated, antigen experienced B cells (Damle, 
Ghiotto et al. 2002). The majority of CLL clones express IgM and IgD, but up to 
20% are class switched to IgG or IgA. The normal counterpart to the CLL cell 
remains controversial. Normal CD5+ B cells (B-l), marginal zone B cells, and 
memory B cells have all been proposed to be “the normal counterpart” to the CLL 
cell (Caligaris-Cappio, Ghia 2007). However, the natural history of CLL 
development remains unclear. Surface phenotype and genetic homogeneity 
between CLL clones of different patients (Moreau, Matutes et al. 1997, Klein, Tu 
et al. 2001) suggests shared mechanisms of transformation, though CLL is 
heterogeneous at the level of molecular and functional features (Hamblin 2002). 
Despite the monoclonal nature of CLL cells, unlike in other B-cell lymphomas no 
unifying mutations have been identified (Chiorazzi, Rai et al. 2005). Whilst long 
considered a disease of apoptotic suppression, as indicated by its slow clinical 
progression, there is strong evidence that supports the notion that CLL clones can 
be turned over at up to 2% of the clone per day (Messmer, Messmer et al. 2005). 
Thus, the disease results from both a failure of CLL cells to die in response to 
normal physiological stimuli, and from support of proliferation. As CLL cells die 
readily in vitro, B cell receptor stimulation and a range of other 
microenvironmental signals are hypothesised to contribute to the initiation and 
perpetuation of CLL in vivo.
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1.2.2 The role of antigen in CLL development and progression
The B cell response to antigen is mediated through the BCR of both normal and 
malignant cells. The repertoire of this antigen receptor is increased by the somatic 
hypermutation process in germinal centres, as well as in marginal zones and 
around lymphoid follicles (William, Euler et al. 2002), after an antigen of 
adequate affinity engages the B cell receptor. This affinity maturation is the 
process by which naive B cells develop into long-lived memory B cells or plasma 
cells (Wahl, Cascalho et al. 1999). Descendent cells with increased affinity for 
antigen are selected to proliferate whilst the less useful cells are usually 
eliminated (Kelsoe 1994) via loss of antigen stimulation and critical survival 
signals.
Antigen stimulation is considered a prerequisite for CLL development regardless 
of IGHV gene mutations (Keating, Chiorazzi et al. 2003). Furthermore, CLL cells 
overexpress activation markers and underexpress markers that are downregulated 
by activation. Compared with age-matched control B cells, CLL cells 
overexpress CD23, CD25, CD69 and CD71, and have lower expression levels of 
CD22, CD79b and Ig, consistent with cellular activation (Chiorazzi, Ferrarini 
2003). BCR surface expression is usually weak in CLL, and these low levels of 
BCR are indicative of anergy caused by chronic stimulation (Stevenson, 
Caligaris-Cappio 2004). B lymphocytes can either progress through the cell cycle 
or die once signal transduction is initiated by the BCR. In the ~50% of CLL cases 
that can transmit BCR signals to the nucleus, stimulation by BCR cross-linking 
can either cause or prevent apoptosis, dependent on the balance between IgM and 
IgD (Zupo, Cutrona et al. 2002, Bernal, Pastore et al. 2001). In the other -50% of
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cases, studies have shown activation of signalling pathways indicative of anergic 
B cells (Muzio, Apollonio et al. 2008). BCR signalling differs between M- and 
UM-clones, with M-CLL being shown to be less responsive than UM-CLL to IgM 
cross-linking (Zenz, Mertens et al. 2010). This may contribute to the differing 
clinical courses seen in these two subgroups.
Non-random use of particular IGHV gene segments (Kipps 1993), non-random 
pairing of VH and VL gene segments (Johnson, Rassenti et al. 1997), somatic 
hypermutation in a proportion of cases, and structural homology among the BCR 
of a proportion of cases (Ghiotto, Fais et al. 2004) all support the idea of CLL 
cells being both antigen experienced and sharing a common set of antigens 
(Chiorazzi, Rai et al. 2005). However, CLL cells frequently have polyreactive 
receptors, which bind multiple antigens, including autoantigens (Broker, Klajman 
et al. 1988, Sthoeger, Wakai et al. 1989). The cell biological effects of BCR 
cross-linking ex-vivo, biological features of CLL cells resembling normal B cells 
with antigenic stimulation, and the effects of accessory T cells on CLL cells all 
support a role for antigen in CLL cell maintenance (Efremov, Gobessi et al. 2007, 
Lanasa 2010).
Downstream of engagement of surface IgM, a survival program is elicited that 
involves activation of NF-kB NF-kB (nuclear factor-KB) (Section 1.6.3), increases 
in Mcl-1, Bcl-2, and Bfl-1 expression, and inhibition of caspase activity (Section 
1.7.1/1.7.2) (Bernal, Pastore et al. 2001). Blocking of PI3-K, which mediates 
BCR signals in a non-redundant manner, can abrogate Mcl-1 induction and impair 
survival (Bernal, Pastore et al. 2001). Sustained activation of the BCR in CLL
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cells has frequently been linked to activation of ERK and Akt kinases, which have 
been shown to be required for the induction of antiapoptotic proteins, including 
Mcl-1, Bcl-xl and XIAP (Section 1.7.2/1.7.10) (Longo, Laurenti et al. 2008). The 
kinases, p38 MAPK, and JNK (Section 1.6.2), as well as NF-AT, can also be 
influenced by BCR engagement (Efremov, Gobessi et al. 2007). Thus, it can be 
envisaged that the nature of the BCR and its stimulation affect clinical course in 
CLL via a complex signalling network that directs cellular growth and survival.
1.2.3 Tumour microenvironment in CLL
The balance of positive and negative signals delivered by the BCR, cell-to-cell 
contact, cytokines, and chemokines determines the fate of the CLL cell 
(Chiorazzi, Rai et al. 2005). The tumour microenviromnent consists of malignant 
cells, host immune cells, stromal elements, and vascular cells that create a niche 
wherein signals can be transmitted through antigen presentation, cell-cell 
interactions, and paracrine signalling via cytokines and chemokines (Lanasa 
2010). When B cells are activated the proteins on the surface are modified, which 
enables interactions with other cells and soluble signalling molecules, facilitating 
survival, proliferation, and differentiation (Chiorazzi, Rai et al. 2005). 
Microenvironmental signals can also affect the fate of CLL cells in the absence of 
BCR stimulation. The microenvironments differ in the bone marrow and 
secondary lymphoid organs. The former contains mesenchymal stem cells 
(MSC), whilst in the latter nurse-like cells (NLCs), T cells and follicular dendritic 
cells are purportedly present (Lanasa 2010). Microenvironmental interactions 
with CLL cells are complex and are the subject of ongoing investigation. 
Accessory cell pro-survival functions are complemented by adhesion molecules
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and lymphokines (Munk Pedersen, Reed 2004). Some purported important CLL- 
supporting molecules are shown in Table 1.2, along with reported cell/s of origin.
Table 1.2. Microenvironmental factors and cell types that support CLL 
development and maintenance
Cell type Microenvironmental factor
Nurse-like cells CXCL12 (SDF-1), CXCL13, BAFF, APRIL, CD31
Marrow stromal cells CXCL12 (SDF-1), CXCL13, CD31,
CD4+ T cells CD 154, IL-4, IFN-a, IFN-y
Various Angiogenic cytokines (VEGF, bFGF, TSP-1),
Microvesicles; Microbial antigens.
(Munk Pedersen, Reed 2004, Burger, Hartmann et al. 2005, Nishio, Endo et al. 
2005, Vogler, Butterworth et al. 2009, Kay, Bone et al. 2002, Ghosh, Secreto et 
al. 2010, Muzio, Scielzo et al. 2009, Ferlin-Bezombes, Jourdan et al. 1998, 
Deaglio, Vaisitti et al. 2006)
Signals such as those of Table 1.2 can tip the balance of cellular apoptotic signals 
in favour of cell survival. The PI3-K pathway has been shown to play a key role 
in CLL survival and growth (Cuni, Perez-Aciego et al. 2004). PI3-K can be 
activated by BCR stimulation (Section 1.2.2) and other survival signals, which 
can lead to Akt and NF-kB pro-survival signalling. Important kinases of CLL are 
explored in more detail in Section 1.6.2. PI3-K activation has been linked to 
protection of pro-survival and caspase inhibitor proteins (Cuni, Perez-Aciego et 
al. 2004). CXCL12 (SDF-1) can activate STAT3 and MAPK pathways (Burger, 
Hartmann et al. 2005). BAFF and APRIL can activate NF-kB and induce Mcl-1 
(Nishio, Endo et al. 2005), and CD 154 can activate NF-kB (Vogler, Butterworth 
et al. 2009). Microvesicles have been shown to stimulate the Akt/mTOR pathway 
(Ghosh, Secreto et al. 2010), whilst Toll-like receptors can induce NF-kB
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activation and Akt under microbial antigen stimulation (Muzio, Scielzo et al. 
2009). Clonal expansion is apparently supported by angiogenic cytokines, such as 
VEGF, and chemokines, such as SDF-1 (Chiorazzi, Rai et al. 2005). CD38 
expression in CLL changes in response to contact with activated CD4(+) T cells, 
and identifies cells that are primed to proliferate (Patten, Buggins et al. 2008). 
CD31 stimulation of CD38 can induce proliferation and increase survival 
(Deaglio, Vaisitti et al. 2006). Downstream signalling consequences of 
microenvironmental stimulation include upregulation of the antiapoptotic BCL2, 
survivin, and MCL1 (Chiorazzi, Rai et al. 2005). IL-4, IFN-a, and IFN-y are pro­
survival molecules that are reported to support CLL cells via T-helper cells (Mimic 
Pedersen, Reed 2004).
1.3 CLL Treatments
1.3.1 Current treatments and clinical trials
Patients requiring treatment are assessed for their ability to tolerate intensive 
therapies. Hence, they are divided according to fitness and TP53 status. Patients 
with no TP53 defects receive chemotherapy-based treatment, whereas those with 
TP53 defects receive non-chemotherapy treatment such as alemtuzumab or 
glucocorticoids (GCs). Alkylators and purine analogues form the backbone of 
modern chemotherapy. Fludarabine has been shown to be superior to 
chlorambucil by the ECOG study (Rai, Peterson et al. 2000), and fludarabine + 
cyclophosphamide has been shown to be superior to fludarabine by the GCLLSG 
CLL4 trial, the US intergroup trial, and LRF CLL4 trial (Eichhorst, Busch et al. 
2006, Flimi, Neuberg et al. 2007, Catovsky, Richards et al. 2007). More recently 
rituximab + fludarabine/ cyclophosphamide was shown to be superior to
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fludarabine + cyclophosphamide alone by the GCLLSG CLL8 trial (Hallek, 
Fischer et al. 2010). This study showed that rituximab + 
fludarabine/cyclophosphamide is associated with a survival advantage compared 
to fludarabine/cyclophosphamide, so rituximab + fludarabine/cyclophosphamide 
is currently considered to be the treatment of choice for fit patients who are able 
to withstand the toxicity. For less fit patients, chlorambucil remains the standard 
treatment. A phase III randomised controlled trial has shown that bendamustine is 
superior to chlorambucil (Knauf, Lissichkov et al. 2009), but the results in the 
chlorambucil arm were very poor, possibly due to the sub-optimal chlorambucil 
dose regimen. In addition, ongoing trials are investigating the possible benefit of 
adding the anti-CD20 antibodies rituximab (GCLLSG CLL11), GA101 (GCLLSG 
CLL11) or ofatumumab (COMPLEMENT-1) to chlorambucil. The International 
Workshop on CLL define relapse as disease progression at least 6 months after 
achieving a CR (complete remission) or PR (partial remission), whilst refractory 
disease is defined as treatment failure or disease progression within 6 months of 
anti-leukaemic therapy. Patients who relapse and have not acquired a TP53 
abnormality can be expected to respond to a further course of their initial therapy 
although the PFS is usually shorter than after initial therapy and repeated courses 
often lead to drug resistance.
For patients with TP53 defects, alemtuzumab (Section 1.3.2) is the treatment of
choice. Recent data from the NCRI CLL206 trial and GCLLSG CLL20 trial
(Stilgenbauer, Zenz 2010) suggest that combining alemtuzumab with GCs results
in superior efficacy. Alemtuzumab-based therapy is also used for patients with
fludarabine-refractory CLL irrespective of TP53 status. Ofatumumab has useful
activity in patients who are refractory to both fludarabine and alemtuzumab or
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with bulky disease refractory to fludarabine (Wierda, Kipps et al. 2010). Other 
agents with therapeutic benefit in CLL include lenalidomide and oblimersen 
(Hallek 2009), and inhibitors of the B-cell receptor signalling pathway, including 
the PI3K delta inhibitor, CAL101.
1.3.2 Alemtuzumab and high-dose glucocorticoids
Though most patients respond to first-line therapy relapse is inevitable, and not all 
achieve complete remission. Patients with deletion or mutation of TP53 at 17pl3 
are very unlikely to respond well to chemotherapy (Grever, Lucas et al. 2007). 
This is unsurprising as p53 mediates the efficacy of a wide range of anti- 
neoplastic agents (Wattel, Preudhomme et al. 1994) by acting as a molecular 
switch that blocks proliferation or initiates apoptosis. Chemo-immunotherapy, 
alemtuzumab, or high-dose corticosteroids are all effective as initial therapy for 
patients with loss of functional p53 (Grever, Lucas et al. 2007). Within recent 
years, monoclonal antibodies have been added to HDMP (high-dose 
methylprednisolone) regimen (Castro, Sandoval-Sus et al. 2008, Castro, James et 
al. 2009). Alemtuzumab is an anti-CD52 monoclonal antibody (MAb) that fixes 
complement and depletes normal lymphocytes and lymphoma cells (Hale, Bright 
et al. 1983). The use of alemtuzumab alone or in combination with high dose 
steroids results in an improved overall-response rate (ORR) and PFS, but the 
results are not as good as seen in previously untreated patients with a TP53 
abnormality. Despite the apparent success of alemtuzumab in clinical trials 
(Lozanski, Heerema et al. 2004), and effectiveness in TP53 defective patients 
(Osuji, Del Giudice et al. 2005), as well as patients that do not respond to standard 
chemotherapy (Stilgenbauer, Dohner 2002), it is not particularly effective against 
nodal disease, with only 12% of all patients with lymph nodes >5 cm responding
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(Grever, Lucas et al. 2007). However, when combined with HDMP, patients with 
widespread cytopenias and bulky lymph nodes can be effectively treated (Pettitt, 
Matutes et al. 2006). Treatment options for patients who fail alemtuzumab-based 
therapy are limited but active agents include ofatumumab, lenalidomide, 
flavopiridol and high-dose glucocorticoids (GCs). The choice of therapy depends 
on patient fitness, previous treatment and drug availability. Patients with high- 
risk CLL who are not fit enough for alemtuzumab may benefit from conventional- 
dose GCs. GCs can also be used to treat chlorambucil-refractory CLL.
Malignant cells from patients with relapsed/refractory CLL have been 
demonstrated to be particularly sensitive to HDMP in vitro, and patient treatment 
response has been shown to correlate with this sensitivity (Bosanquet, McCann et 
al. 1995). Two subsequent studies at the Royal Marsden underlined this 
observation (Thornton, Hamblin et al. 1999, Thornton, Matutes et ah 2003). One 
study of HDMP given at a dose of lgm/m2/d each month was performed in 25 
patients, 15 of whom were fludarabine refractory. An ORR of 70% was achieved 
with a median duration of 12 months. Responses were seen in five of ten patients 
with loss or mutation of the TP53 gene. Overall, responses were seen in about 
half of the patients with fludarabine-refractory CLL regardless of p53 status 
(Thornton, Matutes et al. 2003).
GCs remain an important component of CLL therapy not least because GCs have 
few acute side effects, lack carcinogenic activity, and induce relatively specific 
cell death (Clarke, Purdie et al. 1993). Despite the usefulness of GCs in 
haematological malignancies, some tumours do not respond to GCs particularly
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well, whilst others often develop resistance during therapy (Kaspers, Pieters et al. 
1994, Moalli, Rosen 1994). Therefore, GC resistance in CLL is of clinical 
importance.
1.3.3 Alternatives to alemtuzumab and high-dose glucocorticoids
As well as alternative monoclonal antibody therapies to alemtuzumab, there are 
other treatments that do not rely upon a functional p53 pathway. Re-infusion of 
autologous CLL cells transduced with CD40L has received attention as a potential 
treatment (Wierda, Cantwell et al. 2000). As well as upregulating immune 
accessory molecules and bystander cells, this approach is thought to increase 
sensitivity to activators of the extrinsic death pathway, regardless of p53 status. 
Flavopiridol is a cyclin-dependent kinase (CDK) inhibitor that has been shown to 
be effective in killing CLL cells in vitro (Byrd, Shinn et al. 1998). Early trials 
suggested little clinical benefit, but improvements to administration schedules 
allowed sufficient plasma concentrations to be achieved, and clinical benefits 
have been reported. A phase-1 trial in advanced CLL led to an ORR of 42% with 
a median duration of response of over 12 months (Byrd, Lin et al. 2007). Studies 
are ongoing, though side effects necessitate thorough patient monitoring. R- 
roscovitine, which is under clinical evaluation, has been shown to be CLL cell 
biased in its killing specificity, and is reportedly able to induce killing in p53- 
aberrant samples (Alvi, Austen et al. 2005). Brefeldin, and Jasmonates are further 
examples of compounds that are not dependent upon the integrity of the p53- 
pathway in order to elicit a therapeutic response (Grever, Lucas et al. 2007).
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Autologous stem cell transplant is now feasible in some patients and has low 
treatment-related mortality (Gribben 2009). However, there is no evidence to 
suggest that autologous transplantation is curative in CLL. A randomised trial 
that compared autologous transplantation with watch and wait, in patients who 
achieved CR, very good PR or nodular PR after first or second-line induction 
therapy (Michallet, Dreger et al. 2011), indicated that whilst autologous 
transplantation halved the relapse risk it had no impact on overall survival. Data 
regarding allogeneic stem cell transplant is more encouraging. A retrospective 
study by the European Group for Blood and Marrow Transplantation identified 
that allogeneic hematopoietic stem-cell transplantation (HSCT) is a viable 
treatment for chronic lymphocytic leukaemia with 17p deletion (Schetelig, van 
Biezen et al. 2008). Though there are few late relapses, myeloablative allogeneic 
HSCT is associated with high treatment-related morbidity and mortality, and this 
approach is also only applicable to a small number of patients (Gribben, Hosing et 
al. 2011). The major focus of HSCT in CLL has been reduced-intensity 
conditioning (RIC) allogeneic HSCT, which is applicable to the age distribution 
of CLL and which exploits the graft-versus-lymphoma effect (Gribben, Hosing et 
al. 2011). Recent data from the European Group for Blood and Marrow 
Transplantation suggest that the outcomes following transplants from fully 
matched unrelated donors are identical to sibling donors, which should increase 
the potential donor pool (Michallet, Sobh et al. 2010). Despite recent progress in 
this field, patient selection and treatment timing is under scrutiny. Furthermore, 
considerable morbidity and mortality of the RIC-HSCT, and high incidence of 
chronic extensive graft-versus-host disease mean that stem cell transplant research 
is still an area that requires much development.
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1.4 Glucocorticoids and glucocorticoid-induced killing
1.4.1 Glucocorticoids in normal physiology
GCs are a major class of steroid hormones characterised by their ability to bind to 
and activate the Glucocorticoid Receptor (GR) (Chrousos, Kino 2005), which is a 
member of the nuclear receptor superfamily (Laudet, Hamii et al. 1992). The GR 
is a transcription factor that binds free GC in the cytoplasm and then translocates 
to the nucleus and binds to Glucocorticoid Response Elements (GREs) and 
negative Glucocorticoid Response Elements (nGRES), as well as other 
transcription factors and co-activators (De Bosscher, Vanden Berghe et al. 2003) 
(Section 1.5). In vivo, GCs are synthesised from cholesterol by a series of 
cytochrome P450-catalysed reactions within the adrenal cortex (De Bosscher, 
Vanden Berghe et al. 2003). Cortisol (hydrocortisone when synthetically 
manufactured), the major physiological GC, is synthesised by and secreted from 
the adrenal glands (Greenstein, Ghias et al. 2002). This secretion is dictated by 
the balance of adrenocorticotropin, and corticotropin releasing hormone, which 
are secreted from the anterior pituitary gland, and hypothalamus during stress, 
respectively, in a pulsatile and circadian way (Balsalobre, Brown et al. 2000, 
Reichardt, Schutz 1998). Endogenous GCs and some synthetic GCs bind to 
transcortin (CBG), which serves to regulate exposure (Garrel 1996). Most 
synthetic versions also bind other plasma proteins, with varying binding 
specificities (Breuner, Orchinik 2002). In the liver GCs are quickly metabolised 
by conjugation with a sulphate group or glucuronic acid to be secreted in the 
urine. Free cortisol enters cells freely due to its lipophilic properties, and can be 
deactivated inside cells by conversion to cortisone by type 2 11(3-hydroxysteroid 
dehydrogenase (Yang, Zhang 2004).
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The molecular structure of cortisol and the three predominant therapeutic GCs— 
dexamethasone (Dex), methylprednisolone (Mep), and prednisone—can be seen 
in Figure 1.1. Dex possesses a fluorine atom, which increases the affinity of Dex 
for its receptor.
it-oh
Prodnisono
\ H,C Methylprednlsone
Cortisol
CH,OH
Dexamethasone
Figure 1.1. The molecular structure of cortisol and three therapeutically 
administered GCs (Taken from (Longui 2007)). Methylprednisolone is 
labelled by the alternative name “Methylprednisone”.
GC signalling is implicated in nearly every molecular, cellular, and physiological 
network (Chrousos, Kino 2005), and so is a key co-ordinator of human biological 
processes. Whilst influencing the central nervous system, cardiovascular tone, 
and renal function, GCs are also critical to the activity and character of immune 
and inflammatory reactions (Chrousos, Kino 2005). GCs also impact on the 
reactions that underlie intermediary metabolism (Chrousos, Kino 2005). GCs can 
increase the expression of crucial enzymes of gluconeogenesis, particularly in the
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liver, when the body is in the fasted state. Concomitantly, they mobilise amino 
acids from extra-hepatic tissues, inhibit glucose uptake in muscle and adipose 
tissue, and stimulate fat breakdown in adipose tissue.
1.4.2 Anti-inflammatory action of glucocorticoids
Inflammatory pathways are characterised by positive feedback loops and 
redundancy (Rhen, Cidlowski 2005). As a result of their immunosuppressive 
effects, GCs are used to treat inflammatory conditions as well as autoimmune 
diseases and lymphomas (Rhen, Cidlowski 2005). GCs affect immune responses 
in a number of ways, with effects varying according to cell type and 
developmental stage. GCs affect cortisol regulation by negatively feeding back 
on the pituitary gland (Rhen, Cidlowski 2005). In support of this, suppression of 
the hypothalamo-pituitary-adrenal axis can occur when GCs are used at high dose, 
which can lead to “steroid withdrawal syndrome” (AMATRUDA, 
HOLLINGSWORTH et al. 1960). GCs suppress multiple inflammatory genes 
either by GR-mediated repression of other transcription factors such as NF-kB 
and AP-1 (activator protein-1) (Section 1.6.6), or by transcriptionally increasing 
expression of anti-inflammatory cytokines (Section 1.6.1) or signalling proteins 
such as MAPK-phosphatase and IkB (Barnes 2006) (Section 1.6.2/1.6.6). GCs 
also inhibit the recruitment of cells to sites of inflammation by suppressing the 
production of chemotactic mediators, such as prostaglandins, leukotrienes, and 
adhesion molecules, and by inhibiting cell survival (Barnes 2006).
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1.4.3 Apoptosis and necrosis
GC-induced killing displays many hall-marks of apoptosis (Greenstein, Ghias et 
al. 2002). Apoptosis is an orderly process of cell death that is critical for 
homeostasis in multicellular organisms. Defects in this process can contribute to 
autoimmunity, degenerative disorders, and cancer development (Strasser, 
O'Connor et al. 2000). Many chemotherapeutic agents are reliant on inducing this 
process. Apoptosis can be distinguished from necrosis by the presence of a 
number of features, including proteasome and endonuclease activation, 
condensation of chromatin, a reduction of cell volume, plasma membrane 
blebbing, cytoskeletal disruption, compaction of organelles, and dilation of the 
endoplastic reticulum (Wang, Malone et al. 2003a, Cohen 1997). In necrosis, 
cells swell, cell membranes and organelles are disrupted early in a hap-hazard 
fashion, and there is no apparent condensation of chromatin or cytoplasmic 
blebbing. The latter mode of cell death is potentially very damaging to the 
organism via toxicity and chronic inflammation, and so the execution of apoptosis 
is important for the maintenance of homeostasis (Savill 1997).
Apoptotic signalling can be initiated by extrinsic activation by ligand binding of 
death receptors, or by events within the cell leading to mitochondrial permeability 
transition (Green, Reed 1998). The latter event leads to release of cytochrome c 
and SMAC/DIABLO (Greenstein, Ghias et al. 2002). Cytochrome c positively 
regulates the activation of Apaf-1 and activator caspase-9 (cysteine protease-9), 
whilst SMAC suppresses the inhibitory effect of lAPs on survivin, caspase-9 and 
caspase-3 (Ferri, Kroemer 2001). In the presence of sufficient ATP this leads to 
caspase cleaveage of various cellular targets by the effector caspases, including
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caspase-3, via a caspase cascade (Cohen 1997). Apoptosis-inducing factor (AIF) 
and endonuclease G are also released from mitochondria following mitochondrial 
membrane disruption. AIF contributes to DNA fragmentation and chromatin 
condensation (Susin, Lorenzo et al. 1999), and can induce caspase-independent 
cell death (Daugas, Susin et al. 2000). Endonuclease G is also involved in DNA 
fragmentation during apoptosis (van Loo, Schotte et al. 2001). Phosphatidylserine 
(PS) is a membrane protein that is exposed on the surface of apoptotic cells by 
virtue of a conformational change. In vivo, the exposure of PS on the surface of 
the plasma membrane leads to phagocytosis by neighbouring cells with PS- 
receptors (Fadok, Voelker et al. 1992).
Downstream components of the apoptotic signalling network are constitutively 
expressed and primed for activation in most cell types (Thompson 1995) (Section 
1.7). Therefore, survival signals are required to repress the cell killing machinery. 
The functional importance of caspases in cell death is controversial, as caspase 
inhibition shifts the morphology of death from apoptosis to alternative pathways 
in a variety of models (Kroemer, Martin 2005). Moreover, caspase inhibitors only 
delay GC-mediated cell death and do not alter long-term survival (Kofler 2000). 
This is believed to be due to redundancy between caspase activation and 
mitochondrial damage that cannot be reversed. ATP plays an important role in 
apoptosis, as ATP-depleted cells have been shown to die by necrosis unless ATP 
generation is restored (Leist, Single et al. 1997).
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1.4.4 Glucocorticoid-induced killing
Most of the reported effects of GC at therapeutic levels are mediated by the GO 
receptor (Schmidt, Rainer et al. 2004), and intact receptor is required for GC- 
induced cell killing (Greenstein, Ghias et al. 2002). Numerous models have been 
proposed and studies completed regarding the mechanisms that lead to the tipping 
of the survival balance in GC-treated lymphoid cells, particularly in ALL (acute 
lymphoblastic leukaemia) cells, which are particularly sensitive to GC treatment. 
Some studies of GC action in CLL cells have also been undertaken. Historically, 
GC-induced apoptosis was divided into: initiation via GR activation and 
subsequent gene regulation; decision making, which requires engagement of pro­
survival and proapoptotic factors at the mitochondrial level; and execution, which 
involves caspases and endonucleases (Frankfurt, Rosen 2004). Two schools of 
thought had developed by 2002 regarding GC-induced killing in that it results 
from the expression of death inducing genes or it results from the repression of 
transcription factors that promote survival (Greenstein, Ghias et al. 2002). It now 
appears more likely that elements of both mechanisms act to kill GC-sensitive 
cells. It has further been proposed that two major pathways of GC-induced cell 
death might exist, resulting in apoptotic or necrotic morphologies, depending on 
the availability of the apoptotic machinery (Schmidt, Rainer et al. 2004). The 
former would result from regulation of typical apoptosis genes such as Bcl-2 
family members, whilst the latter from stress and detrimental effects on essential 
cellular functions, such as metabolism, and pH and volume control. More 
recently, in ALL cells, autophagy has been shown to occur as a result of Dex 
treatment, upstream of apoptosis (Laane, Tamm et al. 2009). This mechanism of 
cell death is not as well characterised as apoptosis, but was shown to be dependent
37
on Beclin-1, which is a protein that interacts directly with PI3-K. Regai'dless of 
how GCs kill leukaemic cells, GC-induced apoptosis can be blocked by 
cycloheximide and actinomycin D in the human leukaemia cell line, CEM-C7, 
which suggests dependence of this process on de novo protein and RNA synthesis 
(Wang, Malone et al. 2003a). Interestingly, M-IGHV CLL samples have been 
shown to respond less well than UM-IGHV samples to prednisolone treatment 
(Aleskog, Tobin et al. 2004),
It is not clear whether changes in cellular redox, acid-base balance, or metabolism 
are directly involved in GC-directed CLL killing. Furthermore, whether NF-kB or 
AP-1 play critical roles in this signalling has received little interest in CLL. An 
ever-growing list of other signalling pathways that can affect the GR/GC pathway 
also includes the cell-cycle regulator, c-Myc, and antigen receptor cross-talk, as 
well as cytokine signalling (Frankfurt, Rosen 2004). The signal transduction 
pathways affected by GCs are numerous and complex. However, a model 
proposed by one group provides a simple conceptual framework to build upon 
(Kofler, Schmidt et al. 2003). Pre-receptor defects, GR abnormalities, and 
deficiencies in GR-associated proteins can be classed as upstream mechanisms of 
resistance, whilst defects in specific response pathways, and cross-talk with other 
pathways that can affect or be affected by GCs provide downstream resistance 
mechanisms.
1.4.5 Cross-resistance in CLL
Various laboratories have investigated in vitro resistance of CLL cells to a range 
of anti-neoplastic compounds, and correlations have been tested. Sensitivity of
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CLL cells to methylprednisolone, has been shown to coincide with resistance to 
other drugs, such as fludarabine, cyclophosphamide, and anthracyclines 
(Bosanquet, McCami et al. 1995). This indicates a distinct mechanism of death 
induction for GCs. On the contrary, it has also been suggested that tight 
relationships exist between responses to drugs with very different mechanisms of 
action, (Kivekas, Vilpo et al. 2002) and to this end prednisolone and cyclosporin 
A sensitivity have been linked. Mitoxantrone is a topoisomerase type II inhibitor 
that requires p53 to induce cell death. Resistance to mitoxantrone has been shown 
to exist concurrently with steroid resistance, as well as with that of vincristine (a 
spindle poison and mitotic inhibitor). The former agent is an intercalating agent 
that acts through a range of immunosuppressive mechanisms, which include 
inhibition of B cell function and antibody production. Both mitoxantrone and 
vincristine resistance have been to some extent attributed to P-glycoprotein 
function, which has been implicated as a cause of Dex resistance (Bourgeois, 
Gruol et al. 1993). Taken together, these observations would suggest that GC 
resistance may result from both drug-specific and general mechanisms.
Prior treatment with chlorambucil has been shown to induce sensitivity to steroids 
(Bosanquet, McCann et al. 1995), suggesting that some agents may be able to 
prime CLL cells for GC sensitivity. Contrastingly, prior treatment of patients 
with anthracyclines appeared to have the opposite effect, and induced ex vivo 
resistance to steroids, and platinums (p53-dependent) (Bosanquet, Bell 1996).
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1.5 Glucocorticoid receptor
1.5.1 Cellular pre-GC receptor resistance mechanisms
Resistance to GC treatment could result from insufficient plasma levels in patients 
due to pharmacokinetics. At the cellular level, intracellular GC levels can be 
reduced by over-expression of P-glycoprotein, and the multidrug resistance- 
associated protein (Gottesman, Fojo et al. 2002). Also upstream of receptor 
binding, cortisol resistance can be the result of 1 Ip-hydroxy steroid dehydrogenase 
type 2 activity, which converts cortisol into active cortisone in certain cell types 
(Rabbitt, Lavery et al. 2002). In the absence of the above resistance mechanisms, 
active cellular GC binds to its target receptor, the GR.
1.5.2 Glucocorticoid receptor definition
The GR is a member of the steroid hormone superfamily (Laudet, Hanni et al. 
1992). Multiple human GR proteins are generated from a single gene by 
alternative splicing and alternative translation initiation (Lu, Cidlowski 2004) 
(Section 1.5.4). The NR3C1 gene, which encodes for the GR, is located at 5q31 
(Theriault, Boyd et al. 1989). Each protein is subject to a variety of post- 
translational modifications (Lu, Cidlowski 2004). Thus, different cell types can 
contain unique GR isoform compositions, which are likely to contribute to the 
considerable range of cell-specific responses to GCs (Lu, Cidlowski 2004). 
Receptor members share a variable amino-terminal transactivation domain, a 
central and well-conserved DNA-binding domain, and a moderately conserved 
carboxy-terminal ligand binding domain that also contains activating functions 
(De Bosscher, Vanden Berghe et al. 2003). Whilst ligand-independent activation 
of the GC receptor has been shown to occur in S49 T lymphoma cells following
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physiological stress (Smets, Salomons et al. 1998), the dominant model of GC 
action in lymphopoietic cells is based upon direct activation by GC binding to the 
GR.
1.5.3 Glucocorticoid receptor activation
GCs diffuse across the cytoplasmic membrane and bind to the ubiquitous 
cytoplasmic GR (Figure 1.2) (De Bosscher, Vanden Berghe et al. 2003). Inactive 
GR exists as hsp90/hsp70 bound monomers, and these chaperones are positively 
or negatively regulated by various co-chaperones such as immunophilins, dynein, 
p23, hsp40, CHIP, and Bag-1 (De Bosscher, Vanden Berghe et al. 2003). Ordered 
assembly of the GR complex is necessary for high affinity hormone binding 
(Frankfurt, Rosen 2004). Upon ligand binding the GR heterocomplex undergoes 
molecular rearrangement, resulting in displacement of certain chaperones (Kfir- 
Erenfeld, Sionov et al. 2010). The GR is then phosphorylated at multiple sites, 
which leads to exposure of nuclear localisation sequences (NLSs), immunophilin 
substitution, and dynein recruitement (De Bosscher, Vanden Berghe et al. 2003). 
According to immunofluorescence and fractionation studies, GR-hsp90-FKBP52- 
dynein complex transposes to the nucleus, where GR can dimerise to yield the 
homodimeric DNA-binding form (Davies, Ning et al. 2002, Dittmar, Demady et 
al. 1997). Alternatively, it has been proposed that the GR dimerises prior to 
nuclear translocation, following phosporylation (Davies, Ning et al. 2002, 
Bledsoe, Montana et al. 2002)(Kfir-Erenfeld, Sionov et al. 2010). Co-chaperones 
can alter the regulatory functions of the receptors in the nucleus, as well as ligand 
binding, by dynamic (dis)assembly of various transcription complexes (Morimoto 
2002). Activated GR binds to specific DNA sequences—GREs—as a homodimer
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(Frankfurt, Rosen 2004), and then communicates with the basal transcription 
machinery (Yamamoto, Alberts 1976). This is known as transactivation. The 
dimeric GR transactivates via interaction with nuclear receptor coactivators, and 
other chromatin remodelling complexes and components of the transcription 
machinery as well as with GREs (Chrousos, Kino 2005). As well as positively 
regulating genes, the GR can negatively regulate genes by interaction with a 
negative GRE (nGRE) site (cis-repression), or by direct or indirect interference 
with the transcriptional activity of other transcription factors, such as NF-kB, AP- 
1, CREB, C/EBP, STATs, p53, and Smad (De Bosscher, Vanden Berghe et al. 
2003) (transrepression) (Section 1.6.6).
Figure 1.2. A simplified schematic of activation of and subsequent 
transactivation by the GR (adapted from Ploner, Schmidt et al. 2005). The
hydrophobic glucocorticoid enters the cell passively, and then binds to free GR in 
the cytoplasm. Hyperphosphorylation leads to exposure of NLSs. The GR and its 
remaining chaperones enters the nucleus where the homodimeric GR can bind 
both positive and negative GREs, or other transcription factors, to regulate 
transcription.
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1.5.4 GR variants
Multiple GR variants exist as a result of differential splicing and translation 
initiation. Originally, GR variants were reported as aberrant versions of the 
primary GR protein, with one such study showing that specific exons of the 
hormone binding domain were deleted in multiple myeloma (MM) cell lines 
(Moalli, Pillay et al. 1993). However, it is now the consensus that GR splice 
variants are deliberately expressed in order to tune cellular responses to GCs. Six 
major splice variants have been described. GRa, GRp, GRy, GRP/5, GR-A, and 
GR-B (Kofler, Schmidt et al. 2003) GRa is the full-length version of the GR and 
is 777 amino acids long. GRa is able to bind cortisol, DNA, and other 
transcription factors and is responsible for transcription activation (Frankfurt, 
Rosen 2004). All other isoforms are truncated versions of GRa and possess 
altered hormone binding domains, nuclear localisation sequences, or 
transactivation domains (Figure 1.3), and thus are thought to modulate GRa 
activity (Oakley, Cidlowsld 2011). GR composition varies substantially between 
cell types. For instance, differences in GR expression between the germinal 
centre and the mantle zone in normal follicles, and differences in expression 
among different types of lymphoma have been observed (Okazaki, Yamakawa et 
al. 2006). Whilst GRa can be hormone-activated, GRP does not bind GCs, and 
can act as a dominant negative nuclear inhibitor of activated GRa (Shahidi, 
Vottero et al. 1999, Lewis-Tuffin, Cidlowski 2006). GR5 is detected in many 
tissues and has been shown to stimulate the transcriptional activity of GRa in 
malignant haematological cells (de Lange, Segeren et al. 2001).
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Figure 1.3. Splice variants of the GR (taken from (Kofler, Schmidt et al. 
2003)). The bars represent GR isoforms resulting from alternative splicing, 
polyadenylation, and translation initiation. A/B, C, D, and E refer to specific 
protein regions of nuclear receptors. The numbers denote amino acids. AF, 
sequences implied in transactivation; NLS, nuclear localisation sequence; LBD, 
ligand-binding domain; DBD, DNA-binding domain.
1.5.5 GR expression levels and defects in the GR
Whether levels of GR-isoform expression in haematological malignancies are 
responsible for insensitivity to GCs is controversial. The sensitivity of many 
lymphoid cell lines to GC-induced apoptosis or growth arrest has been shown to 
be correlated with receptor concentration (Gehring, Mugele et al. 1984, 
Bourgeois, Newby 1977, Zilberman, Zafrir et al. 2004, Gruber, Carlet et al. 2009). 
The CEM-C1 ALL cell line is thought to owe its resistance to GCs to low GR 
expression, rather than downstream defects in signalling (Geley, Hartmann et al. 
1996), whilst in primary ALL cells, GRp/GRa ratios have been shown to be 
inversely correlated with sensitivity to GCs (Koga, Matsuzaki et al. 2005). Two 
other studies of ALL patient samples did not reveal a correlation between GR(1
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mRNA levels and GC resistance (Tissing, Lauten et al. 2005, Haarman, Kaspers 
et al. 2004). In one early study using CLL cells, GR levels were shown not to 
correlate with in vitro sensitivity to GC, and it was also demonstrated that GR 
expression in circulating CLL cells did not correlate with antitumor response 
(Levine, Peterson et al. 1985). Contrastingly, a subsequent study demonstrated 
that a sample from a GC resistant CLL patient showed a markedly reduced GRa 
expression (~l/2) relative to untransformed lymphocytes, along with high GR(3 
expression (Shahidi, Vottero et al. 1999). These observations correlated with an 
approximate 10-fold reduction in binding affinity. GR levels have been shown to 
be influenced by cytokines. Pro-inflammatory cytokines can facilitate the 
accumulation of dominant negative GRp, which is proposed as a mechanism of 
GC resistance development (Webster, Oakley et al. 2001).
GR expression levels have been shown to change over time. Most cell types show 
negative autoregulation of GR expression in response to GCs. However, in T 
cells and other cell types sensitive to GC-induced death, positive autoregulation is 
common (Eisen, Elsasser et al. 1988). This is unsurprising given that a GRE 
sequence has been detected in an untranslated exon of the GR (Breslin, Geng et al. 
2001). One study demonstrated that upregulation of GR expression was required 
to induce apoptosis in GC sensitive T cells, and that such autoregulation may be 
required to facilitate a response of sufficient intensity/duration to induce killing 
(Ramdas, Liu et al. 1999). Positive autoregulation of GR expression has also been 
demonstrated in human leukemic CEM cells (Ashraf, Kunapuli et al. 1991), GC- 
sensitive S49 cells (Barrett, Vig et al. 1996), and a GC-sensitive myeloma cell line 
(Gomi, Moriwaki et al. 1990). A more recent study of CEM-C7 cells
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demonstrated that the GR can positively regulate its own expression at the level of 
both GR mRNA transcription and inhibition of GR destabilisation by GCs 
(Pedersen, Geng et al. 2004). The B cell translocation 1 gene is a GC-response 
gene and was recently shown to promote GR auto-induction in ALL (van Galen, 
Kuiper et al. 2010). Despite the evidence for auto-induction in various leukemic 
cell types, GRa transcript expression has been shown to fall in response to Dex in 
CLL cells (Meyers, Taverna et al. 2007), though GC-induced GR downregulation 
has been associated with GC resistance (Gross, Lu et al. 2009).
Mutant versions of GRa with decreased affinity for ligand binding, delayed 
translocation, and abnormal interaction with GR-interacting protein-1 coactivator 
have been observed (Charmandari, Kino et al. 2004). GR mutations have been 
linked to GC resistance in CCRF-CEM leukaemic cell lines (Hala, Hartmann et al. 
1996). Contrastingly, a study of 15 T-ALL cell lines concluded that resistance 
could not be attributed to mutations in GR or variation in expression levels 
(Beesley, Weller et al. 2009). In keeping with these findings, it has also been 
demonstrated that the GR of leukaemia cells harvested from 6 Dex-resistant ALL 
xenografts possessed no defects in ligand-induced translocation and binding to a 
consensus GRE (Bachmann, Gorman et al. 2005). Moreover, defects in the GR 
are rarely encountered in primary ALL samples (Beesley, Weller et al. 2009, 
Irving, Minto et al. 2005, Tissing, Meijerink et al. 2005). However, 
polymorphisms of the GR have been correlated with reduced event-free survival 
in ALL patients (Labuda, Gahier et al. 2010). In CLL cells, it has been observed 
that a GC resistant CLL patient sample possessed -10-fold lower binding affinity 
for Dex, relative to non-malignant lymphocytes from the same patient, and that in
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vitro apoptosis induction by Dex was delayed (Shahidi, Vottero et al. 1999). 
However, an earlier study of CLL cells from GC-treated patients revealed an 
absence of DNA- and steroid-binding site mutations (Soufi, Kaiser et al. 1995).
1.5.6 Post-translational modifications of the GR
Cochaperones can inhibit GCs from binding to the GR, and affect the regulatory 
functions of the receptors by dynamic (dis)assembly of various transcription 
complexes (De Bosscher, Vanden Berghe et al. 2003). Though the GR is 
activated via hyperphosphorylation, each GR isoform is also subject to post- 
translational modifications that further modulate receptor activity. GR protein 
may be modified by phosphorylation, ubiquitination, and sumoylation, which may 
affect ligand binding, translocation to the nucleus, /7,<ms'-activating efficacy, 
protein-protein interactions, or recruitment of cofactors (Ismaili, Garabedian 
2004). Phosphorylation has been studied most extensively. Phosphorylation of 
GRa can both up- and downregulate its transcriptional activity in a gene specific 
maimer. Also, differences at the level of cofactor recruitment, GRa half-life, and 
cellular trafficking have been observed in response to phosphorylation at various 
sites (Oakley, Cidlowski 2011). Most phosphorylation sites of the GR are located 
within the primary transactivation domain, AF-1 (Figure 1.3), and the basal GR 
phosphorylation depends upon the expression and activity of protein kinases 
within the cell (Kfir-Erenfeld, Sionov et al. 2010). GR nuclear-cytoplasmic 
shuttling and transcriptional activity are regulated through phosphorylation by 
MAPKs (p38-MAPK, JNK, ERK), CDKs, and glycogen synthase kinase-3 (GSK- 
3) (Oakley, Cidlowski 2011), as well as interactions with 14-3-3 proteins and heat 
shock proteins (Chrousos, Kino 2005).
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Evidence for other post-translational modification of the GR comes from studies 
of non-haematological cell types. A role for the ubiquitin-proteasome pathway in 
regulating GR protein turnover, which acts to restrict transcriptional signalling by 
GCs, has been observed (Wallace, Cidlowski 2001). Additionally, GR 
sumoylation has been shown to regulate the stability of the protein as well as its 
transcriptional activity (Le Drean, Mincheneau et al. 2002). More recently, 
acetylation of the GR in response to GC treatment has been demonstrated to 
impair GR antagonism for NF-kB (Ito, Yamamura et al. 2006). The GR has also 
been shown to interact with extracellular signals via Rho family Guanine 
nucleotide exchange factor (Kino, Souvatzoglou et al. 2006).
1.5.7 GR-mediated alterations in gene expression
There is an emerging consensus that an interactive network of genes undergoes 
altered expression before the onset of apoptosis in GC-induced killing. Several 
comparative expression microarray studies have been applied to identify the 
spectrum of genes regulated by GCs in both normal lymphocytes and leukaemic 
cells. Approximately 20% of the human leukocyte genome has been indicated to 
be regulated by GCs either directly or indirectly (Galon, Franchimont et al. 2002).
One microarray compilation study has suggested that from over 10,000 genes or 
Expressed Sequence Tags (ESTs) at least 284 genes are directly regulated by the 
GR, with 70% induced and 30% repressed, though identities vary between studies 
(Wang, Malone et al. 2003a). In this particular' comparison, a diverse set of gene 
changes evolved with the onset of death in two well characterised murine
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lymphoma cell lines. These changes involved the pro-survival c-Myc, and NF- 
kB, and an increase in Bim expression, which was also found to be induced in 
CEM-C7 cells, and primary murine thymocytes. Later studies by this group 
uncovered dig2 (Wang, Malone et al. 2003b), which appears to have a pro­
survival function, in WEHI7.2 cells; and thioredoxin-interacting protein (TXNIP) 
as a GC-regulated primary response gene that is involved but not essential in 
induction of apoptosis in WEHI7.2 cells (Wang, Rong et al. 2006). A separate 
study of human lymphoid CEM cells that involved screening of 12,600 genes 
showed that a resistant sub-clone up/downregulated 88 genes prior to the onset of 
death that did not change in the GC-sensitive clones, suggesting that broad-acting 
metabolic switches may lead to a resistant phenotype (Medh, Webb et al. 2003). 
A concomitant analysis demonstrated differential expression between 12h and 
20h, and showed a number of genes that were basally higher in resistant than 
sensitive clones (Webb, Miller et al. 2003). A follow up publication revealed that 
the Dex-sensitive clones shared the regulation of a limited set of genes, whilst the 
apoptosis-resistant clone showed Dex effects on a largely different set of genes. 
(Thompson, Webb et al. 2004). Another study of ALL cell lines identified the 
repression of a notable cluster of transcription, mRNA splicing and protein 
synthesis genes (Obexer, Certa et al. 2001). In a further ALL screen, cells from 
13 patients (3h, 8h) were examined (Tissing, den Boer et al. 2007). 
Approximately 50% of the differentially expressed genes were functionally 
categorised by three major groups; MAPK pathways, NF-kB signalling, and 
carbohydrate metabolism, which emphasises the broad-ranging effects of GCs on 
the transcriptome. A further study in ALL of GC sensitive and resistant ALL cell 
lines, and mouse thymocytes, (6h, 24h) argues against many of the genes of
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interest from model-based studies, and identified a few novel candidates for GC 
resistance in ALL (Schmidt, Rainer et al. 2006). These included a key regulator 
of glucose metabolism, a putative transcription factor, and a protein kinase 
implicated in cell-cycle regulation.
In MM cells Dex has been demonstrated to trigger early induction of cell repair 
machinery, followed by induction of pro-death and anti-survival genes (Chauhan, 
Auclair et al. 2002). A study of the MM cell-line MM1R uncovered a strong 
correlation between induction of GRE transactivation and induction of apoptosis 
using a GRE reporter assay (Sharma, Lichtenstein 2008). GC-sensitive human 
pre-B leukaemia 697 cells have also been monitored (3h, 6h, 24h, 48h) by 
oligonucleotide array to identify which genes are altered by GC treatment. Of 
12,000 genes, 93 were induced and 28 were repressed, including genes that block 
proliferation, cause growth arrest, and regulate apoptosis (Yoshida, Miyashita et 
al. 2002).
In a broad and relatively recent study, microarray technology was used to 
determine whether several types of haematological cells, all sensitive to GC- 
evoked apoptosis, would identify a common set of regulated genes (Miller, 
Komak et al. 2007). Small sets of genes that correlate with GC sensitivity in cells 
from several haematological malignancies were identified, and some of these are 
also regulated in normal mouse thymocytes. Several genes in the set shared by all 
the GC-sensitive leukemic cells tested have been demonstrated to be important for 
GC-dependent apoptosis, including BCL2L11/Bim, DDIT4, DSCR1, TXNIP, 
NFKBIA/lKBa, FKBP5/FKBP51, and TSC22D3/DSIPI/GILZ. IkBcx, GILZ , and 
Bim will be discussed in more detail (Section 1.6.3/1.6.5/1.7). DSCR1 and
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FKBP5 products antagonise the biological effects of the phosphatase calcineurin 
(Tissing, den Boer et ah 2007, Fuentes, Genesca et al. 2000). TXNIP and DDIT4 
products regulate the redox state within the cell (Chung, Jeon et al. 2006, 
Shoshani, Faerman et al. 2002). Other GC-responsive genes implicated in GC- 
mediated growth arrest, immunosuppression, and apoptosis include the serine 
protease grcmzyme A, the tumour suppressor gene zinc finger and BTB domain 
containing 16 (ZBTB16), the G-protein-coupled receptor T-cell death-associated 
gene 8 (TDAG8), tumour necrosis factor a-induced protein (TNFAIP8), the cell 
cycle inhibitors pl9 and p57, and the MAPK dual specificity phosphatase 1 
{DUSP1) (Section 1.6.6) (Kfir-Erenfeld, Sionov et al. 2010).
1.6 Glucocorticoid receptor cross-talk
1.6.1 GR-dependent transrepression
GCs possess potent anti-inflammatory activity, but an nGRE cannot be detected in 
the majority of anti-inflammatory genes. In fact, transcriptional interference has 
been found to mostly result from cross-talk between the GR and other 
transcription factors (Vanden Berghe, De Bosscher et al. 2002, Herrlich, 
Gottlicher 2002). The GR interacts with a number of cytokine-induced 
transcription factors and members of the nuclear hormone receptor superfamily, 
via physical inhibition, disruption of the basal transcription machinery, 
competition for coactivators, and chromatin remodelling (Kfir-Erenfeld, Sionov et 
al. 2010), These include NF-kB, AP-1, NF-AT (nuclear factor of activated T- 
cells), CREB (cAMP response element binding protein), STATs (signal 
transducers and activators of transcription), Oct (octamer-binding transcription 
factor), IRF3 (interferon regulatory factor 3), and the T-cell specific transcription
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factor GATA-3 (Refojo, Liberman et al. 2001 ? Gottlicher, Heck et al. 1998, De 
Bosscher, Haegeman 2009). Important genes repressed by GCs include 
cytokines, chemokines, p27^ c-Myc, and hexokinase (Kfir-Erenfeld, Sionov et al. 
2010).
1.6.2 NF-kB
NF-kB and AP-1 warrant particular interest in the context of GCs due to a well- 
reported antagonism with the GR (De Bosscher, Vanden Berghe et al. 2003). 
However, in a study of CLL cells neither baseline nor prednisolone-induced 
changes in AP-1 promoter binding capacity of AP-1 correlated with GC 
sensitivity (Bailey, Hall et al. 2001). There is conflicting evidence regarding 
whether GR-NF-kB antagonism is critical for GC-induced killing. For example, 
expression of a GR mutant in the Jurkat T-cell line that could transrepress but 
lacked transactivation function killed as effectively as wild-type GR in response 
to GC (Sionov, Spokoini et al. 2008), suggesting that suppression of survival 
factors by GR can be sufficient to induce killing in some contexts. Contrastingly, 
in CEM lymphoblastic T-cells, transrepression has been shown to not be required 
for GC-induced death (Tao, Williams-Skipp et al. 2001). NF-kB activity is higher 
in unstimulated CLL cells than in normal B cells, and has been related to in vitro 
survival (Furman, Asgary et al. 2000, Hewamana, Alghazal et al. 2008). 
Furthermore, the NF-kB pathway inhibitors BAY11-7082 and Kamebakaurin 
have been shown to accelerate apoptosis in -70% of CLL cases, which did not 
involve changes in the expression of Bcl-2 or Mcl-1 (Pickering, de Mel et al. 
2007). Crucially, NF-kB has been shown to be downregulated in response to Dex 
in CLL cells (Furman, Asgary et al. 2000). Taken together the latter observations
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suggest both a key role for NF-kB in CLL cell survival, and a link between GCs 
and NF-kB.
The transcription factor NF-kB regulates many physiological processes, including 
immune regulation, inflammation, proliferation and apoptosis (Neumann, 
Naumann 2007). The NF-kB family of transcription factors is characterised by 
the 300 amino acid Rel homology domain (De Bosscher, Vanden Berghe et al. 
2000). In humans, there are five well characterised subunits of NF-kB: p65 (Rel- 
A), p50 (NF-kBI), p52 (NF-kB2), Rel-B, and c-Rel (Ghosh, May et al. 1998). 
p65:p50 heterodimers are the most common form in B lymphocytes, whilst p50 
homodimers, which lack classical transcription activation domains, can obstruct 
NF-KB-driven transactivation (Sen 2006). p65, p50, and c-Rel DNA binding has 
been consistently demonstrated in CLL, and p65 has been strongly linked with in 
vitro survival of CLL cells, as well as disease progression (Furman, Asgary et al. 
2000, Hewamana, Alghazal et al. 2008). Therefore, these Rel-famliy proteins can 
be considered the principle members of the family in CLL. A physical interaction 
between the GR and p65 and p50 has been demonstrated in vitro, though whilst 
p65 can reciprocally repress GR activity, both p50 and c-Rel cannot (Scheinman, 
Gualberto et al. 1995, Wissink, van Heerde et al. 1997).
NF-kB influences CLL survival by activation of cytokines, their receptors, 
chemotactic proteins, and adhesion molecules, as well as by direct transcription of 
survival-related targets (De Bosscher, Vanden Berghe et al. 2000). NF-kB 
signalling is highly complex, though some of its more notable pro-survival, 
growth and proliferation target genes include: Bcl-xl, Bcl-2A1, Bcl-2, c-FLIP, Bcl-
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w XIAPy c-IAPy c-MyCy c-Myb, Cyclins D1 and D2, and the cytokines IL-2, 1L-6, 
and CD40L (Horie, Watanabe et al. 2006, Vallabhapurapu, Karin 2009). NF-kB 
can inhibit the AP-1 antagonist JNK via the MAPK pathway (Papa, Zazzeroni et 
al. 2004), and can also suppress cytochrome-c release from mitochondria through 
activation of Bcl-2A1 in HT1080I cells (Wang, Guttridge et al. 1999).
1.6.3 Regulation of NF-kB activity
The central mechanism underlying NF-kB regulation is the signal-induced 
proteolytic degradation of the family of IkBs (Neumann, Naumann 2007). This 
mechanism, known as the canonical pathway of NF-kB activation, requires 
phosphorylation of IkB by IKKs (IkB kinases). This frees NF-kB from IkB 
sequestration and facilitates translocation of NF-kB to the nucleus where it can 
exert its effects on transcription (Pickering, de Mel et al. 2007). NF-kB is subject 
to an autoregulatory negative feedback loop as it activates the promoter of IkBu 
(De Bosscher, Vanden Berghe et al. 2003). Additionally, inhibitory post- 
translational modification, especially phosphorylation, of Rel subunits can also 
occur via the non-canonical pathway (Neumann, Naumann 2007). In normal B 
cells both the canonical and non-canonical pathways (Figure 1.5) operate (Sen 
2006). p65 and p50 are specifically activated by the canonical pathway. Further, 
p65 can also be selectively sequestered within the nucleolus, and dimer exchange 
has also been reported (Neumann, Naumann 2007).
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A. B.
Proteasomal
processing
Figure 1.4. A simplified schematic of the canonical and non-canonical 
pathways of NF-kB regulation in B lymphocytes (adapted from (Sen 2006)).
A. The canonical pathway can be activated by a number of extracellular stimuli, 
which activate IKKs that phosphorylate p65-bound IkBs. The p65/p50 
heterodimer is then released from cytoplasmic sequestration and translocates to 
the nucleus to elicit signalling alterations via transactivation and transrepression.
B. The non-canonical pathway selectively activates IKKct, which phosphorylates 
the precursor protein, pi00. Following processing into mature p52, the p52-Rel-B 
heterodimer forms and enters the nucleus.
NF-kB activation is downregulated during CLL cell culture, and so in vivo signals 
are strongly implicated in its regulation (Bernal, Pastore et al. 2001, Furman, 
Asgary et al. 2000). NF-kB is subject to phosphoregulation by various pathways, 
including p38, ERK, JNK, PKA, PKC, PI3-K, and Ras, which can affect 
localisation, dimerisation, translocation, DNA binding, stability, transactivation, 
and cofactor recruitment (De Bosscher, Vanden Berghe et al. 2003). BCR
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stimulation and Akt activation increases NF-kB pro-survival activity via IkB 
degradation (Barragan, Bellosillo et al. 2002). NF-kB activity in CLL is also 
modulated by a variety of cytokines. Most CLL cells express CD40, which can be 
activated by CD40-ligand (CD 154) via cell-cell contact. CD 154 signalling 
augments NF-kB activation (Furman, Asgary et al. 2000). BAFF (B-cell 
activating factor) has also been shown to increase NF-kB activity (Barragan, 
Bellosillo et al. 2002, Claudio, Brown et al. 2002). Notch receptor and ligand 
expression is involved in survival and apoptosis resistance in CLL cells, and is 
associated with increased NF-kB activity, along with C-IAP2 and XIAP 
expression (Rosati, Sabatini et al. 2009). Downstream, GSK-3p prevents 
epigenetic silencing of NF-icB-mediated gene transcription and thus maintains cell 
viability and prosurvival Bcl-2 and XIAP expression in CLL cells, (Ougolkov, 
Bone et al. 2007).
1.6.4 GR-mediated-transrepression of NF-kB
A number of research groups have demonstrated a direct physical association 
between GR and p65 in vitro, and in vivo (Scheinman, Gualberto et al. 1995, 
Nissen, Yamamoto 2000, Ray, Zhang et al. 1995, Adcock, Nasuhara et al. 
1999)(De Bosscher, Vanden Berghe et al. 2003). Several models have been 
proposed to describe the interaction of GR and NF-kB. These include: 
competition for shared promoters; mutual masking of transactivation domains; 
induction of post-translational modifications; and competition for limited 
coactivator proteins (De Bosscher, Vanden Berghe et al. 2003, Greenstein, Ghias 
et al. 2002). The latter mechanism is not strongly supported in the case of 
transrepression, and smuggles with a lack of specificity (De Bosscher, Vanden
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Berghe et al. 2001, Sheppard, Phelps et al. 1998). There is also evidence of 
tethering, in which activated GR blocks recruitment of the basal transcription 
machinery (Nissen, Yamamoto 2000). In ALL cells the NF-kB antagonist tumour 
necrosis factor a-induced protein 3 (TNFAIP3) has been shown to be upregulated 
by GCs (Tissing, den Boer et al. 2007). GCs have also been reported to induce 
IkBol synthesis (Auphan, DiDonato et al. 1995, Scheimnan, Cogswell et al. 1995) 
and thus downregulate NF-kB indirectly, though this observation was highly cell- 
type dependent. Contrastingly, in the presence of the protein synthesis inhibitor 
cycloheximide GCs have still been shown to inhibit NF-kB in some cell types (De 
Bosscher, Schmitz et al. 1997, Wissink, van Heerde et al. 1998), and GC 
analogues exist that upregulate IkBoi but do not inhibit NF-kB activity (Heck, 
Bender et al. 1997). Taken together the latter two observations support a 
mechanism involving a more direct relationship between the GR and NF-kB.
1.6.5 GILZ
The GR can influence NF-kB by inducing GILZ (D'Adamio, Zollo et al. 1997). 
The human GILZ promoter has 6 GREs. GILZ has been demonstrated to interfere 
with NF-kB-mediated transcription in T cells, and to participate in GC-induced 
thymocyte apoptosis (Ayroldi, Migliorati et al. 2001)(Delfino, Agostini et al. 
2004). Furthermore, in mesenchymal stem cells, GILZ is able to block NF-kB 
nuclear translocation (Yang, Zhang et al. 2008). It is expressed in resting B 
lymphocytes, within which it is downregulated when they are activated (Glynne, 
Ghandour et al. 2000). GILZ is characterised by a leucine zipper domain, which 
is a well-conserved protein motif that acts as a DNA-binding site. There are four 
main isoforms that vary in expression between cell types (Soundararajan, Wang et
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al. 2007). GILZ can modulate a variety of cellular functions, including sodium 
channel activity and proliferation (Soundararajan, Wang et al. 2007). For 
instance, in mouse T cells, GILZ diminishes the activity of Ras and Raf targets, 
including ERK1/2 and Akt. Silencing of GILZ in these cells inhibited 
antiproliferative effects of GC (Ayroldi, Zollo et al. 2007). GILZ regulation has 
implications for broader survival signalling. It can suppress MKP-1 activity, 
which in turn can suppress the MAPKs p38 MAP-kinase, ERK, and JNK. 
Furthermore, GILZ has been shown to prevent binding of AP-1 to its target DNA 
and can inhibit activation-induced events in Jurkat T cells (Mittelstadt, Ashwell 
2001). GILZ has also been reported to promote nuclear exclusion of the Foxo3, 
which can inhibit Bim and p27 upregulation (Latre de Late, Pepin et al. 2010). As 
well as being induced by the GR, GILZ can be regulated by PI3-kinase/AKT 
signalling, which contributes to GILZ induction in MM cells (Grugan, Ma et al. 
2008).
1.6.6 The kinome
GR receptor stability, localisation, interactions and transcriptional targets can be 
regulated by kinase activity (Section 1.5.6). Furthermore, GC treatment can lead 
to phosphorylation of the GR by MAPKs, GSK, and CDKs (Sionov, Spokoini et 
al. 2008)(Kassel, Sancono et al. 2001). Protein kinases, including MEK/ERK, 
PI3-K/Akt and m-TOR, can antagonise GC-induced apoptosis of haematopoietic 
cells, (Miller, Garza et al. 2007).
The mitogen-activated protein kinases, ERK, JNK, and p38 phosphorylate and 
activate transcription factors that promote proliferation and inflammation, such as
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NF-kB and AP-1 (Clark, Lasa 2003) (Section 1.6.2), via parallel kinase cascades. 
Opposingly, GR activation is predominantly anti-inflammatory (Rogatsky, Logan 
et al. 1998). Of the three pathways, ERK usually provides pro-survival signals, 
whilst JNK and p38 favour apoptosis (Xia, Dickens et al. 1995). ERK, p38, and 
JNK are inactivated via GC-mediated upregulation of MAPK phosphatase-1 
(MKP-1) in many cell types (Abraham, Clark 2006, Horsch, de Wet et al. 2007). 
As GILZ can be upregulated by GCs (Section 1.6.5), and can mediate ERK 
signalling in this context (Ayroldi, Zollo et al. 2007), induction of the GILZ and 
MKP-1 genes provides a mechanism by which GCs can modulate all three of the 
major MAPK pathways. Bim induction (Section 1.7) by GC in an ALL cell line 
has been shown to depend on the activation of p38 MAP kinase (Lu, Quearry et 
al. 2006), which may be attributable to Foxo3a activation (Cai, Xia 2008). 
However, p38 inhibition has been shown to not affect GC-induced apoptosis of 
highly GC sensitive thymocytes and thymic lymphoma cells (Spokoini, Kfir- 
Erenfeld et al. 2010).
GSK3 has been shown to play a role in GC-induced apoptosis in an MM cell line 
as well as in T cells (Spokoini, Kfir-Erenfeld et al. 2010). GSK3 is a 
serine/threonine kinase that acts on a variety of susbstrates including metabolic 
enzymes and transcription factors, including NF-kB. It has two main isoforms; a 
and p. Unlike most kinases it is active in resting cells (Galliher-Beckley, 
Williams et al. 2008). Several other kinases inhibit GSK, including Akt protein 
kinase, cAMP-dependent protein kinase A (PKA), and serum and GC-induced 
kinase SGK1 (Kfir-Erenfeld, Sionov et al. 2010). Phosphorylation of Sei’404 of the 
GR by active GSK3P can protect against Dex killing in U-2 osteoblast cells, in
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part due to retention of the GR in the cytosol (Galliher-Beckley, Williams et al. 
2008). In a T cell line, GC has been shown to increase GSK3p activity via 
phosphorylation of Ser9 (Spokoini, Kfir-Erenfeld et al. 2010). GC has been 
demonstrated to displace GSK3a from the GR in GC-sensitive thymocytes and 
thymic lymphoma cells, leading to GSK3a/[3 inhibition of Bim and GC-induced 
killing (Spokoini, Kfir-Erenfeld et al. 2010). Conversely, GSK3 inhibition 
prevents GC-mediated Bim upregulation in follicular lymphoma cells (Nuutinen, 
Ropponen et al. 2009).
PI3-K can also play a role in GC sensitivity of lymphoid cells (Section 1.2.3). For 
instance, inhibition of PI3-K but not that of ERK or PKC8 can enhance Dex- 
induced apoptosis in Follicular Lymphoma cells (Nuutinen, Postila et al. 2006). 
PI3-K activation has been shown to prevent downregulation of the downstream 
pro-survival proteins: Bcl-xl, FLIPL, and XIAP (Cuni, Perez-Aciego et al. 2004), 
The PK (protein kinase) family has also been reported to be involved in GC- 
induced killing of lymphoid cells. Calcium-independent PKC activation has been 
shown to be involved in GC-induced apoptosis of thymocytes (Asada, Zhao et al. 
1998), whilst in CLL PKA has been demonstrated to be required for GC-induced 
apoptosis by modulating GR-mediated signal transduction (Tiwari, Dong et al. 
2005). Moreover, in CLL cells inhibition of PI3-K or PKC has been shown to 
increase Dex-induced apoptosis in the presence of survival factors (Barragan, 
Bellosillo et al. 2002). GC action has been linked to interaction with the 
activating T-cell receptor-associated Src-family kinases, including Lck, Lyk, and 
Fyn in T cells (Ghosh, Baatar et al. 2009, Lowenberg, Tuynman et al. 2005), 
which have been shown to antagonise GC-induced killing (Iwata, Hanaoka et al.
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1991). Though predominantly a kinase of T cell origin, Lck mRNA expression 
has been positively correlated with Dex resistance in CLL cells, and its inhibition 
has been shown to enhance GC sensitivity of CLL cells (Harr, Caimi et al. 2010).
CDK- and MAPK-mediated phosphorylation of the GR exert opposing effects on 
transcriptional activity. Thus, pathways affecting cell proliferation can affect the 
response to GCs. In support of this idea, Gq/Gj arrested ALL cells show increased 
sensitivity to GCs (Obexer, Hagenbuchner et al. 2009). GCs have been shown to 
act upon various regulators of cell cycle progression. For instance, CDK2 is 
crucial for GC-induced apoptosis of thymocytes (Frankfurt, Rosen 2004). 
Downregulation of c-Myc accompanies apoptosis by GCs in CEM-C7 cells, and 
sustained expression of c-Myc provides protection against GC-induced killing 
(Thompson 1998). Contrastingly, cyclin D3 and c-Myc have been shown to 
induce cell cycle arrest but not apoptosis in CCRF-CEM lymphoblastic leukaemia 
cells (Ausserlechner, Obexer et al. 2004). The proteasome is a protease complex 
located in the cytoplasm and nucleus that degrades polyubiquitinylated proteins 
(Ciechanover 1994). The proteasome has been implicated in GC-induced killing 
by proteasome inhibition experiments (Vugmeyster, Borodovsky et al. 2002). 
Recognized targets of the proteasome include transcription factors that regulate 
genes necessary for cell proliferation (c-Fos), enzymes whose activity is crucial 
for cell proliferation {ornithine decarboxylase), and cell cycle regulatory proteins 
(p27Kip}) (Frankfurt, Rosen 2004). Thus, the proteasome may influence GC- 
induced killing via effects at the level of cell-cycle regulation.
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1.6.7 Inhibitor of apoptosis proteins (lAPs)
NF-kB has been shown to transactivate the antiapoptotic lAPs. lAPs are involved 
in cell division, apoptosis, or survival pathways (LaCasse, Mahoney et al. 2008). 
lAPs have been shown to inhibit caspases-3, -7, and -9 (Salvesen, Duckett 2002), 
and thus modulate apoptosis. SMAC/Diablo physically inhibits lAPs following 
mitochondrial perturbation (Du, Fang et al. 2000), and lAPs are able to catalyse 
their own ubiquitination for degradation by the proteasome (Yang, Fang et al. 
2000). lAPs are potentially relevant to this study as they are elevated in CLL 
relative to other leukaemias and lymphomas (Schattner 2002). It has also been 
shown that c~IAP2 and XIAP, as well as BcI-2 are elevated at mRNA level by 
more than one fold in CLL relative to a panel of lymphoid malignancies (de 
Graaf, van Krieken et al. 2005). Moreover, the IAP family of proteins can 
suppress apoptosis induced by a range of triggers, including GCs, and 
overexpression of XIAP can lead to an accumulation of apoptotic resistant 
immature T cells (Conte, Liston et al. 2001). The main role of lAPs in 
suppression of apoptosis is to antagonise the extrinsic death receptor pathway. 
This pathway depends on caspases for the initiation of apoptosis. Despite the less 
essential role of caspases in the intrinsic pathway, IAP activity may impact upon 
killing via this pathway. lAPs inhibit the activation of effector caspases, have 
been correlated with poor prognosis, and show elevated expression in 
haematological malignancies (Fulda 2009). XIAP is the most strongly supported 
member of the family as possessing marked anti-caspase activity (Eckelman, 
Salvesen et al. 2006).
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1.6.8 Cytokines
Cytokine signalling affects survival, as well as differentiation and proliferation. 
Most cytokines signal through the Jak-STAT pathway, which is dependent upon 
cytokine binding to cell surface receptors, activation of STAT proteins, and 
alterations in target genes (Rogatsky, Ivashkiv 2006). STAT proteins act in 
concert with other transcription factors and cofactors, which can both up- and 
downregulate their activity. There is evidence of an interaction of pro- 
inflammatory STATs with the anti-inflammatory GR (Rogatsky, Ivashkiv 2006). 
Several cytokines have been shown to counteract GC-induced killing, including 
those expressed by thymic epithelial cells (Gao, Kinoshita et al. 1996). IL-6 and 
IFN-a inhibit GC-induced apoptosis in myeloma cells (Ferlin-Bezombes, Jourdan 
et al. 1998, Chauhan, Pandey et al. 1997). Also, IL-6, IL-4, and IL-9 have been 
shown to inhibit GC-induced killing of thymocytes (Van Snick, Houssiau et al. 
1996, Bauer, Liu et al. 1998). IL-15 inhibits GC-induced apoptosis in activated B 
cells (Bulfone-Paus, Ungureanu et al. 1997). a-IFN, IL-4, and IFN-y can inhibit 
GC-induced DNA fragmentation in CLL cells (Panayiotidis, Ganeshaguru et al. 
1994), and IL-4 can protect CLL cells from steroid-induced apoptosis (Mainou- 
Fowler, Prentice 1996). SOCS1, the suppressor of cytokine signalling, is 
suggested to act as an early mediator of the cross-talk between GC and cytokine 
signalling (Haffner, Jurgeit et al. 2008), whilst STAT-3 has been shown to be a 
coactivator of GR transactivation (Zhang, Jones et al. 1997). Cytokine rescue 
from GC-induced apoptosis in T-cells is mediated through inhibition of IkBu 
expression (Xie, Seward et al. 1997).
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1.7 Glucocorticoids and the apoptotic balance
1.7.1 Core mechanism of the intrinsic apoptosis pathway
Apoptosis (Section 1.4.3) plays a critical role in the killing of malignant cells by 
chemotherapy and radiation, particularly in lymphoid cells (Johnstone, Ruefli et 
al. 2002, Cory, Adams 2002). The BH3-only subgroup of proteins of the Bcl-2 
family particularly stands out as being important in apoptosis due to its 
universality (Huang, Strasser 2000). BH3-only proteins are transcriptionally 
activated, post-translationally modified (particularly by phosporylation), or 
released from sequestration in response to death stimuli (Puthalakath, Strasser 
2002). Bcl-2 family proteins have distinct binding partners (Chen, Willis et al. 
2005). Unsurprisingly, proapoptotic family members with restricted targets are 
weaker killers. The proapoptotic BH3-only Bim and Puma have been shown to 
potently engage all antiapoptotic members (Chen, Willis et al. 2005), emphasising 
their importance in particular.
The primary model of intrinsic apoptosis activation involves proapoptotic 
members of the family binding and antagonising antiapoptotic members (Certo, 
Del Gaizo Moore et al. 2006), which leads to indirect activation of the effector 
proteins Bax and/or Bak (Danial, Korsmeyer 2004) (Figure 1.5). In response to 
death and damage signals, sensitiser BH3-only proteins inhibit antiapoptotic 
proteins, thus preventing their repression of activator BH3-only proteins, and 
multi-domain proapoptotic proteins. Activator proteins can also repress multi- 
domain antiapoptotic proteins. As well as the direct activation model, an indirect 
Bax/Bak activation model has been supported by cell free studies, whereby Bax
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and Bak are bound and activated directly by proapoptotic proteins (Kuwana, 
Bouchier-Hayes et al. 2005). Following Bax/Bak activation, pores are formed in 
the outer mitochondrial membrane resulting in mitochondrial depolarisation and 
release of cytochrome c and Smac/DIABLO, and caspase activation (Danial, 
Korsmeyer 2004) (Section 1.4.3). BH3-only profiling studies have been 
particularly illuminating in the field of Bcl-2 family research. This method has 
been used to determine cellular dependence on specific antiapoptotic proteins, by 
measuring the pattern of mitochondrial sensitivity to a panel of peptides derived 
from the BH3 domains of the BH3-only proteins (Certo, Del Gaizo Moore et al. 
2006).
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Death and damage signals
Widespread 
proteolysis 
cell death
Figure 1.5. The mitochondrial cell death pathway (Adapted from (Del Gaizo 
Moore, Brown et al. 2007). Bad, Bik, Noxa, Bmf, Hrk, and PUMA are sensitiser 
BH3-only proteins. Bid and Bim are activators, whilst Bax and Bak are 
executioners. Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and Bcl2-Al (Bfl-1) are antiapoptotic.
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1.7.2 Apoptotic proteins in CLL
In CLL cells the expression of the BCL-2 gene family is shifted towards 
protection from apoptosis, as Bcl-2 members are frequently overexpressed in 
leukaemic cells (Gottardi, Alfarano et ah 1996)(Ploner, Schmidt et al. 2005). The 
sensitiser BH3-only proteins Bmf and Noxa, as well as the antiapoptotic Bcl-2 are 
elevated in CLL cells (Mackus, Kater et al. 2005). In a prominent study of 58 
CLL patient samples, the expression of apoptosis-regulating proteins was 
measured and compared with in-vivo and in-vitro response to chemotherapy 
(Kitada, Andersen et al. 1998). Several Bcl-2 family proteins, including Bcl-2, 
Bcl-xl, Mcl-1, Bax and Bak, BAD, BAG-1 Caspase-3 were evaluated. Of note, 
Bcl-2, Mcl-1, BAG-1, Bax, Bak, and Caspase-3 were commonly expressed in 
circulating CLL cells, whilst Bcl-xl, and Bad proteins were not. Failure to 
achieve complete remission was linked to Mcl-1 overexpression, which 
emphasises the importance of this antiapoptotic protein. The identification of 
BAG-1 as being partially associated with failure to achieve complete remission is 
interesting in the context of GC response as it is a GR-chaperone that modulates 
GR function (Schmidt, Wochnik et al. 2003).
1.7.3 Bcl-2 family members and GCs
Induction of proapoptotic Bcl-2 family proteins and repression of their 
antiapoptotic counterparts has been observed in response to GCs. Prednisone 
treatment has been shown to induce a decrease in Bcl-2 and Bcl-xl levels in ~50% 
of primary ALL cells, with Bax upregulation detected in 14/21 samples (Casale, 
Addeo et al. 2003). A later systematic analysis of Bcl-2 family expression, GC 
regulation, and function of Bcl-2 molecules in primary ALL lymphoblasts has
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been performed (Ploner, Rainer et al. 2008). The prominent effects that were 
observed were Bmf and Bim induction, and repression of Noxa; the repression of 
the latter has since been shown to impair GC sensitivity (Ploner, Rainer et al. 
2009). Within these investigations, knockdowns within CCRF-CEM cells 
emphasised the importance of Bim, and to a lesser extent Bmf, to GC-regulated 
apoptosis. Antiapoptotic proteins were not regulated consistently by GCs, with 
overexpression and knockdowns leading only to delayed death onset. Single 
knock-outs of proapoptotic Bim (Bouillet, Metcalf et al. 1999), and Puma or Noxa 
(Villunger, Michalak et al. 2003) show some resistance to GC treatment.
Further evidence supports a role for Bim as a mediator of GC cytotoxicity. In 
Dex-treated ALL cells, changes in the expression of Bim, as well as targets of c- 
Myc and NF-kB have been detected (Wang, Malone et al. 2003a). Bim mRNA 
and protein corresponding to all 3 major isoforms of Bim were induced over 24h 
in ALL cells, preceding the onset of death, and this finding was developed by 
immunoblotting in CEM-C7 cells and murine thymocytes. Further to this, a panel 
of B-ALL cell lines showed Bim protein induction to correlate with GC 
sensitivity, and siRNA knockdown of Bim expression was related to increased 
cell survival (Abrams, Robertson et al. 2004). Bim shRNA dramatically inhibited 
Dex-induced apoptosis in another study using a T-ALL cell line (Lu, Quearry et 
al. 2006). A compelling series of experiments underlined Bim as possessing 
particular relevance in GC-induced killing of CLL cells (Iglesias-Serret, de Frias 
et al. 2007). The effect of lOmM Dex (24h) on the mRNA expression of a series 
of death-specific proteins in 9 CLL patient samples was studied. This covered 
BH3-only and Bax-like proapoptotic proteins, Bcl-2-like antiapoptotic proteins,
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IAP family proteins, and others. Bim expression almost doubled, whilst Bad, Bmf, 
and Noxa were unchanged. Mcl~l and HIAP1 were repressed by approximately a 
quarter, and FLIP expression approximately doubled. Thus, Bim and FLIP 
induction were particularly prominent. As FLIP is an apoptosis-suppressing 
protein that blocks early events in TRAIL/TNF family death receptor signalling it 
is unlikely to play an important role in GC-induced killing.
Puma as well as Bim, but not Noxa, has been shown to contribute substantially to 
Dex-induced killing of lymphocytes of a BCL-2 transgenic mouse (Erlacher, 
Michalak et al. 2005). Puma had previously been shown to be induced by Dex in 
thymocytes (Han, Flemington et al. 2001), and Puma deficiency can partially 
protect thymocytes from GC-induced killing (Villunger, Michalak et al. 2003). 
Further to these findings, the CDK inhibitor CDKN2A has been shown to 
sensitise T-ALL cells to FAS and GC-induced killing via Puma induction and 
Mcl-l/Bcl-2 repression. Despite this evidence. Puma is not upregulated in pre-B 
cells in response to Dex, whilst Bim is (Erlacher, Michalak et al. 2005). 
Similarly, GC does not upregulate Puma in mouse ALL xenografts (Xu, Wang et 
al. 2006).
Data supporting an important role for Bmf in GC-induced killing is limited. Bmf 
is a BH3-only Bcl-2 family member that is normally sequestered to myosin V 
motors by binding to the dynein light chain (DLC) 2. Certain damage signals lead 
to Bmf release and Bcl-2 antagonism. Loss of Bmf in mice can protect a range of 
B-lymphocytes against GC-induced killing (Labi, Erlacher et al. 2008). 
Furthermore, Bmf -/- mice develop B-cell lymphadenopathy. A further member
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of the Bcl-2 family that is not strongly supported as being important in GO 
induced killing is Bad. However, Bad induction has been shown to occur in 
thymocytes in response to GCs (Mok, Gil-Gomez et al. 1999). Also, as Bad is 
held in its inactive phosphorylated state by a 14-3-3 protein (Wang, Pathan et al. 
1999), GR sequestration of the chaperone (Kino, Souvatzoglou et al. 2003) could 
hypothetically free Bad to facilitate downstream death signalling.
1.7.4 Bim
Human Bim is encoded by the BIM gene on chromosome 2ql2-13 and consists of 
6 exons including a non-translated exon. More than 18 isoforms have been 
reported in human cells (Adachi, Zhao et al. 2005). The three major isoforms— 
Bim-EL, Bim-L, and Bim-S (Figure 1.6)—are consistently observed in 
haematopoietic cells, including CLL (Kfir-Erenfeld, Sionov et al. 2010). Bim-S is 
the most potent isoform (O'Connor, Strasser et al. 1998), probably by virtue of its 
lack of post-translationally modifiable domains. Bim has an important role in 
haematopoietic cell homeostasis and responses to a wide variety of 
chemotherapeutic drugs, and can be upregulated in response to cellular* stress, UV, 
and growth factor withdrawal (Bouillet, Metcalf et al. 1999). Furthermore, Bim- 
deficient granulocytes are resistant to spontaneous death in culture, and mice 
lacking Bim contain strikingly high numbers of leukocytes (Bouillet, Metcalf et 
al. 1999). Bim has also been shown to be critical in BCR-driven B cell apoptosis 
(Enders, Bouillet et al. 2003).
Bim-induced killing has been reported to involve antagonism of prosurvival Bim 
binding partners, but also direct Bax activation. A recent study using mice with
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mutated Bim BH3 domains (Merino, Giam et al. 2009) supported this direct 
activation model. However, other groups have previously suggested that the 
direct activation model is invalid (Ewings, Wiggins et al. 2007). Bim-AD (a less 
well studied and less abundant isoform) and Bim-S can heterodimerise both with 
the death antagonists Bcl-2 and Bcl-xl, and with death-inducing Bax. Moreover, 
by studying a mutated version of Bim-AD that can bind Bax but not Bcl-2, it has 
been shown that Bim can directly activate Bax-mediated cell death (Marani, 
Tenev et al. 2002). With respect to the other isoforms of Bim, an indirect 
activation model is better supported whereby Bim displaces Bcl-2 family proteins 
from Bax and Bak, which leads to oligomerisation of Bax and Bak, and pore 
formation. A further less well supported model of proapoptotic Bim signalling 
purports that Bim translocation to the ER mediates ER stress signalling 
(Morishima, Nakanishi et al. 2004).
DLC1 Hydrophobic
ERK1/2 JNK BH3 Tall ERK1/2-
.....A. w A %,.....A ^ % dependant
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Figure 1.6 The three major Bim isoforms of CLL cells (Adapted from (Ley, 
Ewings et al. 2005)). The structure of some of the proteins arising from 
alternative splicing of Bim transcript is shown, with the BH3-only domain and the 
hydrophobic C-terminal highlighted. Bim-S is encoded by exons 2, 5 and 6. 
Bim-L is encoded by exons 2, 4, 5 and 6. Exon 4 includes a binding site for 
DLC1, and JNK phosphorylation sites, including Thr56 in Bim-L. Bim-EL is
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encoded by exons 2, 3, 4, 5 and 6. Exon 3 includes an ERK1/2 docking domain 
(FSF) and ERK1/2 phosphorylation sites, including Sei*69. ERK1/2-dependent 
phosphorylation of Bim-EL targets it for proteasomal degradation and may 
prevent binding to Bax. The numbers below the Bim-EL figure represent the 
different exons.
1.7.5 Bim Regulation
In several studies involving intact cells, Bim mRNA is regulated by survival 
signals that act through Forkhead and Akt transcription factors. In thymocytes 
Bim mRNA can be induced as early as 30 minutes in response to GCs (Zhao, Li et 
al. 2007). New protein synthesis has been shown to be required for Bim mRNA 
upregulation (Abrams, Robertson et al. 2004), but other evidence suggests that 
protein synthesis is not required (Lu, Quearry et al. 2006). Despite the 
observation that Bim protein levels increase during spontaneous apoptosis in CLL 
cells (Iglesias-Serret, de Frias et al. 2007), mRNA levels do not appear to. The 
Bim promoter does not contain a classical GRE, However, signalling upstream of 
Bim can be directed by GCs, resulting in both transcriptional and post-translation 
control. Foxo3a/FKHRLl, RUNX3, and E2F1 (ER stress detector) are suggested 
to mediate Bim upregulation (Dijkers, Medema et al. 2000, Zhao, Tan et al. 2005, 
Yamamura, Lee et al. 2006). Foxo transcription factors, especially Foxo3a, have 
been shown to regulate Bim in various cell types (Sunters, Fernandez de Mattos et 
al. 2003, Urbich, Knau et al. 2005, Gilley, Coffer et al. 2003, Stahl, Dijkers et al. 
2002). Importantly, siRNA knockdown of Foxo3a can significantly reduce GC- 
induced apoptosis in lymphocytes (Ma, Xie et al. 2008). Interestingly, Bim 
induction by GC in an ALL cell line has been shown to depend on the activation 
of p38 MAP kinase (Lu, Quearry et al. 2006).
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Mere upregulation of Bim is insufficient for apoptosis in T lymphoma cells (Kfir, 
Sionov et al. 2007), and possibly other lymphoid cell types. Despite this finding it 
is unclear how GCs might activate Bim, though various post-translational 
modifications have been observed (Figure 1.6). Bim is expressed in healthy cells 
where Bim-EL and Bim-L can be maintained in an inactive form by binding to 
microtubules (Puthalakath, Huang et al. 1999). Release of Bim-EL and Bim-L 
from cytoskeletal sequestration and relief of ERK phosphorylation of Bim-EL can 
facilitate Bim activation (Puthalakath, Huang et al. 1999, Ley, Balmanno et al. 
2003). More specifically, Bim-EL protein is targeted for ubitquitinylation and 
proteasomal degradation by ERK phosphorylation of Bim Ser69 (Fukazawa, 
Noguchi et al. 2004). This Bim phosphorylation may also impair interactions 
between Bim and Bax to prevent the oligomerisation of Bax (Ley, Ewings et al. 
2005, Marani, Hancock et al. 2004). Bim release from microtubules takes place 
in the absence of caspase activation, and so is not simply a mechanism of 
apoptotic amplification (Puthalakath, Strasser 2002). Bim protein can be 
modulated by both survival signals and the proteasome (Iglesias-Serret, de Frias et 
al. 2007). Phosphorylation of Bim-L by JNK can prevent Bim sequestration by 
dynein (Ley, Ewings et al. 2005), whilst phosphorylation of Bim-EL has also been 
shown to release the apoptotic protein from microtubules, and induce apoptosis 
via p38-mediated Seres phosphorylation (Chen, Zhou 2004, Cai, Chang et al. 
2006). p38 is required for GC-induced Bim upregulation in CEM T-ALL cells 
(Lu, Quearry et al. 2006) (Section 1.6.6). GSK3 may be responsible for Bim 
activation through a direct interaction (Spokoini, Kflr-Erenfeld et al. 
2010)(Section 1.6.6).
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As well as ERK, RACK1 (Receptor for Activated C-Kinase 1) and SOCS 
(Suppressor of Cytokine Signalling) have been shown to ubiquitinylate Bim-EL 
for degradation upon paclitaxel treatment of breast cancer cells, whilst GrblO (an 
insulin receptor-binding protein) has been shown to inhibit Bim-L by 
phosphorylation in I-IEK294 cells (Zhang, Cheng et al. 2008, Hu, Zhang et al. 
2010). Bim-EL is predominantly serine phosphorylated in murine lymphoma 
lymphocytes and thymocytes, which has been reported to prevent Bim-induced 
apoptosis (Seward, von Haller et al. 2003). Downstream of apoptosis induction, 
Bim-EL can be cleaved by caspases to yield a hyperactive form, with higher 
affinity for Bcl-2, leading to amplification of apoptotic signals (Chen, Zhou 
2004).
1.7.6 Bim antagonists
A compelling study of Bim binding partners showed that Mcl-2, Bcl-XL, and Bcl- 
2 are pulled down with all three major Bim isoforms in co-inununoprecipitation 
experiments using human B cells (Gomez-Bougie, Bataille et al. 2005). DLC8 
was found to associate only weakly with Bim-EL and Bim-L. Furthermore, 
subcellular fractionation showed predominant localisation of Bim and Bim 
supressors to the mitochondrial fraction. The Mcl-l/Bim complex was the most 
abundant of the three dominant complexes. ABT-737, a BH3-only mimetic, is a 
potent killer of CLL cells, and can displace proapoptotic proteins from Bcl-2, Bcl- 
xl, and Bcl-w (Certo, Del Gaizo Moore et al. 2006), but not from Mcl-1 or Bcl- 
2A1 (Oltersdorf, Elmore et al. 2005, van Delft, Wei et al. 2006). BH3-only 
profiling (Section 1.7.1) uncovered the importance of Bcl-2 sequestration of Bim 
in CLL survival (Del Gaizo Moore, Brown et al. 2007). In this study, ABT-737
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antagonism was shown to be likely the result of Bim displacement from the Bel- 
2/Bim complex. Moreover, a further study has shown that co-incubation of CLL 
samples with Dex and ABT-737 can sensitise CLL samples to the BH-3 only 
mimetic (Mason, Khaw et al. 2009). However, this could not be predicted by 
responses to either agent alone. This relationship between Bim and Bcl-2 is 
further supported by evidence that the two proteins can mutually effect the 
expression of each other. In T cells, absence of Bim causes a drop in Bcl-2 
protein levels, whilst Bcl-2 overexpression leads to an increase in both Bim 
mRNA and protein (Jorgensen, McKee et al. 2007).
Bcl-2 protein is consistently elevated in CLL relative to normal B cells and other 
lymphoid cells, though the level varies significantly between cases. 
Overexpression of Bcl-2 in human pre-B lymphocytes and myeloma cell lines can 
prevent apoptosis (Alnemri, Fernandes et al. 1992), and Bcl-2 knockout mice 
display accelerated apoptosis of thymocytes in response to GCs (Veis, Sorenson et 
al. 1993). Moreover, Bcl-2 mRNA and protein (48h) has been knocked down by 
antisense RNA, which correlated with increased apoptosis (Pepper, Thomas et al. 
1999b). Clinically, high levels of Bcl-2 have been associated with shorter overall 
survival in previously treated patients, and resistance to fludarabine treatment 
(Buggins, Pepper 2010). However, one study of ex vivo drug sensitivity of CLL 
samples showed that Bcl-2 expression did not associate with sensitivity at all 
(Bosanquet, Sturm et al. 2002). High Bcl-2 expression in CLL has been attributed 
to stimulation by IL-8 (Molica, Vitelli et al. 1999), nucleolin stabilisation of Bcl-2 
mRNA (Otake, Soundararajan et al. 2007), hypomethylation of the promoter 
region of the BCL2 gene (Hanada, Delia et al. 1993), and miR-15 and miR-16
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deletion or downregulation (Buggins, Pepper 2010). Bcl-2 has also been reported 
to be upregulated by the cytokines IFN-a/y and IL-l/IL-2, IL-4, and IL-6.
Mcl-1 confers GC resistance in various cell types (Lopez-Royuela, Balsas et al. 
2010, Wei, Twomey et al. 2006, Saffar, Dragon et al. 2008). Mcl-1 has also been 
implicated in drug resistance as it is strongly associated with failure to achieve a 
complete response to chlorambucil, fludarabine, and rituximab (Buggins, Pepper 
2010). Overexpression in transgenic mice predisposes to lymphomagenesis, and 
Mcl-1 is required for lymphoma and MM cell survival, as demonstrated by 
antisense ablation (Packham, Stevenson 2005). Mcl-1 expression is rapidly 
altered by transcription and protein stability by various environmental cues. It has 
a rapid turnover and can be targeted by ubiquitination for proteasomal 
degradation. During apoptosis, Mcl-1 is an efficient caspase substrate (Clohessy, 
Zhuang et al. 2004). Interestingly, caspase cleavage can turn Mcl-1 from a pro­
survival molecule to proapoptotic (Michels, Johnson et al. 2005). The 
proapoptotic Bak associates with Mcl-1 and Bcl-xl, but not Bcl-2, Bcl-w, or Al 
(Willis, Chen et al. 2005).
1.7.7 Bax and Bak
Bax is a cytosolic protein that translocates to the mitochondrion and undergoes a 
conformational change and oligomerisation as a critical activating step of 
apoptosis in CLL (Dewson, Snowden et al. 2003, Vogler, Dinsdale et al. 2008). 
Bak resides at the outer mitochondrial membrane (OMM) and is also activated by 
conformational change and oligomerisation. It has been shown that increased 
proteasomal degradation of Bax is a common feature of poor prognosis in CLL
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(Agrawal, Liu et al. 2008), which confirms the importance of this protein in CLL 
cell killing. Thymocytes from double knock-out mice lacking Bax and Bak are 
GC resistant (Rathmell, Lindsten et al. 2002). In ALL GCs do not significantly 
alter Bax or Bak expression (Bachmami, Gorman et al. 2007), but do lead to their 
activation (Rambal, Panaguiton et al. 2009, Laane, Panaretakis et al. 2007). 
Moreover, using fluorescence microscopy and Western blotting, a strong 
correlation has been observed between the number of Dex-induced apoptotic CLL 
cells and the percentage of cells stained with antibodies that recognise active Bax 
and Bak conformation (Bellosillo, Villamor et al. 2002), as well as the number of 
cells displaying Bax integration into the mitochondrial membrane. Therefore, 
Dex-induced apoptosis is associated with changes in intracellular localisation of 
Bax, and conformational changes of Bax and Bak in CLL. It was also shown that 
caspase inhibitors do not compromise this interaction, suggesting that this process 
occurs upstream of caspase activation.
In ALL cell lines, the Bax-Bcl-2 ratio has been positively correlated with Dex 
sensitivity (Salomons, Brady et al. 1997), and high Bcl-2-Bax ratios in CLL cells 
may predict a drug resistance phenotype (Pepper, Thomas et al. 1999a). Contrary 
to these findings, in one study of 39 CLL samples and 8 drugs, reduced Bax levels 
did not correlate with ex vivo resistance to purine analogs and corticosteroids 
(P>0.5), despite a correlation existing between Bax levels and traditional 
therapies; anthracyclines, alkylating agents and vincristine (all P<0.5). 
(Bosanquet, Sturm et al. 2002). Thus, this study supports the existence of distinct 
mechanisms of GC and purine analog action from those of alkylating agents, 
vinca-alkaloids, and anthracyclines.
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1.8 GCs and cellular distress
GCs can perturb homeostasis by transcription dependent and by non-transcription 
dependent mechanisms. The former includes regulation of genes involved in 
metabolism, oxygen radical control, calcium flux, or pH and volume control 
(Schmidt, Rainer et al. 2004). The latter includes rapid nongenomic effects, 
which have been shown to occur within minutes of GC exposure (Song, Buttgereit 
2006). These include a transient increase in calcium, alterations in redox status, 
elevation of intracellular hydrogen peroxide and other reactive oxygen species 
(ROS), lysosomal release of cathepsin B, and activation of sphingomyelinase with 
subsequent ceramide production (Spokoini, Kfir-Erenfeld et al. 2010). In T cells 
GC treatment can induce transient increases in cytosolic calcium concentrations 
and calmodulin activation, the release of protein kinases from the GR complex, 
release of cathepsin B form lysosomes, and activation of sphingomyelinase to 
produce ceramide and sphingosine (Cifone, Migliorati et al. 1999, McConkey, 
Hartzell et al. 1989, Wang, Muller et al. 2006, Lepine, Lakatos et al. 2004).
An important role for alterations in metabolism and cellular homeostasis in GC- 
mediated killing has previously been evidenced. Inhibitors of Ca2+ activated 
proteases have been shown to inhibit thymocyte GC-induced killing (Squier, 
Cohen 1997). Inositol triphosphate receptor (IP3R) is a Ca2+ channel that can 
facilitate loss of calcium homeostasis and thus induce death. Lymphocytes 
undergoing apoptosis in response to GCs have been found to display increased 
expression of inositol triphosphate receptor (IP3R) (Frankfurt, Rosen 2004), and 
IP3R-deficient T-cells have been shown to be resistant to GC-induced apoptosis. 
Sphingomyelin hydrolysis to produce ceramide and sphingosine occurs following
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cell membrane disruption and internalisation of sphingomyelin (Tepper, Ruurs et 
al. 2000), which facilitates blebbing and shedding of membrane vesicles. 
Ceramide can also potentiate the proapoptotic action of Bax (Pastorino, Tafani et 
al. 1999), and it can activate, the proapoptotic protein, Bad (Stoica, Movsesyan et 
al. 2003). Furthermore, ceramide can lead to release of cytochrome c and AIF (Di 
Paola, Zaccagnino et al. 2004). GCs can rapidly activate phosphatidyl-inositol- 
specific phospholipase C via PKC, and induce diacylglycerol generation, which is 
required for sphingomyelinase activation and ceramide production in thymocytes 
(Cifone, Migliorati et al. 1999). Hydorgen peroxide production, along with 
molecular oxygen, has been shown to contribute to GC-induced killing of 
thymocytes, (Tonomura, McLaughlin et al. 2003). Glutathione is an antioxidant 
that opposes the damaging effects of ROS, free radicals and peroxides. Dex 
resistance has been shown to correlate with an increase in glutathione level 
(Inoue, Takemura et al. 2002) in a pre-B cell line, and glutathione S-transferase 
expression has been associated with both T-ALL relapse and failure of GC to 
activate Bim and p38 in CCRF-CEM cells (Hosono, Kishi et al. 2010).
Other cellular effects of GCs that may be of importance to GC-induced killing 
include alterations in glucose metabolism, cell volume control, and direct 
mitochondrial interference by the GR. Prednisolone resistance can be modulated 
by inhibition of glycolysis in ALL cells (Hulleman, Kazemier et al. 2009). K+ 
(potassium ions) contributes to cell volume control, and thus its regulation is 
important to cell homeostasis. An inhibitor of K+ plasma membrane channels has 
been found to be an effective inhibitor of GC-induced apoptosis of thymocytes 
(Dallaporta, Marchetti et al. 1999). However, dysregulation of K+ is a
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consequence of the commitment to apoptosis, as a significant efflux of 
intracellular sodium and potassium occurs during apoptosis, which is thought to 
contribute to cell shrinkage. Contrastingly, inhibition of cation movement can 
actually inhibit apoptosis (Hughes, Bortner et al. 1997). Rapid and persistent 
translocation of the GR to mitochondria in GC-sensitive lymphoid cells in 
response to GC treatment has been observed (Sionov, Cohen et al. 2006, Talaber, 
Boldizsar et al. 2009). It has been suggested that steroid hormones can activate 
mitochondrial gene transcription (Demonacos, Karayanni et al. 1996, Scheller, 
Seibel et al. 2003), and an interaction of the GR with the redox-regulating 
thioredoxin has been reported (Psarra, Hermann et al. 2009). GR can also interact 
with the mitochondrial death-associated protein DAPS (Hulkko, Zilliacus 2002).
1.9 Thesis Purpose and Overall Strategy
The mechanism of GC-induced killing in CLL cells is relatively undefined and 
little is known about resistance. A summary of reported mechanisms of GC- 
induced killing of haematopoietic cells is shown in Figure 1.7. The working 
hypothesis of this thesis is that defective pro-death/anti-survival signalling in 
response to GC stimulation causes insensitivity of CLL cells to GC. Thus, the 
aims of this thesis were to understand why some samples respond to GC treatment 
while others do not, identify markers of resistance, and elucidate potential 
strategies for restoring sensitivity of CLL cells to GCs. To achieve these aims a 
panel of primary CLL samples were characterised for sensitivity to GC treatment, 
and the most and least responsive samples were compared and contrasted to 
establish at what point(s) death signalling mediated by the GC receptor was 
blocked in the resistant samples.
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Figure 1.7 Mechanisms of GC-induced killing of haematopoietic cells 
(adapted from (Kfir-Erenfeld, Sionov et al. 2010)). GR is bound to a heat shock 
complex in the cytosol in the absence of ligand. Upon ligand binding the GR 
heterocomplex undergoes molecular rearrangement, the GR is phosphorylated at 
several serine residues, and either undergoes dimerisation or first translocates to 
the nucleus. GR has been reported to translocate to the mitochondria as well as 
the nucleus of GC-sensitive lymphoid cells. In the nucleus, the GR 
transcriptionally activates and represses a range of targets. Bim is of particular 
importance for the initiation of apoptosis, and is indirectly upregulated by 
FoxG3a, which is dependent upon p38 activity. GSK3 can affect the efficacy of 
Bim by phosphorylation. Bim either directly activates Bax and Bak or 
antagonises antiapoptotic agonists of these apoptotic effector proteins. GR 
inhibits prosurvival and proinflammatory gene regulation by NF-kB and AP-1, 
and inhibits cell cycle progression via c-Myc, amongst other targets. GR also 
represses NF-kB at the cytoplasmic level by inducing GILZ and IkB. GILZ 
upregulation can increase Bim-EL expression via ERK inhibition.
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Chapter 2: Glucocorticoid-induced 
killing of CLL samples
2.1 Introduction
Though most CLL patients respond to first-line therapy relapse is inevitable, and 
not all achieve complete remission. As CLL progresses following initial therapy, 
the frequency of abnormal p53 function increases to nearly 50% of patients, 
possibly due to treatment driven mutation and subsequent clonal selection 
(Lozanski, Heerema et al. 2004). Those patients with deletion or mutation of 
TP53 at 17pl3q are very unlikely to respond well to chemotherapy (Grever, Lucas 
et al. 2007) (Section 1.1.3), however, alemtuzumab is effective in these patients, 
and recent data from the GCLLSG CLL2G trial (Stilgenbauer, Zenz 2010) 
suggests that combining alemtuzumab with GCs yields improved efficacy 
(Section 1.3.2). Furthermore, cells from patients with relapsed/refractory CLL 
and p53 aberrations have been demonstrated to be particularly sensitive to HDMP 
(Thornton, Hamblin et al. 1999, Thornton, Matutes et al. 2003). Despite the 
usefulness of GCs in such patients, some tumours simply do not respond to GCs 
(primary resistance), whilst others often develop resistance during therapy 
(secondary resistance) (Kaspers, Pieters et al. 1994, Moalli, Rosen 1994). 
Therefore, there is a pressing need to elucidate GC resistance mechanisms in 
CLL.
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“GC resistance” can be absolute or relative; apply to all or specific effects of GCs; 
occur at the level of the entire organism or affect a particular cell clone; can be 
specific or apply to all GCs; and be reversible or irreversible (Kofler, Schmidt et 
al 2003). For the purpose of this investigation, GC resistance will be defined as 
the relative in vitro insensitivity of primary CLL samples to specific GCs. In vitro 
sensitivity can be considered clinically relevant as patient treatment response has 
been previously shown to correlate with in vitro sensitivity of CLL samples to GC 
treatment (Bosanquet, McCami et al. 1995).
There is a substantial literature relating to the complexities of GC-induced killing 
of haematopoietic cells. This killing displays many hall-marks of apoptosis 
(Greenstein, Ghias et al. 2002) (Section 1.4.4), though alternative pathways of 
killing that can lead to a necrotic character have also been proposed (Schmidt, 
Rainer et al. 2004). Induction of proapoptotic BH3 proteins (Wang, Malone et al. 
2003a, Han, Flemington et al. 2001) and repression of their antiapoptotic 
counterparts (Chauhan, Auclair et al. 2002, Casale, Addeo et al. 2003) has been 
observed in response to GCs in various haematopoietic cell types (Section 1.7). 
Moreover, indicators of apoptosis have frequently been observed in CLL cells in 
response to GC treatment (Tiwari, Dong et al. 2005, Chandra, Gilbreath et al. 
1997, McConkey, Chandra 1999).
In vitro sensitivity of CLL cells to methylprednisolone has been shown to 
correlate with resistance to other drugs, such as fludarabine, cyclophosphamide,
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and anthracyclines (Bosanquet, McCann et al. 1995), and so GC-specific 
signalling defects may lead to resistance (Section 1.4.5). Alternatively, a multi- 
drug resistance mechanism may predispose GC resistance, as in vitro sensitivity 
of CLL cells to prednisolone and cyclosporin A has been shown to correlate 
(Kivekas, Vilpo et al. 2002) despite these agents acting via very different 
mechanisms. Furthermore, resistance to mitoxantrone (p53-dependent) has also 
been shown to exist concurrently with steroid resistance (p53-independent), as 
well as with that of vincristine (Bourgeois, Gruol et al. 1993).
Rai stage, IGHV status, TP53 deletion/mutation, and CD38 expression facilitate 
the designation of poor prognosis patients (Section 1.1.3), whilst treatment history 
can affect efficacy of future treatment. Prior treatment with chlorambucil has 
been shown to induce sensitivity to steroids (Bosanquet, McCann et al. 1995), and 
treatment of patients with anthracyclins can induce resistance to steroids (p53- 
independent) and platinums (p53-dependent) (Bosanquet, Bell 1996) (Section 
1.4.5). Patients that require treatment with GCs are those with disease refractory 
to or relapsed from frontline chemotherapies (Section 1.3.2). Such disease often, 
but not always, possesses aberrations in the p53 pathway (Pettitt, Matutes et al. 
2006). However, though p53 pathway aberration predicts for poor response to 
chemotherapy, it is not predictive of GC response (Thornton, Matutes et al. 2003). 
A previous study within this research group revealed a correlation between p53 
dysfunction and other poor prognosis indicators, including \3M~IGHV and 
expression of CD38 in CLL cells (Lin, Sherrington et al. 2002). Patients 
expressing UM-/GLTF tend to show signs of more aggressive disease and have a
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reduced survival compared to patients with (mutated) M-IGHV (Section 1.1.3). 
Furthermore, prednisolone resistance has been correlated with ^A-IGHV (Aleskog, 
Tobin et al. 2004).
Previous work from within this department has shown that CLL cells respond to 
varying degrees when treated with Dex in vitro. This GC is commonly used in the 
treatment of patients with lymphoproliferative disorders in continental Europe, 
and features regularly in the scientific literature discussed in Chapter 1. The 
primary aim of this chapter was to establish which CLL samples of a panel of 
over 50 samples were most sensitive and resistant to Dex, and to validate the 
methodology used to achieve this aim. This would allow selection of the most 
sensitive and resistant samples to be compared and contrasted.
85
2.2 Materials and Methods
2.2.1 CLL patients
All of the patient samples studied were from the University of Liverpool 
Leukaemia Bank. Samples are annotated with a range of clinical and laboratory 
data, including some important CLL biomarkers such as mutation status of 
immunoglobulin heavy chain variable gene (IGHV) and TP53 gene deletion. 
These samples were obtained from patients who had at least 5 x 109 B 
lymphocytes/1 (5000/pl) in the peripheral blood and a typical CLL 
immunophenotype (mature lymphocytes expressing CD19, CDS, CD23, and 
weak, clonally restricted surface immunoglobulin light chain) (Hallek 2009). 
Peripheral blood CLL samples were obtained with informed consent and with the 
approval of the Liverpool Research Ethics Committee.
2.2.2 Sample selection
Samples for initial screening of drug sensitivity were selected from the biobank on 
the basis that they were in plentiful supply (>40 vials) and possessed white blood 
cell count of >30xl09/l. In this way, the samples selected were of relatively high 
CLL cell purity and were sufficiently abundant to be available for sequential 
experiments.
2.2.3 Cell isolation and storage
Peripheral blood mononuclear cells from CLL patients were prepared by 
centrifugation (500rcf, 30mins) over Lymphoprep (d=T.077, Nycomed, Oslo, 
Norway). Cells were then washed in PBS and slowly resuspended in an ice-cold
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solution of RPMI (GIBCO) + 10% fetal calf serum (PCS, Biosera, East Suusex, 
UK) and 10% dimethyl sulphoxide (DMSO; Sigma, Poole, Dorset, UK). Cells 
were then aliquoted into cryotubes at 1-3 x 107/ml, frozen at -80°C and finally 
cryopreserved in liquid nitrogen.
2.2.4 Poly-HEMA coating of tissue culture plates
Poly-HEMA (poly(2-hydroxyethyl methacrylate)) is a hydrophilic, non-toxic 
polymer that prevents cell adhesion (Folkman, Moscona 1978). For coating of 
tissue culture plates, a poly-HEMA stock (120mg/ml in 95% ethanol; Sigma) was 
diluted to 12mg/ml in 95% ethanol and specific volumes aliquoted into the wells 
(30j_d for 96-well plates, and 200pi for 24-well plates). The plates were then 
incubated for at least 48hours at 37°C to allow evaporation, until dry.
2.2.5. In-house cell culture
Cryopreserved cells (1ml) were thawed rapidly at 37°C, and resuspended slowly 
to a final volume of 8-12mls per vial (maximum of 2 vials per universal) with 
RPMI 1640 medium (GIBCO) supplemented with 10% FCS (Biosera, East 
Suusex, UK), 2mM L-glutamine (Invitrogen), and lOOU/ml penicillin + lOOpg/ml 
streptomycin (Invitrogen). Following centrifugation at 500rcf for 5 minutes, cells 
were washed in 1ml of PBS, counted, and resuspended at double concentration in 
the above medium. Cells were cultured at 2xl06 cells/ml (~lxl06 cells/cm2), at 
37°C and 5% CO2, in poly-HEMA-precoated tissue culture plates with 96 flat- 
bottomed wells, in the presence or absence of cyclodextrin-encapsulated
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dexamethasone (Sigma, Poole, Dorset, UK). Following incubation for 1-3 days 
cells were harvested, centrifuged at 500rcf for 5min, resuspended at double 
concentration, and then counted using either a standard manual haemo cytometer 
and microscope, or an automatic Cellometer Auto T4 Haemocytometer 
(Nexcelom Bioscience, MA, USA) in Nexcelom Cell Counting Chambers.
2.2.6 Measurement of cell viability by flow cytometry
2.2.6.1 Propidium Iodide (PI) viability measurement
PI is a fluorochrome that can be used to measure cell death by flow cytometry. PI 
freely enters both live and dead cells but is selectively excluded by live cells 
(Darzynkiewicz, Bruno et al. 1992).
To analyse cell viability by FACS, cultured cells were resuspended and added to 
an equal volume of PI (Sigma, Poole, Dorset, UK) at 5pg/ml in PBS in a FACS 
tube. Following incubation on ice in the dark for 30 minutes, analysis was carried 
out using a FACScan flow cytometer (Becton Dickinson, Oxford, UK). Live cells 
appear as Pi-dim, while dead cells are Pi-bright. 10,000 events were collected as 
standard. Representative data for this method of viability measurement is shown 
in Figure 2.2.1.
The formula ((Viability(UT)-Viabihty(T))/Viability(UT))xl00 was used to define 
percentage killing relative to untreated controls.
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Figure 2.2.1. Representative FACS plots showing viability measurement by 
PI exclusion. Following 48h culture with/without (w/wo) lOOnM Dex, CLL 
samples were stained with 2.5pg/ml PI and analysed by FACS. The scatter plots 
indicate cell size and granularity by forward and side scatter, respectively, 
allowing intact live and dead cells to be segregated from cellular debris (left of the 
gated region). The histograms show red fluorescence due to PI. The gate, Ml, 
marks cells that are Pi-dim, and thus represent live cells. The upper plot and 
histogram show CLL cell viability in an untreated control (-Dex) while the lower 
plot and histogram show viability in the same sample after in vitro exposure to 
1 OOnM Dex (+Dex).
2.2.6.2 DiOC6 (3,3'-dihexyloxacarbocyanine) and PI viability 
measurement
DiOCe (3,3'-dihexyloxacarbocyanine) is a green fluorescent molecule that is 
actively concentrated in the respiring mitochondria of live cells. Loss of DiOCe 
staining indicates disruption of the mitochondrial transmembrane potential
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(Tedeschi 1974). This is an early and irreversible event during the induction of 
apoptosis (Brenner, Kroemer 2000). Therefore, apoptotic cells show decreased 
DiOCfi staining. Double staining with DiOCf, and PI allows distinct populations 
of cells to be identified, ranging from viable cells (DiOC6 bright, PI dim) to early 
apoptotic (DIOCg dim, PI dim), to late apoptotic/necrotic (DiOCe dim, PI bright).
Cells in culture media were incubated with 25nM DiOC6 (Sigma, Poole, Dorset, 
UK) for 15mins in a 37°C incubator prior to incubation with PI, and FACS 
analysis as described in Section 2.2.6.1.
2.2.6.3 Annexin V and PI viability measurement
Amiexin V binds to Phosphatidylserine, which is exposed on the surface of 
apoptotic cells and is thus considered an early marker of apoptosis induction 
(Koopman, Reutelmgsperger et al. 1994). Double staining with PI allows the 
identification of live cells (annexin V dim, PI dim), early apoptotic cells (annexin 
V bright, PI dim) and late apoptotic/necrotic cells (annexin V bright, PI bright).
4x105 cells in volumes of 200pl were transferred to FACS tubes and washed in 
PBS. 400pl of binding buffer (0.01 M HEPES, pH 7.4; 0.14 M NaCl; 2.5 mM 
CaCf) was added to each sample and mixed by pipetting, before adding 3 pi 
Amiexin Y FITC (BD Biosciences). Samples were incubated for lOmin at R/T 
(room temperature) in the dark before incubation with PI and FACS analysis as 
described in Section 2.2.6.1.
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2.2.7 Measurement of drug-induced cell killing by Tumour Response 
to Antineoplastic Compounds (TRAC) assay 
2.2.7.1 Drug-coated plate make-up
Drugs were dissolved in appropriate solvent according to manufacturer’s 
instructions, and serial dilutions were made up at a range of concentrations known 
to facilitate the elucidation of LC90 values. Concentrations were checked by UV 
spectrophotometry. Vacuum concentration for 40-80 minutes at medium heat was 
used to bind the drug to appropriate wells of the 96-well plates. Drugs were 
plated out at concentrations ranging from below to very much higher than 
concentrations considered therapeutically relevant.
2.2.7.2 Sample preparation
Samples from the university of Liverpool Biobank were removed from liquid 
nitrogen storage and transferred immediately to dry ice, on which they were 
transported by air to Royal United Hospital, Bath (for TRAC drug sensitivity 
screening). Upon receipt, the cells were transferred to a -80°C freezer. The 
cryopreserved cells (1ml) were thawed rapidly at 37°C and resuspended to a final 
volume of 8-12mls with Complete COa-independently buffered medium. 
Following centrifugation at 500rcf for 5 minutes, cells were washed in 1ml of 
Wash COi-independently buffered medium, supplemented with Gentamicin and 
L-Glutamine. Samples were then counted and resuspended in Ultracure Set-up 
medium (DMEM plus Bovine Extracts and Human Insulin), supplemented with
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Gentamicin and L-glutamine. Cells were incubated at 3.3x106 cells/ml, at 37°C 
and 5% CO2, in tissue culture plates with U-shaped wells, to facilitate clustering, 
and an estimate of initial viability was made for quality control puiposes.
2.2.13 Take off and staining
After 4 days, cell culture plates were removed from the incubator and cells were 
transferred by pipetting to Octospot slides held within holding blocks. The 
assembled blocks were briefly agitated, and the slides then spun on a cytospin at 
1200rpm for 4 minutes. The slides were dried under a stream of cold air for a few 
minutes and then stained by Eosin/Thiazin using an Aerospray Slide Stainer.
2.2.7.4 Scoring of TRAC assay slides
Day 4 control slides were observed to estimate the percentage of malignant cells. 
If 20 live malignant cells could not be seen in the control spots, the assay was 
deemed invalid. Counts of representative spreads of cells were performed using 
10 by 10 square eyepiece graticule inserted into the microscope eyepiece. When 
possible, approximately 100 cells were counted by selecting random fields. The 
average figure for the various control spots was taken to be “100% tumour 
survival”. The pattern and density of cells per field were carefully considered, to 
be combined with the 100% tumour survival figure in estimation of drug treated 
slides. The drug treated slides were then scored by comparison to the untreated
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control of the slide being studied and the control slide. The scores were 
predefined as 0,1,5,10,15,20,30,40,50,60,70,80,90, and 100% relative viability.
The LC90 position is defined as the lowest drug concentration at which 90% of 
malignant cells are killed; i.e. 10% are left alive as compared with control. For 
this reason, if 12-15% of cells were considered alive 15% was recorded. If no live 
cells could be seen a count of 0% was recorded, and 1 cell was noted as 1%. To 
ensure accuracy, all scores were performed twice by different operators (kindly 
facilitated by Biomedical Scientists at Bath Royal United Hospital Cancer 
Research). On the few occasions when pass thresholds for scoring discrepancies 
were breached, slides were repeat scored by both operators. LC90S were 
calculated as previously described (Bosanquet, Bell 1996).
2.2.8 Preparation of protein samples and Western blotting
Cell samples were harvested and lysed in 200j.il SDS Sample Buffer, containing 
125mM Tris-HCl (pH6.8), 20% glycerol (Sigma), 4% SDS (Fisher Scientific, 
Loughborough, Leicestershire, UK), 10% (3-mercaptoethanol (Sigma) and 0.006% 
bromophenol blue (VWR International, Lutterworth, Leicestershire, UK). The 
samples were sonicated at 30Hz in pulses 5secs in length, and then heated for 
15mins at 95 °C prior to being loaded for Western blotting.
Polyacrylamide gel electrophoresis (PAGE) was performed using running gels of 
12-15% Ultrapure Protogel 37.5:1 Acrylamide :Bis-acrylamide (National 
Diagnostics), and stacking gels of 5%. 20pl of each CLL cell lysate was loaded. 
Proteins were separated by electrophoresis in Electrophoresis Buffer (0.025M
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Trizma Base, 0.192M Glycine, 0.1% SDS) at 30mA/gel, and were then transferred 
onto Immobilon-P PVDF membranes (Millipore, Watford, UK) in transfer buffer 
(0.025M Trizma Base, 0.192M Glycine) at 400mA for Ih per transfer unit. 
Membranes were blocked for at least 30mins in 5% non-fat powdered milk 
(Tesco, UK) in TBS plus Tween-20 (TBS-T; Sigma), before incubation with 
primary and secondary antibody combinations as required. Wash steps consisted 
of 4 steps of 5mins each in TBS-T (0.1% Tween-20, Boros, UK).
Membranes were probed with primary antibodies in TBS-T for Ih at room 
temperature or overnight at 4°C as suggested in the manufacturers’ instructions, 
followed by peroxidase-conjugated goat polyclonal anti-rabbit or anti-mouse 
secondary layer antibody (Santa Cruz, CA, USA), as specified in Table 2.2.1. 
Proteins were visualised by enhanced chemiluminescence using Immobilon 
Western Chemiluminescent HRP substrate (Millipore, Billerica, MA, US), or 
Amersham ECL Advance Western blotting Detection Kit (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK), as instructed by the manufacturers.
Table 2.2.1 Antibodies used in immunoblotting. Antibody incubations were 
for Ih at R/T or O/N at 4°C.
Primary Antibody Dilution Secondary Antibody Dilution
PARP Mouse PAb 1/4000 5% milk Goat Anti-Mouse HRP 1/5000
RnD Systems TBS-T Santa Cruz
p-Actin Mouse MAb AC-74 1/10000 5% Goat Anti-Rabbit HRP 1/5000
Sigma milk TBS-T Santa Cruz
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2.2.9 Clinical data
All CLL patient samples used in this study were obtained with informed consent 
for storage in the University of Liverpool Leukaemia Bank and use in a wide 
range of scientific studies. Clinical data were extracted from patient’s medical 
notes and stored in a password protected central departmental database (in 
accordance with data protection regulations).
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2.3 Results
2.3.1 Determination of the optimal Dex dose and incubation period
The primary aim of this investigation was to establish that CLL cells show 
varying degrees of sensitivity to Dex in vitro, to allow selection of the most 
sensitive and resistant samples for comparison studies. It was first necessary to 
determine appropriate concentrations of the compound for screening of a 
representative cohort of patient samples. Killing was measured by PI exclusion 
and FACS (Section 2.2.6.1). Figure 2.3.1 displays the effect of a range of Dex 
concentrations on 4 CLL samples over the course of 3 days. Most of the 
reduction in viability of sample 2499—the most sensitive case—was observed at a 
Dex concentration of between 1 and lOnM Dex, and killing began to plateau as 
the Dex concentration reached lOOnM. In all samples viability was very similar at 
Dex concentrations between lOOnM and lOOOnM, though higher doses did appear 
to achieve slightly more killing in at each timepoint. Killing was seen as early as 
24h, whilst variation in sensitivity between samples was more apparent by 48h, 
lOOnM Dex was the lowest dose to induce close to maximum killing over the 
course of 3 days, thus highlighting this dose as potentially useful in further 
studies. The low standard deviations observed between triplicate samples 
provided confidence that this assay was of sufficient accuracy.
2.3.2 Establishing a CLL Dex-response profile
A panel of CLL samples were initially screened for their sensitivity to killing by 
lOOpM Dex (n^S 1). Available samples (n=46) from 44 patients (Table 2.3.1) 
were also tested for their sensitivity to the lower dose of lOOnM Dex in order to 
deduce whether sensitivity was consistent at a more clinically relevant dose.
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Figure 2.3.2 shows samples ranked by Dex sensitivity at 48h. Killing data at this 
timepoint gave a clear separation of samples without compromising the assay with 
the high spontaneous death that was apparent in certain samples by 72h. The 
most distal samples in the sensitivity spectrum were then arbitrarily assigned as 
sensitive and resistant. It is clear that Dex sensitivity is spread evenly from the 
most sensitive to the most resistant case. Of particular note, sensitivity at 24h 
does not correlate well with sensitivity at 48h or 72h, whilst 48h and 72h killing 
values coincide much more closely. The lack of a correlation between 24h and 
48h killing possibly reflects a killing mechanism that features multiple pathways 
that are activated at differing rates.
Table 2.3.1 Clinical and laboratory variables for 44 CLL patients/46 CLL 
samples (pairs of samples from separate bleeds of 2 patients were included)
Sex (patients) Male: 25
Female: 19
Age at diagnosis (patients) Mean: 67.2 (95% Cl: 64.2-70.2)
Prior therapy (patients) Yes: 20
No: 24
WBC (109/L) (samples) 110.5 (95% 0:89.5-131.5)
IGHV (samples) Mutated: 19/42
Unmutated 23/42
Cytogenetics (samples) 17p-: 5/27
llq-: 2/26
+12: 5/23
13q: 22/32
p53 dysfunction (samples) Normal: 20/35
Abnormal:15/35
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Figure 2.3.1. Dex dose/response curves for one GC-sensitive, one GC-
resistant, and two GC-intermediate-response CLL samples. CLL samples 
were treated with a range of doses (in triplicate) of Dex, ranging from between 0 
and lOOOOOnM Dex for 24, 48, and 72h. The fraction of cellular events collected 
that were alive—“PI Dim”— is shown, as determined by FACS. Each line 
represents a separate case. The error bars represent the standard deviation of 3 
samples.
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Figure 2.3.2. Dex sensitivity spectrum for a panel of CLL samples. Top. A 
panel of 51 CLL samples was screened at up to 3 timepoints to determine 
response to a saturating dose of Dex (lOOpM), as measured by PI 
exclusion/FACS. Bottom. 46 samples were also tested with a lower dose of 
lOOnM Dex. The bars represent relative killing relative to untreated controls as 
determined by PI fluorescence. Standard deviation for one separate independent 
experiment is shown.
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The sample/patient cohort used to designate samples for further study is shown in 
Table 2.3.1. This cohort is fairly representative according to epidemiological 
data. More specifically, more male than female patients were included, which is 
consistent with observations that CLL is more common in males than females 
(Gribben 2010); and mean age at diagnosis was 67.2yrs, which is close to the 
72yrs average reported by Dores et al (Dores, Anderson et al. 2007) (Section 
1.1.2). A minority of samples were from patients with deletions of 17p or 1 Iq, or 
with trisomy 12, which is consistent with reports suggesting that these three 
aberrations occur in less than 25% of patients (Zenz, Mertens et al. 2010, Oscier, 
Matutes et al. 1997) (Section 1.1.3). ~50% of patients had received prior therapy, 
whilst IGHV was mutated in -50% of samples. p53 dysfunction was present in 
approximately half of the samples for which data was available.
lOOnM and lOOjaM killing scores were directly compared (Figure 2.3.3) (24h 
n=33, R2=0.688, P0.005; 48h n=33, R2=0.947 PO.OOS; 72h n=19, R2=0.755, 
jP<0.005). The strong correlations observed for killing at 1,2, and 3 days support 
the use of the lOOnM data for determination of GC resistance and use in future 
experiments, and also support the idea that GC resistance in the sample cohort is 
not simply a dose effect that can be easily overcome.
Calcium release from the mitochondria of CLL cells has been detected as early as 
6h, and caspase activity as early as 3h in response to GC treatment (Chandra, 
Gilbreath et al. 1997, McConkey, Chandra 1999). Thus, to further define the 
kinetics of Dex-induced killing in the samples of this study, killing was measured 
between 2h and 20h in 3 sensitive samples (Figure 2.3.4). Cells were stained with
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DiOCf, in addition to PI so that early as well as late apoptotic events could be 
quantified (Section 2.2.6.2). It is noteworthy that 2/3 samples showed clear 
evidence of Dex-induced killing from as early as 12h. Case 2116 shows more 
prominent spontaneous death than samples 2273 and 2533, illustrating the 
heterogeneity of these clinical samples. It is also clear that killing was less 
marked when only PI was used to measure viability, as would be expected.
To evaluate the possible impact of variation in cell density between experiments, 
GC sensitivity was compared using CLL cells seeded at different densities. Thus, 
CLL cells from two sensitive samples (2273, 2533) and one resistant (2546) 
sample were seeded at 2xl06/ml and 5xl06/ml and exposed to lOOnM Dex for 24h 
and 48h. No significant difference in Dex-induced killing was observed between 
CLL cells seeded at the two cell densities (/^O.OS) (Figure 2.3.5). At 48h, the 
maximum change in sensitivity was less than 10%. More importantly, this change 
did not alter the sensitivity grouping of the samples.
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Figure 2.3.3. lOOnM and lOOfiM Dex sensitivity data strongly correlate. The
separate sets of sensitivity data shown in Figure 2.3.2 were compared using linear 
regression: 24h n=33, R2=0.688, P<0.005; 48h n=33, R2=0.947 P<0.005; 72h 
n=19, R2=0.755, PO.OOS.
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Figure 2.3.4. Dex begins to kill sensitive samples as early as 4 hours after 
treatment. Samples were cultured for 2, 4, 6, 8, 12, 16, and 20h and viability was 
detected by DiOC6/PI staining and FACS analysis. Percentage viability for the 
DiOC6/PI charts (left) represent the proportion of cells that are DiOC6+/PI-, whilst 
the PI only charts represent the proportion of cells that are PI- only (right).
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Figure 2.3.5. Cell concentration/density does not significantly alter Dex 
sensitivity as measured by Propidium lodide/FACS. 3 CLL samples were 
cultured at two cell concentrations/densities for 24 and 48h, and the effect of Dex 
on killing was contrasted by PI/FACS. P-values represent 2-tailed Mests for 
difference.
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2.3.3 Validation of Dex-induced CLL cell death measured by 
PI/FACS with TRAC (Tumour Response to Antineoplastic 
Compounds) assay
To further increase confidence that the samples for further examination were 
representative of sensitive and resistant phenotypes, a selection of samples were 
screened using the established TRAC (Tumour Response to Antineoplastic 
Compounds) assay, as described in Section 2.2.7. Whereas the PI/FACS survival 
assay featured only one or two doses of Dex (Section 2.3.2), this 4-day 
chemoresponse assay provided LC90 values, as samples were treated with a range 
of concentrations of the cytotoxic agents used. LC90 is defined as the 
concentration of an agent that is required to kill 90% of cells in a sample. 
Therefore, it provides a more robust measurement of drug sensitivity than simply 
measuring the killing at a fixed dose. The TRAC assay also conserves patient 
material by allowing use of a relatively low number of cells, as compared to other 
commonly used killing assays such as MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide). Another advantage of this method is that cells can 
be identified morphologically at the end-point, thus avoiding issues with sample 
purity. There is compelling data to suggest that choice of chemotherapy in CLL 
can be effectively guided by TRAC assay (Bosanquet, McCann et al. 1995).
As Figure 2.3.6 shows, there was a clear correlation between the measurements of 
these two assays, thus supporting the concept of using the PI method to define 
sensitive and resistant samples (n=34, R2=0.579, P<0.005).
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2.3.4 Comparison of in vitro sensitivity of CLL samples to Dex with 
sensitivity to fludarabine and other GCs
It is well established that the nucleoside analogue fludarabine kills CLL cells 
through p53-dependent mechanisms (Pettitt, Sherrington et al. 1999, Pettitt 2003), 
whereas GC killing of CLL cells is not dependent upon the integrity of the p53 
pathway (Thornton, Matutes et al. 2003). By comparing the effect of these 
different agents on CLL cell viability it was possible to deduce whether the GC 
resistance mechanism was one of general drug resistance (Figure 2.3.7). 
Furthermore, by screening the other GCs 6-Methylprednisolone (Mep) and 
Hydrocortisone (Hz) it was possible to define GC resistance of the CLL sample 
cohort as either specific or broad-acting. Figure 2.3.7 (B, C, and D) shows that 
the correlations as measured by linear regression between sensitivity to different 
GCs are significant, with all P-values below 0.05 and R2 above 0.7. In keeping 
with a previous study in CLL (Bosanquet, McCann et al. 1995) fludarabine 
sensitivity did not correlate with Dex sensitivity. Thus, GC resistance in the 
samples of this study was not likely to be a multi-drug resistance mechanism, and 
GC sensitivity within this investigation could be further defined as to apply to 
GCs in general, and not Dex in isolation.
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Figure 2.3.6. Dex LC90 as derived by TRAC assay correlates with PI/FACS 
assay killing data. LC90S were derived from a panel of up to 38 samples using 
TRAC assay scores following 4 day culture, and compared with 48h killing data 
from Figure 2.3.2. LC90S are shown on a logarithmic scale. Linear regression was 
performed: n=34, R2=0.579, P<0.005.
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Figure 2.3.7. Dex sensitivity does not correlate with fludarabine sensivity, 
though GC sensitivities all strongly correlate. Fludarabine sensitivity does not 
correlate with Dex sensitivity (A), whereas GC sensitivity is strongly correlated 
(B/C/D). LC90S were derived from a panel of up to 38 samples, using TRAC 
assay scores following 4 day culture. Plots of LC90S are shown on logarithmic 
scales. Power regression was performed for: A. Dex v Flu (n=32); B. Dex v Mep 
(6-methylprednisolone) (n=38, R2=0.725, /*=<().005) ; C. Dex v Hz 
(hydrocortisone) (n=38, R2=0.777, p<0.005); D. Mep v Hz (n=38, R2=0.833, 
p<0.005).
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2.3.5 Apoptosis contributes to Dex-induced CLL cell death
Indicators of apoptosis have previously been observed in CLL cells in response to 
Dex treatment (Tiwari, Dong et ah 2005, Chandra, Gilbreath et ah 1997, 
McConkey, Chandra 1999). It was decided to confirm the occurrence of 
apoptosis in the samples of this study. Phosphatidylserine (PS) exposure is a 
marker of apoptosis as it is exposed on the surface of apoptotic cells from early 
through late apoptosis (Koopman, Reutelingsperger et al. 1994) (Section 2.2.6.2). 
FITC-conjugated annexin-V binds to PS, and is detectable by FACS. A group of 
sensitive and resistant samples were tested for annexin-V staining and PI 
exclusion concomitantly (Figure 2.3.8). Samples were cultured for 24h in order to 
facilitate a commitment to killing without causing sensitive samples to completely 
enter the late apoptotic phase (Figure 2.3.4). Pl-bright/annexin-bright events 
(upper right) represent late apoptotic or necrotic cells, whilst the Pl-dim/annexin- 
bright events are early apoptotic (upper left). The detection of the latter 
population indicates that death was occurring by apoptosis as opposed to necrosis. 
In confirmation of the sensitivity designations, the sensitive samples showed 
viability reduction of between 32% and 58%, whilst the resistant samples 
displayed only 2% and 16% reductions in viability.
A further marker of apoptosis is Poly-ADP Ribose Polymerase (PARP) cleavage, 
as PARP is cleaved by effector caspases as a downstream event in apoptosis in 
CLL cells (Pettitt, Cawley 2000). Figure 2.3.9 shows by Western blotting that 
PARP was indeed cleaved in response to Dex in CLL samples, and also shows a 
higher propensity for this phenomenon in sensitive than resistant samples, 
indicating that apoptosis was more prevalent in the most sensitive samples.
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Sample 2185 of the sensitive group appeared to show the greatest PARP cleavage. 
It is of note that the ratio of cleaved to uncleaved PARP is higher at 12h than 24h, 
which possibly indicates that cleaved PARP is degraded more rapidly than it is 
formed after 24 hours in these samples. As is the case with both killing (Figure 
2.3.2) and PS exposure (Figure 2.3.5), resistant samples did show some PARP 
cleavage, rather than a complete absence. However, overall the sensitive samples 
showed considerably more Dex-induced PARP cleavage at both time points. 
Taken together, the PS exposure (Figure 2.3.8) and PARP cleavage data supports 
a role for apoptosis in the GC-induced killing of CLL cells, which is in keeping 
with previous studies.
In order to confirm the idea that caspase activation was not an essential 
component of killing, as has been reported previously (Kroemer, Martin 2005), 
two sensitive samples were cultured for 24 and 48h w/wo lOOnM Dex and the 
caspase inhibitor z-vad.fmk. Z-vad.fmk appeared to protect only 1/2 samples 
(hence all P>0.05) from loss of mitochondrial integrity as measured by loss of 
DiOCe positivity (Figure 2.3.10). However, this effect was of a lower order of 
magnitude when PI positivity rather than DiOCe negativity was used to measure 
killing. Therefore, caspase activation is likely to contribute to Dex-induced 
killing of certain CLL samples, though it does not appear to be an essential 
component (Figure 2.3.9).
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Figure 2.3.8. Dex induces cell killing via a mechanism that involves 
phosphatidylserine exposure. 4 sensitive and 2 resistant samples were cultured 
for 24h w/wo lOOnM Dex. Cells that appear to be annexin V and PI null are 
considered viable (lower left). Annexin V positivity alone indicates early 
apoptosis (upper left), whilst dual positivity indicates late apoptosis (upper right).
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Figure 2.3.9. PARP cleavage is more readily detectable in sensitive than 
resistant samples. Western blots showing uncleaved (113kDa) and cleaved 
(89kDa) PARP CLL samples were cultured for Oh, 12h, and 24h w/wo lOOnM 
Dex. Lysates were produced using SDS-sample buffer, and the resulting samples 
were separated by SDS-PAGE.
Figure 2.3.10. Caspase inhibitor does not rescue sensitive samples from the 
killing effect of Dex. Two sensitive cases were cultured for up to 48h +/- lOOnM 
Dex in the presence or absence of z-vad.fmk. Left. Killing as measured by 
mitochondrial membrane depolarisation (24h /*=0.99, 48h F=0.52 paired t tests 
for difference). Right. Killing as measured by PI staining (24h /*=0.57, 48h 
P=0.89 paired t tests for difference).
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2.3.6 Clinical and laboratory variables for study samples
It was important to compare clinical and laboratory variables to Dex sensitivity 
scores in case mechanistically relevant valuables were highlighted, and to further 
confirm the validity of the sample cohort. IGHV mutation status is an important 
predictor of poor prognosis (Hamblin, Davis et al. 1999). Samples with UM- 
IGHV (n=23) had a median sensitivity approximately two-fold higher than those 
with Wi-IGHV (n=19) (Figure 2.3.11). As unmutated IGHV predicts a more 
aggressive form of the disease (Lin, Sherrington et al. 2002), this correlation 
illustrates the potential usefulness of Dex in poor prognosis patients, and is in 
keeping with a previous study of GC sensitivity in CLL (Aleskog, Tobin et al. 
2004).
Table 2.3.2 displays selected clinical and laboratory variables for each of the 
samples designated either GC sensitive or GC resistant. When the two sensitivity 
groups are contrasted (Table 2.3.3) it appears that mean age at diagnosis, mean 
white blood cell count (WBC), and Binet stage distribution were similar. 
However, there was a higher ratio of females to males in the resistant group 
(resistant=T, sensitive=0.33). Moreover, there was a much higher ratio of M- 
IGHV to XIM-IGHV in the resistant group (resistant=2.5, sensitive=0.22), in 
keeping with Figure 2.3.11. Ratio of p53 dysfunction to “normal” was higher 
amongst resistant than sensitive cases (resistant=0.75, sensitive=0.375), though 
the majority of cases within both groups are “normal”. Furthermore, there was a 
higher ratio of previously treated to untreated patients in the sensitive group 
(sensitive^, resistant=0.45), which supports the reported effectiveness of GCs in 
treating refractory CLL (Thornton, Hamblin et al. 1999).
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Previous treatment of patients with chlorambucil can sensitise CLL cells to GC- 
induced killing (Bosanquet, McCann et al. 1995) (Section 1.4.5), though in this 
study 4/16 resistant as well as 4/12 sensitive patients had previously been treated 
with chlorambucil.
Regarding FISH data, ATM deletion (llq) was rare in both groups (ratios to 
“normaF’^O.! 11), as was llq/14q ti*anslocation (1/16 cases). Most cases 
displayed a deletion of 13q, which was more prevalent in the sensitive cases 
(ratios to “normal”; sensitive=2.33, resistant=1.4). This was unsurprising given 
that these deletions occur in around 50% of patients (Fitchett, Griffiths et al. 
1987). Whilst trisomy 12 was rare, it was more common in resistant cases (ratios 
to “normal”; sensitive=0.111, resistant=0.5).
TP53 deletion/mutation is the most clear indicator of poor treatment outcome in 
CLL (Furman 2010). In keeping with the p53 dysfunction data, TP53 deletions 
were more common in the resistant group (ratios to “normal”; resistant=0.57, 
sensitive=0.111). This finding is in contrast with previous reports that suggest a 
redundant role for p53 in GC-induced killing of CLL cells (Pettitt, Matutes et al. 
2006, Thornton, Matutes et al. 2003, Clarke, Purdie et al. 1993).
If spontaneous death in vitro were linked to Dex sensitivity, defects in CLL 
survival would be implicated in the phenomenon of Dex resistance. Figure 2.3.12 
shows the lack of a statistically significant correlation between these two 
variables, and so it is not likely that defects in generic CLL survival signalling are 
responsible for Dex resistance.
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Table 2.3.2 Clinical and laboratory variables for GC sensitive and GC 
resistant samples
[*=age at first sample, **=estimate based upon LC, (P)=data from previous bleed, (S)=data from
subsequent bleed]
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Figure 2.3.11. Samples with VM-IGHV tend to be killed more effectively by 
Dex than those with mutated versions. 48h lOOnM Dex-killing data was 
compared to IGHV status in samples from the study cohort (n=8S/10R, Mann- 
Whitney U test jP=0.041). Mutation status was defined as <2%=unmutated.
Table 2.3.3 Clinical and laboratory variables by sensitivity group
Sensitive Resistant
Mean Age at Diagnosis (years) 63.3 58.8
Sex 9M/3F 8M/8F
Mean WBC 107.3 112.3
Binet (A/B/C) 1A/1B/1C 6A/2B
Previoustreatment (Y/N) 6Y/6N 5Y/11N
IGHV (UM/M) 9UM/2M 4UM/10M
p53 dysfucntion (wt/dys) 8wt/3dys 8wt/6dys
17p-(del/norm) 1 del/9 norm 4 del/7 norm
llq- (del/norm) 1 del/9 norm 1 del/9 norm
13q- (del/norm) 7 del/3 norm 7 del/5 norm
Trisomy 12 (tri/norm) 1 tri/9 norm 3 tri/6 norm
llq 14q translocation (trans/norm) 0 trans/8 norm 1 trans/8 norm
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Figure 2.3.12 Spontaneous death of CLL cells during in vitro culture does 
not significantly correlate with Dex-induced killing. Spontaneous death of 
CLL samples was established by comparison of viability at tO with viability at 48h 
(n=51, R2=0.061,/>=0.079).
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2.4 Discussion
The aims of this chapter were to define the sensitivity to Dex of a panel of CLL 
samples, and to characterise the mode of killing. Also, sensitivity to Dex-induced 
killing was related to clinical and laboratory variables.
In vitro GC-sensitivity assays narrow the search for GC resistance in CLL to the 
cellular context. This means that potential resistance mechanisms lying in 
pharmacokinetics, including sequestration of GC by plasma-borne proteins, and 
differing degrees of liver metabolism and excretion between individual patients 
cannot be considered. Also, the increasingly well defined involvement of in vivo 
microenvironment (Ghia, Circosta et al. 2005) (Section 1.2.3) was not tested as 
part of this investigation. Nevertheless, in vitro sensitivity can be considered 
clinically relevant as patient treatment response has been previously shown to 
correlate with the in vitro GC sensitivity of CLL samples (Bosanquet, McCann et 
al. 1995).
Changes in cell viability over the course of 3 days following treatment with Dex 
were primarily measured using an established PI flow cytometry method (Pettitt, 
Sherrington et al. 1999) that allowed detection of both apoptotic and necrotic 
cells. CLL cell samples showed a range of sensitivities to Dex treatment using 
this method. PI exclusion does not define mode of killing but it is a marker of 
cells that are in the latter stages of death, as fluorescence is seen to increase 
following perturbation of the nuclear membrane and binding of PI to DNA 
(Darzynkiewicz, Bruno et al. 1992). However, though this method involves 
gating on live and dead cells, it does not take into consideration cell count post-
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culture, and so excludes obliterated cells and cellular fragments. This is likely to 
lead to an underestimation of the number of dead cells in a sample, and thus 
reduce the apparent range of GC sensitivity in the study cohort. However, 
sensitivity ranking should not be affected, and so the benefits of this high- 
throughput, rapid viability measurement outweigh the weaknesses. Previous 
experiments within this research group showed that GCs kill CLL cells gradually 
in culture over the course of days rather than hours, and so initial experiments 
were performed over a 3 day timecourse.
To further strengthen the data collected by flow cytometry, and to identify 
whether GC sensitivity correlated with that of fludarabine, a separate method was 
used on a panel of the samples originally screened. The assay that was chosen 
was the Tumour Response to Antineoplastic Compounds (TRAC) assay 
(Bosanquet, McCann et al. 1995) due to its conservative requirement for cellular 
material, and its generation of LC90S using a semi-automated procedure. Thus, in 
order to support the data generated by PI/FACS, the TRAC assay was used to 
validate the sensitivity spectrum that had been previously defined. As might be 
expected, there was a correlation between the two methods, although it was 
imperfect. This imperfection between the two methods may have been because 
the TRAC allows visual discrimination of cellular fragments as well as live and 
dead cells. Furthermore, the timepoints of choice were 2 days apart, and LC90S 
are of higher stringency than measurement of single-dose killing. Nevertheless, a 
reasonable correlation was observed between these two assays, thereby supporting 
the use of the PI/FACS method to define the GC sensitivity of the CLL samples.
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Furthermore, GC sensitivity did not correlate with sensitivity to fludarabine, thus 
suggesting the identification of a resistance mechanism specific to GCs.
To gain further insight into the mechanism and kinetics of Dex-induced killing, 
further assays were performed. GCs have previously been shown to kill CLL 
cells through a mechanism that involves apoptosis (Tiwari, Dong et al. 2005, 
Chandra, Gilbreath et al. 1997, McConkey, Chandra 1999). Markers of apoptosis 
include PARP cleavage, PS exposure, membrane blebbing, DNA laddering, and 
mitochondrial perturbation with cytochrome c and SMAC release, and caspase 
activation (Wang, Malone et al. 2003a, Cohen 1997, Pettitt, Cawley 2000). The 
former two apoptotic markers were selected for this study as this meant that small 
amounts of cellular material were required, and the methods had previously been 
established in this laboratory. It is clear that Dex treatment in the CLL samples 
tested killed by a mechanism that involved apoptosis, as demonstrated by PS 
exposure and PARP cleavage. Caspase inhibitors have previously been reported 
to alter the mode but not the extent of killing of haematopoietic cells (Kroemer, 
Martin 2005). Nevertheless, to ensure that this was true for GC-induced killing of 
CLL cells, the effect of a pan-caspase inhibitor on GC-induced killing was tested. 
As expected, inhibition of caspase activity did not appear to significantly alter the 
extent of Dex-induced killing, despite the apparent hindrance of mitochondrial 
depolarisation. Therefore, CLL cells co-treated with GCs and caspase inhibitor 
possibly die by a mechanism akin to apoptosis that lacks certain hallmarks, or a 
necrotic mechanism (Section 1.7.1).
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As expected from previous findings (Aleskog, Tobin et ah 2004), samples with 
XJM-IGHV appeared to respond better to Dex treatment than those with >2% 
deviation from germline. This could indicate that the nature of BCR signalling or 
the level of differentiation of a CLL population affects GC sensitivity. 
Additionally, in opposition to a previous clinical study of CLL (Thornton, 
Matutes et al. 2003) TP53 deletion was more prevalent in the GC-resistant group, 
which might suggest that aberrations in factors that can impact upon p53- 
mediated killing play a role in GC resistance in CLL. It would not appear that 
previous treatment of patients with chlorambucil sensitised samples to GC within 
this study. However, the ratio of previously treated to untreated patients was 
higher in the sensitive group of samples, which possibly suggests a role for 
previous treatment in GC sensitisation.
Having established an in-vitro response to Dex profile for a cohort of CLL 
samples, the most sensitive and most resistant samples could further be compared 
and contrasted to establish differences in GC-related signalling between the two 
sensitivity groups. Many of the effects of GCs at therapeutic levels are mediated 
by the GC receptor (Schmidt, Rainer et al. 2004), and intact receptor is required 
for cell killing (Greenstein, Ghias et al. 2002) (Section 1.4.4). Therefore, studies 
of differences in GC receptor expression and function provided a promising 
avenue for investigation.
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ChapterS: Glucocorticoid 
receptor expression and 
transcriptional activity
3.1 Introduction
In Chapter 2, the relative sensitivity of a panel of CLL samples to Dex-induced 
killing was determined. Moreover, it was confirmed that GC sensitivity in this 
cohort does not simply reflect multidrug resistance or a predisposition to 
spontaneous apoptosis. Furthermore, Dex-induced killing was confirmed to 
involve apoptosis.
As described in Section 1.5.3, GCs enter the cell by a passive mechanism and then 
bind to the GR (defined in Section 1.5.2) in the cytoplasm. Molecular 
rearrangement (Kfir-Erenfeld, Sionov et al. 2010) and hyperphosphorylation leads 
to exposure of nuclear localisation sequences (De Bosscher, Vanden Berghe et al. 
2003). Either a GR-hsp90-FKBP52-dynein complex then migrates to the nucleus, 
where dissociation can occur to yield GR in the homodimeric DN A-binding form 
(Davies, Ning et al. 2002, Dittmar, Demady et al. 1997), or GR dimerises in the 
cytoplasm prior to nuclear translocation (Davies, Ning et al. 2002, Bledsoe, 
Montana et al. 2002)(Kfir-Erenfeld, Sionov et al. 2010).
GRa is the full-length version of the GR. GRot is responsible for transcription 
activation (Frankfurt, Rosen 2004) (Section 1.4.5), whilst all other isoforms are 
truncated versions of GRa and possess altered hormone binding domains, nuclear
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localisation sequences, or transactivation domains, and thus are thought to 
modulate GRa activity (Oakley, Cidlowski 2011). GRp does not bind GCs, and 
can act as a dominant negative nuclear inhibitor of activated GRa (Shahidi, 
Vottero et al. 1999, Lewis-Tuffm, Cidlowski 2006). GRS is detected in many 
tissues and has been shown to stimulate the transcriptional activity of GRa in 
malignant haematological cells (de Lange, Segeren et al. 2001).
As discussed in Section 1.5, GC respsonse may be affected by various aspects of 
the GR and associated signals. GR isoform expression (Section 1.5.4) and GR 
mutations/polymorphisms (Section 1.5.5), GR post-translational modifications 
(Section 1.5.6), and aspects of the GR complex have all been reported to play a 
role in GR transactivation. Therefore, there are many levels at which the GRs of 
samples from each Dex sensitivity group could be compared and contrasted. With 
respect to the importance of GR isoform expression in GC-induced killing there is 
conflicting evidence. In one study, GR levels have been shown to not correlate 
with in vitro sensitivity of CLL cells to GC (Levine, Peterson et al. 1985), whilst 
in another study, a sample from a GC resistant CLL patient showed markedly 
reduced GRa expression and high GRP expression, along with reduced binding 
affinity for Dex relative to non-malignant lymphocytes (Shahidi, Vottero et al. 
1999). With regards to mutations/polymorphisms, a study of CLL cells from GC- 
treated patients revealed an absence of DNA- and steroid-binding site mutations 
(Soufx, Kaiser et al. 1995).
Given the importance of the study by Iglesias et al (Iglesias-Serret, de Frias et al. 
2007) (Section 1.5.7) to the selection of GC-induced genes in CLL, this study will
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be briefly described. In MLPA (Multiplex Ligation-dependent Probe 
Amplification) studies, probes that hybridise to the target sequence are amplified 
rather than sequences from cDNA samples (Schouten, McElgunn et al. 2002). In 
contrast to a standard multiplex PCR, a single pair of PCR primers is used for 
MLPA amplification. The resulting amplification products can be analysed by 
capillary electrophoresis. Comparing the peak pattern obtained to that of reference 
samples indicates which sequences show aberrant copy numbers. Gene 
expression profiling of 9 CLL patient samples by RT-MLPA showed that Bim and 
FLIP mRNA were induced (expression approximately doubled) by Dex at 24h. 
McllL was consistently downregulated but to a lesser extent. The RT-MLPA 
screening panel included members of the Bcl-2 family including BH3-only 
proapoptotic, Bax-like proapoptotic, and Bcl-2-like antiapoptotic family members, 
together with members of the IAP family and other miscellaneous apoptosis- 
related genes. Of particular note, Bad, BMF, and NOXA were not altered in 
response to Dex at this timepoint.
Given the relevance of the GR to both GC-related signalling (Schmidt, Rainer et 
al. 2004) and killing (Greenstein, Ghias et al. 2002) (Section 1.4.4), and various 
evidence from previous studies (Section 1.5), it is possible that qualitative or 
quantitative defects in the GR and its complex might contribute to a GC resistant 
phenotype in CLL cells. Furthermore, GC resistance might result from alterations 
in GR activation via post-translational modifications. Therefore, as a first step in 
comparing sensitive and resistant samples to elucidate resistance mechanisms, 
differences in the GR were sought between the two groups.
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3.2 Materials and Methods
3.2.1 Cell isolation
Peripheral blood mononuclear cells were isolated and stored as described in 
Section 2.2.3.
Blood samples from patients with high neutrophil counts were acquired and 
Polymorphprep (Nylomed Pharma AS, Oslo) was used to harvest the neutrophils 
according to the manufacturer’s instructions.
3.2.2 CLL cell culture
Cells were thawed, and cultured at densities of 5x106 cells/ml under the 
conditions described in Section 2.2.5, for 6h/17.5h/21.5h.
3.2.3 Preparation of protein samples and Western blotting
Samples were harvested and lysed in SDS Sample Buffer, containing 125mM 
Tris-HCl (pH6.8), 20% glycerol (Sigma), 4% SDS (Fisher Scientific, 
Loughborough, Leicestershire, UK), 10% p-mercaptoethanol (Sigma) and 0.006% 
bromophenol blue (VWR International, Lutterworth, Leicestershire, UK).
Western blotting was performed as in Section 2.2.8, using the antibodies specified 
in Table 3.2.1.
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Table 3.2.1 Antibodies used in immunoblotting. Antibody incubations were for 
Ih at R/T or O/N at 4°C.
Primary Antibody Dilution Secondary Antibody Dilution
GR Rabbit PAb 1/1000 5% milk TBS-T Goat Anti-Rabbit HRP 1/2000
Santa Cruz Santa Cruz
GRp Rabbit PAb 1/500 5% milk TBS-T Goat Anti-Rabbit HRP 1/1000
Abeam Santa Cruz
p-Ac tin Mouse PAb 1/10000 5% milk TBS-T Goat Anti-Mouse HRP 1/5000
Sigma Santa Cruz
3.2.4 RNA reverse transcription to cDNA
Total cellular RNA was extracted from up to 5 xlO6 cells using the RNeasy kit 
and shredder columns according to the manufacturer’s instructions (Qiagen, 
Crawley, Sussex, UK), and was then reverse transcribed using an oligo(dT)i5 
primer with MMLV reverse transcriptase (Promega Southampton, Hampshire, 
UK). All of the RNA preparations showed a 260nm/280nm OD ratio of at least 
1.6. 2p,g of RNA in 25pi were mixed with 2pi of the oligo(dT)i5 primer, and 
heated at 70°C for 5min. The samples were transferred to ice and then Ipl 
RNAsin, 8pl 5x RT buffer, 2pl dNTPs, and 2pl of MMLV-RTase were added. 
Following a Ih reverse transcription at 37°C, and a lOmin 65°C deactivation step, 
the cDNA samples were frozen at -20°C.
3.2.5 Standard PCR
1 pi of cDNA was used in a 50pl PCR to amplify the regions of interest using 
0.5pl Taq polymerase and the supplied polymerase buffer (Promega), 3mM MgCl, 
0.2mM dNTPs and up to 0.4pmol/pl of both forward and reverse primers (listed in
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table 3.2.2). PCR products were then separated by electrophoresis on 1-2% 
agarose gels in 0.5 x TBE buffer (Sigma), stained with ethidium bromide (EtBr) 
and visualised with UV.
GRfi was measured by standard PCR using 0.4pmol/pl of forward and reverse 
primer, and an annealing temperature of 61°C. The resulting product was 393bp 
in length.
Bim-EL/L/S were detected by standard PCR using 0.4pmol/pl of forward and 
reverse primer, and an annealing temperature of 61°C. The resulting products 
were 481 bp (EL), 312bp (L), and 233bp (5) nucleotides in length.
p-Actin (ACTE) was detected by standard PCR using 0.4pmol/pl of forward and 
reverse primer, and an annealing temperature of 61 °C. The resulting product was 
626bp in length.
3.2.6 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
All real-time PCRs were carried out in triplicate using an Opticon 2 thermal 
cycler (MJ Research, Waltham, Mass., USA), or in duplicate using a Stratagene 
Mx3005P PCR machine (Agilent, Stockport, UK), alongside no-template controls 
for each set of primers. Programs consisted of a lOmin 95°C melt step, followed 
by up to 44 cycles of 30s at 94°C, 30s at the appropriate annealing temperature, 
and a 72°C extension step of 30s. A melt curve was performed from 55°C to 
95°C, following a 30s melt step. A lOmin extension step completed the program.
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Each 25j.il reaction included 12.5j.il of either DyNamo Master Mix (Finnzymes, 
Espoo, Finland) or Applied Biosystems Power SyBr Green (Applied Biosystems, 
Warrington, UK) (including Tbr polymerase, SYBR Green I, 5mM Mg2+ and 
dNTPs), and up to 0.4pmole of each relevant forward and reverse oligonucleotide 
primer. 0.5pi stock cDNA was used in each 25pi (1/50) reaction. Following the 
extension step of each cycle, the fluorescence level was measured at 76-83°C.
The relative levels of transcripts were normalised to those of ACTB or ribosomal 
protein L27 (RPL27). Arbitrary expression levels were calculated from the 
number of cycles taken to reach a fixed fluorescence intensity (threshold) during 
the linear phase of amplification (Ct values). The formula “power(2,-(Cttarget“ 
Qiiormahseiy, was apppecj to yield a relative quantity of transcript of each target 
gene in each sample.
Table 3.2.2 displays real-time PCR conditions for amplification of each gene 
studied.
Table 3.2.2. qRT-PCR conditions for target genes.
Target Primer
Concentration
(pmol/pl)
Master
Mix
Anneal
Temp
(°C)
Read
Temp
(°C)
Product 
Length (bp)
ACTB 0.4 Dynamo 59 85 626
GRa 0.16 Dynamo 60 78 408
GRS 0.4 Applied
Biosystems
57 72 365
RPL27 0.4 Dynamo 60 79 345
Bim-EL 0.4 Applied
Biosystems
58 83 355
GILZ 0.24 Dynamo 60 81 401
GAPDH 0.4 Dynamo 60 82 452
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Primer sequences for PCR are listed below.
ACTS
Actin For: 5’-CCTCGCCTTTGCCGATCC - 3’
Actin Rev: 5’- GGATCTTCATGAGGTAGTCAGTC-3’ 
GRa
GR For 2: 5 ’ -CTGTGTTTTGCTCCTGATCTG-3J 
GR Rev a 2: 55-GATTTCAGCTAACATCTCGGG-39 
GRS/GRfi
GRFor : 5 ’ -TGTTTTGCTCCTGATCTGA-3 ’
GR Rev 8: 5,-GTTTCTGCCATACCTATTTG-3, 
GRRev p: S’-TGAGCGCCAAGATTGTTG^’
RPL27
RPL27 For: 5 ’ -GACGCAAAGCTGTCATCGTG-3 ’ 
RL27 Rev: 5’-GCAGTTTCTGGAAGAACCAC-35 
Bim-EL/BIM-EL/L/S
BIM-EL-F: 5 ’ -AATCCTGAAGGCAATCACGGA-3 ’ 
BIM-F1: 5 ’ -ATGGCAAAGGAACCTTCTGATG-3 ’ 
BIM-R5: 59 -CGTTAAACTCGTCTCCGATAC-39
GILZ
GILZ 1 F: 55-ACCGAAATGTATCAGACCCCC-39 
GILZ 1 R: 59 -ACTTACACCGCAGAACCACCA-35
GAPDH
GAPDH For: 5,-ACCACAGTCCATGCCATCAC-3, 
GAPDH Rev: S’-TCCACCACCCTGTTGCTGTA-S’
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Each PCR product could be detected as a single band on agarose gels following 
the number of cycles sufficient to reach the designated thresholds for quantitation 
by qRT-PCR (Figure 3.2.1.1 A/3.2.1.2 A). Amplification plots display the 
threshold (horizontal lines), placed to intercept the linear phase of product 
amplification (Figure 3.2.1.1 B/3.2.1.2 B). Dissociation curves for qRT-PCR 
products display segregation between primer dimer and product peaks, allowing 
quantitation by placement of read temperature beyond the melting point of the 
primer dimer (Figure 3.2.1.1 C /3.2.1.2 C).
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Figure 3.2.1.1 qRT-PCR products for ACTB, GRa, and GR6 are of the 
expected size, and can be reliably measured by qRT-PCR. A. Following 44 
cycles of QRT-PCR, products (right lane) were separated on 1% agarose gels 
alongside lOObp marker (left lane). Blue arrows highlight 500bp marker. Product 
sizes were: 626bp for ACTB, 408bp for GRa and 365bp for GRS. B. 
Amplification plots show threshold placement based upon amplification profile.
C. Dissociation curves show segregation of primer dimer from product peak, 
which allowed measurement of specific product abundance.
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Figure 3.2.1.2 qRT-PCR products for RPL27, Bim-EL, GILZ, and GAPDH 
are of the expected size, and can be reliably measured by qRT-PCR. A.
Following 44 cycles of qRT-PCR, products (right lane) were separated on 1% 
agarose gels alongside lOObp marker (right lane). Blue arrows highlight 500bp 
marker. Product sizes were: 345bp for RPL27, 255bp for Bim-EL, 401 bp for 
GILZ and 452bp for GAPDH. B. Amplification plots show threshold placement 
based upon amplification profile. C. Dissociation curves show segregation of 
primer dimer from product peak, which allowed measurement of specific product 
abundance.
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3.3 Results
3.3.1 Basal expression of key GR isoforms
It was first important to identify whether major differences in GR levels existed 
between sensitive and resistant samples. Expression of GRct, GR6, and GRfJ in 
particular is relevant to CLL (Oakley, Cidlowski 2011, Shahidi, Vottero et al. 
1999, de Lange, Segeren et al. 2001) (Section 1.5.4/1.5.5), and so the baseline 
mRNA expression of each isoform was measured to identify whether expression 
of GR isoforms in the samples of this study was associated with sensitivity to 
Dex.
GRa mRNA levels were highest in certain sensitive samples, but the median 
expression for each sensitivity group was very similar (jP>0.05) (Figure 3.3.1), 
Contrastingly, sensitive samples appeared to express higher GR6 mRNA than 
resistant samples (P <0.05). However, this corresponded to only an approximate 
doubling of the median expression between resistant and sensitive samples. 
Therefore, in keeping with a previous study in CLL (Levine, Peterson et al. 1985), 
GRa mRNA expression at baseline was probably not associated with GC 
sensitivity, whilst GRS mRNA expression at baseline may have been involved.
GR(i differs from GRa and GR6 in that it can act as a suppressor of GR 
heterodimer function (Shahidi, Vottero et al. 1999, Lewis-Tuffin, Cidlowski 
2006). Therefore, it would be expected that if the baseline expression of this 
isoform were significantly different between sensitive and resistant samples then 
the resistant samples would contain the highest levels. Neutrophils contain 
relatively high levels of GRp (Strickland, Kisich et al. 2001), and so cDNA from
130
neutrophils served as a positive control for optimisation. GR[1 mRNA baseline 
expression was found to be almost undetectable in sensitive and resistant CLL 
samples (Figure 3.3.2). In contrast, a positive control neutrophil sample showed a 
significant level of expression by standard PCR. Therefore, GRP mRNA 
expression at baseline did not support an important role for GRp in GC resistance 
in this study. This is perhaps unsurprising given that the concentration of GRa 
mRNA in CEM-C7, a T-cell acute lymphoblastic leukaemia cell-line, is 100-fold 
higher than that of GRp mRNA (Pedersen, Vedeckis 2003).
To better define the expression of the various GR isoforms it was critical to look 
at baseline protein expression. At the time of this investigation, there was no 
commercially available GRS antibody. Though GRp mRNA expression was not 
quantifiable in CLL samples (Figure 3.3.2), it was possible to measure protein 
levels. Therefore, levels of GRa and GRp protein alone were measured using 
Western blotting (Figure 3.3.3 A).
In keeping with the mRNA data (Figure 3.3.1), there was no clear difference in 
protein expression of the GRa isoform between sensitive and resistant samples 
(P>0.05) (Figure 3.3.3 B). In the case of the antagonistic GRp isoform there was 
also no significant difference between the two groups of samples (P>0.05). This 
finding is in contrast with a previous study of GC resistance in CLL (Shahidi, 
Vottero et al. 1999), but is supported by a separate study (Levine, Peterson et al. 
1985). It was concluded that the baseline protein expression of GRa and GRp 
were unlikely to be responsible for the failure of Dex-induced apoptosis in 
resistant samples.
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Figure 3.3.1. Baseline expression of GRa mRNA does not correlate with Dex 
sensitivity group, whilst expression of GRS mRNA appears to be higher in 
sensitive than resistant samples (10 sensitive vs. 10 resistant). qRT-PCR was 
performed to quantify expression of GRa and GRS mRNA. All target quantities 
were normalised to Actin, which acted as a loading control. P-values represent 
Mann-Whitney U tests for group difference: GRa P=0.257; GRS /*=0.041.
<------GR(3
Figure 3.3.2. GRp mRNA is detectable by standard PCR in neutropil but not 
CLL samples. Equal concentrations of neutrophil cDNA and that of a sensitive 
and resistant CLL sample were used in standard PCR to amplify GRp mRNA 
using an annealing temperature of 61 °C. The resulting products were separated 
on 1% agarose gels alongside lOObp marker (left lane). The GRp product 
resolved at 398bp, as expected.
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Figure 3.3.3. Neither baseline protein expression of GRa nor GRp correlates 
with GC sensitivity (9 sensitive vs. 6 resistant samples). A. Representative 
Western blots for GRa (left) and GRp (right). Sensitive samples (S) and resistant 
samples (R) are highlighted. B. Relative quantity of each protein to Actin was 
evaluated by densitometry. P-values represent Mann-Whitney U tests for group 
difference: GRa P^O.814; GRp /M).239.
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3.3.2 Transcriptional readout validation
There is much evidence to suggest that the GR contributes to GC-induced killing 
by regulating gene transcription, as described in Section 1.5.7. Hence, a diverse 
set of gene expression changes have been observed in leukaemic cell types. These 
include genes that block proliferation, cause growth arrest, and regulate apoptosis 
(Schmidt, Rainer et al. 2006, Yoshida, Miyashita et al. 2002); and genes that 
impact upon MAPK pathways, NF-kB signalling, and carbohydrate metabolism 
(Tissing, den Boer et al. 2007). Small sets of genes have been identified that 
correlate with GC sensitivity in cells from several hematologic malignancies 
(Miller, Komak et al. 2007). These included both Bim, a proapoptotic member of 
the BH3-only group of Bcl-2 family proteins; and GILZ, a target with numerous 
roles that include NF-kB antagonism. Bim mRNA and protein induction by GCs 
has been demonstrated in several ALL models (Wang, Malone et al. 2003a, Lu, 
Quearry et al. 2006, Ploner, Rainer et al. 2008, Abrams, Robertson et al. 2004, 
Erlacher, Michalak et al. 2005, Bachmann, Gorman et al. 2007) and primary CLL 
cells (Iglesias-Serret, de Frias et al. 2007). GILZ mRNA has been shown to be 
induced by GCs in T cells and ALL models (Mittelstadt, Ashwell 2001, 
Bachmann, Gorman et al. 2007).
It has been suggested that the scale and duration of GR expression can influence 
GC-induced signalling (Section 1.5.5). In T cells and other cell types sensitive to 
GC-induced death, positive autoregulation is commonly observed, and sometimes 
a requirement (Eisen, Elsasser et al. 1988)(Ramdas, Liu et al. 1999)(Ashraf, 
Kunapuli et al. 1991)(Barrett, Vig et al. 1996)(Gomi, Moriwaki et al. 
1990)(Pedersen, Geng et al. 2004). Despite this evidence for auto induction, GRa
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transcript expression has been shown to fall in response to Dex in CLL cells 
(Meyers, Taverna et al. 2007).
Though baseline expression of GR isoforms was similar between the two groups 
of samples, a functional study of the capacity of GR to transcribe target genes 
would provide direct functional evidence to test whether the GRs of the two 
groups of samples differed significantly in their ability to initiate transcription. If 
the GR of sensitive samples but not resistant samples could be shown to regulate 
target genes in response to Dex, it would be clear that studies of the GR and its 
regulation would be required to pin-point GR-related defects in resistant samples. 
If no clear difference in transcription of target genes existed between the two 
groups, the investigation would move downstream beyond GR transcriptional 
activity. Therefore, mRNA expression of Bim, GILZ, and GRa were used to 
measure the integrity of GR-mediated transcription of pro-death genes.
Bim exists as three major splice variants in lymphoid cells (Abrams, Robertson et 
al. 2004). In order to quantify Bim transcript by qRT-PCR, it was first necessary 
to demonstrate that measurement of a single Bim mRNA transcript could be used 
to represent Bim mRNA per se. This could be achieved by showing that the ratio 
of expression of the three dominant isoforms was similar with and without Dex 
treatment, using primers that could amplify all three isoforms by standard PCR. 
By amplifying Bim for only 25 cycles (close to the exponential phase of 
amplification) it was possible to estimate transcript abundance. It appeared that 
the three Bim isoforms were both detectable and Dex-inducible (Figure 3.3.4). 
Moreover, the ratio of Bim mRNA expression between the three dominant
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isoforms was similar with and without Dex treatment (Figure 3.3.4). Therefore, 
measurement of Bim-EL expression could be used to represent Bim.
Prior to screening samples to identify whether target genes were upregulated, it 
was important to select an appropriate gene for normalisation of qRT-PCR data, 
as many commonly used normalising genes vary between experimental conditions 
as well as cell types (de Jonge, Fehrmami et al. 2007). It was expected that some 
change in normaliser expression would occur post-treatment, as sample quality 
might be compromised by the initiation of killing. However, as GCs can impact 
upon up to 20% of the human leukocyte genome (Galon, Franchimont et al. 
2002), care had to be taken to not choose a normaliser that was itself being 
considerably altered by GR action. Within this research group, three commonly 
used housekeeping genes for quantitative PCR include ACTS (structural), 
GAPDH (glycolysis), and RPL27 (ribosomal). The use of ACTB as a normaliser 
was rejected due to the substantial downregulation of this gene upon Dex 
treatment (Figure 3.3.5A). Though changes were also detected in GAPDH, and 
RPL27 (Figure 3.3.5A), comparison of expression of these two housekeeping 
genes correlated fairly well (Figure 3.3.5B). As RPL27 displayed a smaller range 
of Dex-induced expression change than GAPDH (Figure 3.3.5B), and produced a 
melt curve of higher integrity by qRT-PCR (Figure 3.2.1.2), this gene was 
selected as the housekeeping gene for further studies.
136
Bim-EL
Bim-L - 
Bim-S -
Figure 3.3.4. Bint mRNA expression appears to be induced in CLL cells in 
response to Dex, and the expression of Bim-EL, Bim-L, and Bim-S appear to 
strongly correlate. CLL samples were cultured w/wo lOOpM Dex for 6h and 
17.5h. Bim was amplified from resulting cDNA samples by 25 cycles of standard 
PCR. PCR products were separated by agarose gel electrophoresis and visualised 
with ethidium bromide, which allowed quantity determination via densitometry.
GAPDH Ct
Figure 3.3.5. Of a panel of potential normalising genes, RPL27 appears to be 
altered least between samples incuabetd w/wo Dex. Blue lines = sensitive 
samples; red lines = resistant samples. A. Number of cycles required to reach 
threshold (Ct) for 2 sensitive (blue) and 2 resistant (red) samples cultured for 
21.5h w/wo lOOnM Dex. B. GAPDH vs. RL27 Ct.
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3.3.3 Transcriptional readout of GR activity
Timepoints selected for measurement of mRNA expression were Oh, 6h, and 
21.5h in order to provide both an indication of early alterations in gene expression 
mediated by GCs, and to provide data relating to an intermediate timepoint 
between 6h and 48h (the timepoint used to define sample sensitivity groups). 
These timepoints were in keeping with those used previously in studies of the 
effects of GCs on CLL cells and an ALL cell line (Lu, Quearry et al. 2006, 
Iglesias-Serret, de Frias et al. 2007). More specifically, an approximate doubling 
of Bim mRNA abundance by 24h and close to maximum Bim protein expression 
at both 24h and 48h has been observed upon GC treatment of CLL cells (Iglesias- 
Serret, de Frias et al. 2007). Bim mRNA has been shown to be significantly 
induced by between 8h and 16h after GC treatment in an ALL cell line, which was 
maintained until up to 24h, while Bim protein induction was shown as early as 
16h (Lu, Quearry et al. 2006). Significant Bim induction has also been observed 
in ALL cells in response to Dex over a 24h incubation, which preceded the onset 
of death (Wang, Malone et al. 2003a). Generally, studies of mRNA changes in 
response to GCs in leukocytes measure expression within a 24h period (Section 
1.5.7).
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Figure 3.3.6. Resistance of CLL cells to GC treatment does not appear to 
result from a failure to transcribe proapoptotic target genes or downregulate 
ACTB. Samples were cultured w/wo lOOnM Dex for 6 (n=9S/9R) and 21.5h 
(n=10S/10R). cDNA was used to quantify transcript abundance by qRT-PCR of 
Bim-EL, GILZ, GRa, and ACTB, relative to RPL27. In line charts, black lines =
sensitive samples, whilst grey lines = resistant samples. Bim and GILZ appear to 
be significantly induced at 6h and 21.5h (Wilcoxon PO.OOO/O.OOO), whilst GRa 
(Wilcoxon .P=0.01/0.008) and ACTB (Wilcoxon P^O.002/0.000) expression is 
significantly downregulated. Stem and leaf plots show untreated (UT), Dex 
treated (T), and fold change expression of each transcript relative to RPL27 by 
sensitivity group and timepoint (blue bars = 6h, green bars = 21.5h).
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Table 3.3.1. P-values for statistical comparisons of expression and fold 
change of GR-regulated genes between sensitive and resistant samples show 
no significant differences. P-values represent Mann-Whitney U tests for group 
versus group difference for data displayed in Figure 3.3.6.
6h 21.5h
Untreated Treated Fold
change
Untreated Treated Fold
change
Bim-EL 0.691 0.102 0.122 0.131 0.226 0.88
GILZ 0.122 0.085 0.627 0.257 0.29 0.496
GRol 0.691 0.627 0.757 0.940 0.545 0.762
ACTB 0.093 0.122 0.31 0.226 1 0.496
Table 3.3.2 Group median expression and fold change of GR-regulated genes
Untreated Treated Fold change
Timepoint 6h 21.5h 6k 21.5h 6h 21.5h
Sensitivity S R S R S R S R S R S R
Bim-EL 1.2 1.4 0.8 0.6 6.6 3.2 2.1 1.5 6.6 2.8 3.0 2.4
GILZ 0.4 0.2 0.2 0.2 3.1 1.6 1.3 0.1 6.0 5.9 6.0 7.2
GRa 1.3 1.2 0.6 0.7 0.9 0.8 0.4 0.4 0.6 0.8 0.7 0.6
ACTB 4.8 2.7 6.4 4.5 3.0 1.7 1.6 1.7 0.6 0.7 0.3 0.4
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In accordance with a previous study of GC-treated CLL cells (Iglesias-Serret, de 
Frias et al. 2007) and Figure 3.3.4, Bim-EL expression was upregulated by Dex in 
the CLL samples at both 6h and 21.5h (PO.OOO) (Figure 3.3.6). Also in keeping 
with previous studies of T cells and ALL models (Mittelstadt, Ashwell 2001, 
Bachmann, Gorman et al. 2007), GILZ was induced by Dex at both timepoints 
(PO.OOO). GRa transcript was downregulated in most samples at 6h and 21.5h 
(P=0.01/0.008), which was consistent with a previous study of CLL cells 
(Meyers, Taverna et al. 2007). ACTB also appeared to be downregulated in most 
samples at both timepoints (jP=0.002/0.000).
The line charts and stem-leaf plots of Figure 3.3.6 suggest a tendency for Dex to 
upregulate Bim-EL and GILZ at 6h more in sensitive than resistant samples, which 
implies a difference between the two groups in terms of GR-trans activation 
capacity. In fact, five sensitive samples displayed induction at 6h of a greater 
magnitude than that observed in any resistant case for both Bim-EL (median 
expression after Dex treatment 6.6 versus 3.2) and GILZ (median expression after 
Dex treatment 3.1 versus 1.6) (Table 3.3.2). Furthermore, median Dex-induced 
fold change in Bim-EL expression at 6h was 6.6 for the sensitive group, and less 
than half this value, 2.8, for the resistant group. However, when the statistics 
were considered (Table 3.3.1) all hypotheses regarding differences in baseline, 
Dex-induced or fold change expression were rejected (/*>().05). Furthermore, the 
two groups displayed very similar profiles of expression of all targets at 21.5h 
(Figure 3.3.6), and median fold change in GILZ, GRa and ACTB expression was 
very similar at both timepoints (Table 3.3.2). Taken together, these observations
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suggest that failure of GC-induced alteration of target genes is not predominantly 
responsible for resistance to Dex (D'Adamio, Zollo et al. 1997).
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3.4 Discussion
The aim of this chapter was to compare GC sensitive and GC resistant CLL 
samples for GR expression and function.
To address the first of these aims, baseline expression of the three major lymphoid 
GR isoforms (Oakley, Cidlowski 201 l)(Shahidi, Vottero et al. 1999, Lewis- 
Tuffin, Cidlowski 2006)(de Lange, Segeren et al. 2001) was measured at the 
mRNA and protein level. All comparisons between sensitive and resistant 
samples suggest that no differences existed between the two groups in terms of 
baseline GR mRNA and protein expression, apart from mRNA expression of GRS, 
which was more highly expressed at baseline in sensitive samples, though by only 
1-fold. This finding indicates that insufficient expression of GR8 might 
contribute to the resistance of CLL cells to Dex treatment, as GR5 has been 
reported to positively contribute to GR-mediated signalling (de Lange, Segeren et 
al. 2001). However, this could not be confirmed at the protein level due to the 
lack of a suitable antibody, and so this aspect of the study may be worth 
developing in the future. As GRa mRNA and protein levels were similar between 
the two sensitivity groups, differences in the expression of this isoform could not 
account for Dex resistance in this study. GRp protein expression was not 
associated with sensitivity, and GRfi mRNA levels were sub-quantifiable in CLL 
samples. Various studies could have been performed to identify receptor 
expression over time, and to test whether Dex treatment had an impact upon 
protein expression level. However, due to the multiple possible differences in GR 
expression and regulation that might exist (Section 1.5), it was decided to study
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the capacity of the GR to regulate target genes in the two sensitivity groups in the 
first instance.
To assess functionality of the GR, induction of proapoptotic genes that are 
reported to be GC induced in lymphoid cells (Ramdas, Liu et al. 1999, Mittelstadt, 
Ashwell 2001, Iglesias-Serret, de Frias et al. 2007, Bachmann, Gorman et al. 
2007) were used as a readout of GR signalling capacity. Additionally, samples 
were screened for ACTB expression as this was originally a potential normalising 
gene for qRT-PCR (Figure 3.3.5). Bim-EL and GILZ were upregulated by Dex 
treatment in both sensitive and resistant samples. GRa was generally 
downregulated in samples of both sensitivity groups, suggesting that 
autoregulation of the GR is not critical in GC-induced killing of CLL cells. ACTB 
was downregulated by Dex treatment in samples of both groups, which perhaps 
indicates a role for GCs in dysregulation of the cytoskeleton in CLL.
Careful examination of the qPCR functional readout data showed that a handful of 
sensitive samples upregulated Bim-EL and GILZ beyond the level reached by any 
resistant case. This suggested that there was a tendency for sensitive samples to 
show higher GR pro-death transcriptional activity than resistant cases. It may 
have been interesting to focus on the group of sensitive samples that showed the 
highest induction of Bim-EL and GILZ for further studies of the receptor and its 
activation, and future work in this area would be justified. Also, as transcriptional 
regulation is often dynamic, the measurement of a more thorough timecourse in 
expression of the target mRNAs may have been useful. Nonetheless, statistically 
the qPCR functional readout data rejects the hypothesis that a GR-mediated
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transactivation defect exists in resistant samples. Moreover, the GR of resistant 
samples appeared to transcribe targets in response to Dex that were shown to be 
upregulated in sensitive samples.
The aim of this investigation was to identify key aberrations in GC-induced 
killing in resistant samples. As GR-related defects did not appear to be 
responsible for GC resistance of CLL samples, it was decided to examine events 
downstream, beyond GR transcription. To begin, it was decided that a parallel 
level of GR signalling in the form of NF-kB signalling would be studied. NF-kB 
is both an important mediator of CLL survival (Furman, Asgary et al. 2000) and a 
known GR antagonist (Ray, Zhang et al. 1995) (Section 1.6).
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Chapter 4: Glucocorticoid 
receptor cross-talk
4.1 Introduction
The previous chapter showed that defects in GR-mediated transcription are 
unlikely to predominantly responsible for GC resistance in CLL cells. Therefore, 
parallel and downstream signalling pathways were considered for further 
exploration.
The GR interacts with a number of cytokine-induced transcription factors and 
members of the nuclear hormone receptor superfamily, including NF-kB, AP-1, 
NF-AT, CREB, STAT, and Oct (Refojo, Liberman et al. 2001, Gottlicher, Heck et 
al. 1998) (Section 1.6.1). Of the key survival signalling pathways in CLL, NF-kB 
(Section 1.6.2) is both constitutively active in vitro, and has been shown to be 
essential to maintaining viability (Cuni, Perez-Aciego et al. 2004, Hewamana, 
Alghazal et al. 2008). Moreover, NF-kB provides a direct link with the GR as the 
GR can compete for NF-kB promoters, or co-activator proteins such as CBP/p300, 
and induce post-translational modifications (De Bosscher, Vanden Berghe et al. 
2003, Greenstein, Ghias et al. 2002), and can also directly associate with the p65 
subunit (Scheinman, Gualberto et al. 1995, Nissen, Yamamoto 2000, Ray, Zhang 
et al. 1995, Adcock, Nasuhara et al. 1999) (Section 1.6.4). GR can also 
transactivate GILZ (D'Adamio, Zollo et al. 1997), as has already been indicated 
(Figure 3.3.6), and IkBo (Auphan, DiDonato et al. 1995, Scheinman, Cogswell et 
al. 1995). GILZ and IkB(x have both been shown to repress NF-kB activity (Yang,
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Zhang et al. 2008, Ayroldi, Zollo et al. 2007)(De Bosscher, Vanden Berghe et al. 
2003) (Section 1.6.3/1.6.5). Critically, NF-kB has been shown to be 
downregulated in response to Dex in CLL (Furman, Asgary et al. 2000) cells, 
which supports a role for NF-kB in GC-induced killing.
As described in Section 1.6.2, the principle NF-kB proteins in CLL are p65, p50, 
and c-Rel DNA, as their promoter binding activity has been consistently 
demonstrated in CLL, and p65 has been strongly linked with in vitro survival of 
CLL cells, as well as disease progression (Furman, Asgary et al. 2000, 
Hewamana, Alghazal et al. 2008, Schattner 2002). Furthermore, a physical 
interaction between the GR and p65 and p50 has previously been demonstrated in 
vitro, though only p65 can reciprocally repress GR activity as p50 lacks a 
transactivation domain (Scheinman, Gualberto et al. 1995, Wissink, van Heerde et 
al. 1997). p65:p50 heterodimers are the most commonly observed form of NF-kB 
in B cells (Sen 2006). Interestingly, p50 homodimers, which lack classical 
transcription activation domains, can obstruct Rel complexes that feature active 
p65 (Sen 2006). NF-kB pro-survival, growth and proliferation target genes 
include: Bd-xl, Bcl~2Al, Bcl~2, c-FLIP, Bcl-w XIAP, c-JAP, c-Myc, c-Myb, 
Cyclins D1 and D2, and the cytokines IL-2, IL-6, and CD40L (Horie, Watanabe et 
al. 2006, Vallabhapurapu, Karin 2009). Given the importance of some of these 
targets in CLL cell survival, it is not surprising that NF-kB activity has been 
positively correlated with in vitro survival of CLL cells (Hewamana, Alghazal et 
al. 2008).
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Regulation of NF-kB is described in Section 1.6.3. The central mechanism 
underlying NF-kB regulation is the proteolytic degradation of the family of IkBs 
(Neumann, Naumann 2007). This “canonical” pathway of NF-kB activation 
involves phosphorylation of iKBa by IKKJ3, which prevents IkBoi from repressing 
NF- kB. NF-kB activates the promoter of IKBa and thus its expression is subject 
to an autoregulatory negative feedback loop. NF-kB activity can also be regulated 
via inhibitory post-translational modification, especially phosphorylation, of Rel 
subunits via the non-canonical pathway (Neumann, Naumann 2007).
Lck is a BCR-associated kinase that regulates BCR signalling (Section 1.6.6). 
Lck mRNA expression has been positively correlated with Dex resistance in CLL 
cells, and its inhibition has been shown to enhance GC sensitivity (Harr, Caimi et 
al. 2010). Therefore, elevated Lck protein expression, which is yet to be reported, 
might play a role in the resistance of the cohort used in this study. GSK-3a/J3 is a 
serine/threonine kinase that acts a variety of susbstrates (Section 1.6.6). GSK-3 
activity has been recently reported as a factor that can contribute to GC sensitivity 
in haematopoietic cancer cells (Kfir-Erenfeld, Sionov et al. 2010). 
Phosphorylation of Sei'404 of the GR by GSK-3 [3 can protect against Dex killing in 
U-2 OS cells (Galliher-Beckley, Williams et al. 2008), and GSK-3 inhibition in T 
cells has been shown to inhibit Bim-induced killing (Spokoini, Kfir-Erenfeld et al. 
2010). In CLL cells, GSK-3 (3 prevents epigenetic silencing of NF-kB-mediated 
gene transcription and thus maintains cell viability and prosurvival Bcl-2 and 
XIAP expression (Ougolkov, Bone et al. 2007). Therefore, differences in GSK- 
3 [3 expression or phosphorylation may contribute to Dex-resistance in CLL cells.
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C-IAP2 and XIAP are elevated at mRNA level by more than one fold in CLL 
relative to a panel of lymphoid malignancies (de Graaf, van Krieken et ah 2005) 
(Section 1.6.7). The IAP family of proteins can suppress apoptosis induced by a 
range of triggers, and overexpression of XIAP can lead to an accumulation of GC- 
resistant immature T cells (Conte, Liston et al. 2001). XIAP is reported to possess 
the most marked anti-caspase activity of the IAP family (Eckelman, Salvesen et 
al. 2006). Therefore, elevated expression of lAPs, might hinder GC-induced 
apoptosis in CLL cells.
The aim of this chapter was to elucidate whether pathways important to CLL 
survival are involved in GC resistance through either constitutive or induced 
signalling. For the reasons outlined above, NF-kB was the selected as an 
appropriate start point.
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4.2 Materials and Methods
4.2.1 Purification of B lymphocytes
Negative purification of B cells was used rather than positive purification in order 
to avoid stimulation of the target cells.
2-5x10 mononuclear cells from peripheral blood of patients with CLL were 
incubated in 400|il of 4°C degassed purification buffer (PBS pH7.2, 0.5% BSA, 
2mM EDTA) for 20min, in the presence of 20pl of each FITC-conjugated anti- 
CD3, anti-CD 14, and anti-CD 16 antibodies (BD Biosciences), which label T cells, 
monocytes, macrophages, neutrophils, and NK cells. Samples were then 
centrifuged at 500rcf for 3mins at 4°C, washed in 80pl purification buffer, 
centrifuged again, and resuspended in 160pi purification buffer. 20pl of anti-
FITC magnetic beads (Miltenyi Biotech, Bisley, UK) were then added to each 
sample.
Cell/magnetic bead suspensions were incubated at 4°C for 15mins and then 
pelleted, washed, resuspended in 80pi purification buffer, and applied to a Mini 
Macs column (Miltenyi Biotech) for 5mins. The CD3+, CD16+, or CD14+ cells 
remain in the column by virtue of the attached beads, which allows collection of 
the unlabelled CD 19+ B cells that flow through.
1ml of buffer was added to the column three times to aid the flow through and 
collection of B cells. B-cell purity was found to be >93% following this 
purification, as shown by CD19-PE positivity and CD3, CD 14, and CD16-FITC
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negativity, relative to IgG stained control samples. A representative CLL case 
post purification is shown in Figure 4.2.1.
The B cell purity of the CLL samples was determined by flow cytometry, using a 
Becton Dickinson FACSCalibur machine and a PE-conjugated anti CD 19 
antibody (Figure 4.2.1). In this example, B cells were shown to account for >97% 
of the detected events.
FITC
Figure 4.2.1. Representative plots showing B cell purity following 
purification. CD3, CD14, and CD16-FITC (x-axis) versus IgG-PE (left) or 
CD19-PE (right) (y-axis). Left. IgGl acts as a negative control for CD 19 
binding. Right. Cells are shown to be 97% CD19+/CD3-, CD14-, and CD16- 
(upper left quadrant). CD3, CD 14, and CD 16 expressing cell contamination is 
indicated by FITC positivity (lower right quadrant).
4.2.2 CLL cell culture
Cells were thawed from liquid nitrogen, and cultured at densities of 5xl06 cells/ml 
under the conditions described in Section 2.2.5.
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4.2.3 CIX cell stimulation/inhibition
Bay11-7082 (Calbiochem) was diluted in DMSO (dimethyl sulphoxide) and used 
at a range of concentrations, up to 8pM. CLL cells were incubated at 5xl06/ml 
for 18.5h. DMSO was added to untreated controls as appropriate.
To stimulate cells with CpG/ODN (oligodeoxynucleotides) type-B, CLL cells 
(2xl06/ml) were cultured in the presence of CpG (Invivogen) at 0.5pg/ml for 4h.
For crosslinking, F(ab)2 fragment of a goat anti-human IgM, Fc5|i fragment 
specific antibody (Jackson ImmunoResearch, Stratech, Soham (UK)) was used to 
treat CLL cells at 10ng/ml for lOmins at 37°C/5% C02.
4.2.4 Standard sample preparation and Western blotting
Samples were lysed either in a clear sample buffer containing 125mM Tris-HCl 
(pH6.8), 20% glycerol (Sigma), and 4% SDS (Fisher Scientific, Loughborough, 
Leicestershire, UK), or in RIPA buffer containing 50mM Tris, (pH7.6), 150mM 
NaCl, 25mM Na-pyrophosphate, 50mM Na-glycerophoshpate decahydrate, 2mM 
EDTA and 2mM EGTA.
Determination of protein concentration was carried out in duplicate using the 
Biorad DC protein assay (Biorad, CA, USA), according to the manufacturer’s 
instructions. This assay is similar to the Lowry assay (LOWRY, ROSEBROUGH 
et al. 1951), in which protein concentration is exhibited by a colour change of the 
sample solution, involving reduction of the reagent folin and oxidation of
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aromatic residues. Samples had to be diluted to protein concentrations of between 
0.2 and 1.5 mg/ml to allow reliable quantitation. Protein concentration was 
measured at 650—750 nm with a standard laboratory spectrophotometer or 
microplate reader.
The remaining components of SDS-sample buffer were added to samples at final 
concentrations of 10% (3-mercaptoethanol (Sigma) and 0.006% bromophenol blue 
(VWR International, Lutterworth, Leicestershire, UK) following quantitation and 
normalisation of sample concentration.
Western blotting was performed as described in Section 2.2.8, using the 
antibodies specified in Table 4.2.1, below.
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Table 4.2.1 Antibodies used in immunoblotting. Antibody incubations were 
for Hi at R/T or O/N at 4°C.
Primary Antibody Conditions Secondaiy Antibody Conditions
Calnexin Rabbit PAb
Abeam
1/2000 5% milk TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
HDAC1 Mouse MAb M02 
Abnova
1/1000 5% milk TBS-T Goat Anti-Mouse HRP 
Santa Cruz
1/5000
Histone H3 Rabbit PAb
Call Signalling
1/1000 5% milk TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/2000
Lck Mouse MAb 3A5
Santa Cruz
1/2000 5% Advanced block 
TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
GSK-3p Rabbit PAb
Cell Signalling
1/2000 5% BSA TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
p-GSK-3a/p Rabbit PAb
Cell Signalling
1/2000 5% BSA TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
C-IAP2 Rabbit MAb 58C7 
Cell Signalling
1/2000 5% BSA TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
XIAP Rabbit MAb 3B6
Cell Signalling
1/1000 5% milk TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
P-Actin Mouse PAb
Sigma
1/10000 5% milk TBS-T Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
P-IkBq Mouse
Cell Signalling
1/2000 5% Advanced block 
TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
IkBq Rabbit PAb
Santa Cruz
1/2000 5% Advanced Block 
TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
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4.2.5 Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR)
qRT-PCR was performed as in Section 3,2,6. Table 4.2.2, below, shows the 
parameters of the reactions performed.
Table 4.2.2 qRT-PCR conditions
Target Primer
Concentration
(pmol/pl)
Master
Mix
Anneal
Temperature
(°C)
Read
Temperature
(°C)
Product
Length
(bp)
Bcl-xl 0.2 Dynamo 60 82 309
Bcl-2A1 0.4 Dynamo 58 N/A 539
Primer sequences are shown in the list below.
Bcl-xl
FOR-55 -TGCGTGGAA AGCGTAGAC AAG-3 ’ 
RE V-5 ’ - AGG AT GT GGT GGAGC AG AG AA-3 ’.
Bfl-1
FOR-5 ’ -GGC AG A AGAT G AC AG ACT GTG A A-35 
B AC-55 -TGGTC A AC AGTATTGCTTC AGG A-3 ’
Amplification plots and dissociation curves for PCR are shown if Figure 4.2.2.
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Figure 4.2.2 qRT-PCR amplification plots and dissociation curves. Left. The 
amplification plot shows placement of the threshold within the exponential phase 
of amplification for Bcl-xl (horizontal line). Right. The dissociation plots show 
placement of the read-temperatures for each PCR, beyond interference from 
primer dimer and any non-specific product (left of blue arrows).
4.2.6 Soluble Nuclear Protein Isolation Optimisation
Non-denaturing nuclear isolation is performed as follows (Jakob 1992): 
Generally, a hypotonic (of higher osmotic potential than the cells) buffer is used 
to induce swelling and some disruption of the cytoplasmic membrane. Next, 
replacement with a hypertonic (of lower osmotic potential than the cells) buffer 
leads to rapid shrinkage of the cells and is accompanied by extensive cell lysis. 
Nuclei are then separated from other cellular components by centrifugation. The 
primary aim is to lyse the cell membrane without lysing the nuclear membrane, 
which is particularly difficult given that nuclear membrane and cytoplasmic
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membranes are structurally and chemically alike. This issue is particularly 
relevant to CLL cells as they possess particularly large nuclei, which renders their 
nuclear membranes highly vulnerable to methods of disruption that target the 
plasma membrane.
In order to perform functional assays on isolated nuclear proteins, once the 
nuclear pellet has been isolated, a conservative approach is required to ensure that 
any active target is maintained in its active state. Therefore, rather than using 
reagents that alter protein chemistry or structure, a method that makes use of 
osmotic changes is once again preferable. If the salt concentration is high enough, 
this approach not only preserves the nuclear membrane so as to keep DNA from 
engulfing the desired protein, but also strips promoter-bound transcription factors 
without the need to sheer/digest the DNA. Avoidance of DNA sonication is 
preferable because it may impact on protein integrity. A further concern is 
particularly relevant to any NF-kB activity assay. Since migration of this 
transcription factor from cytoplasm to nucleus is a key event in its activation (De 
Bosscher, Vanden Berghe et al. 2003), any contamination of the nuclear fraction 
by the cytoplasmic fraction would invalidate the measurements.
To optimise the nuclear isolation step, a range of hypertonic buffers was tested. 
These buffers differed in their osmolality and detergent concentration. Once the 
basic cellular lysis buffer had been selected, NP40 (detergent) concentration and 
length of exposure were optimised (Figure 4.2.3). Cells were cultured at 5x106 
cells per well of 24-well plates. Simultaneous nuclear protein extractions were 
performed as described in Section 4.2.7. Samples were lysed in lOOpl cell lysis
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buffer, and 20j.il of sample was loaded per lane (~lxl06 cells worth of material) of 
a polyacrylamide gel. Western blot for Calnexin (cytoplasmic), HDAC and 
Histone-H3 (nuclear) (Figure 4.2.3) allowed identification of cytoplasmic and 
nuclear components, respectively.
The cytoplasmic marker, calnexin, presented mainly in the pelleted nuclear 
fraction when an NP40 concentration of 0.02% was used, indicating insufficient 
lysis of the cytoplasmic membrane in the first lysis step. At 0.05% and 0.1% 
NP40, the cytoplasmic marker almost disappeared from the nuclear fraction, and a 
1 Omin incubation with the detergent appeared to have no effect. Therefore, NP40 
was required at a minimum concentration of 0.05% in order to achieve adequate 
lysis of the cytoplasmic membrane. Hence, the optimal conditions were defined 
as 0.1% NP40 with no incubation between NP40 addition and subsequent 
centrifugation.
As the Active Motif ELISA method had been selected for subsequent 
measurement of NF-kB activity, it was decided to use this company’s 
commercially available hypertonic buffer for consistency.
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Figure 4.2.3 Effect of NP40 concentration and incubation time on 
segregation of nuclear and cytoplasmic markers following CLL cell nuclear 
isolation. As expected, Calnexin, HDAC and H3 proteins resolved at lOOkDa, 
55kDa, and 14kD, respectively. L = WCL, C = cytoplasmic fraction, N = nuclear 
fraction. The lanes representing the NP40 concentration and detergent incubation 
time subsequently used in the purification procedure are denoted by a star.
4.2.7 Nuclear Protein Isolation from CLL cells
1/100 DTT (dithiothreotin), 1/100 protease inhibitors, and 1/100 phosphatase 
inhibitors were added to hypotonic Lysis Buffer A [0.1M MgCl2, 2M Kcl, 0.1M 
HEPES ((4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid)], and to hypertonic 
TransAM Complete Lysis Buffer (Active Motif, Belgium). Cellular material 
equivalent to ~5xl06 cells was washed in PBS and resuspended in a small residual 
amount by vigorous flicking. 180pl Lysis Buffer A was added to samples, which 
were gently agitated into suspension. Samples were then left on ice for 15min, 
and 20|il 1% NP40 was added before very gentle agitation. Samples were
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immediately spun at 650rcf for 5min. Supernatant was decanted, and samples 
were washed in a further 200pl Lysis Buffer A. 50pi Complete Lysis Buffer was 
added, and the nuclear pellet was left on a plate shaker set at 600rpm on ice for 
30min, with samples briefly vortexed at high speed every lOmin. Samples were 
centrifuged at maximum speed for lOmin, and the supernatant was removed 
before tubes were transferred to -80°C storage.
Protein determination was performed in duplicate by RC/DC Bradford Assay 
(Biorad), which overcomes the reducing activity of DTT in Complete Lysis 
Buffer by precipitation and resuspension of protein samples. The assay was 
performed in duplicate. Duplicate samples that displayed an average 
spectrophotometric measurement with CV (percent coefficient of variation) of 
over 20% were remeasured.
4.2.8 ELISA of NF-kB activity
NF-kB activation status can be measured/inferred by a number of methods. 
Levels of NF-kB or IkB—the NF-kB suppressor—proteins can be measured by 
Western blotting. However, I-kB plays a role in inhibiting cytoplsamic NF-kB 
up-stream in the canonical pathway, and does not indicate differences in NF-kB 
activity resulting from alternative pathways (Heck, Bender et al. 1997). 
Furthermore, probing for NF-kB levels within nuclear extracts would not detect 
differences in activity.
Within in vitro systems, reporter genes are considered a highly informative way of 
measuring transcription factor activity (Nordeen 1988). In studies of NF-kB
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activity, luciferase or p-galactosidase can be placed under the control of a 
promoter that contains an NF-kB consensus binding sequence. Nevertheless, 
reporter gene assays have to be performed several times to ensure reliability, and 
assays have to be carefully standardised.
Gel retardation assays, more commonly referred to as Electrophoretic Mobility 
Shift Assays (EMSA), offer an assessment of DNA binding activity of 
transcription factors (Fried 1989), such as NF-kB. Cell extracts are incubated 
with either a radiolabelled or biotin-conjugated double-stranded oligonucleotide 
probe containing a consensus binding sequence, which only NF-kB that is free 
from repressors and in its active conformation may bind. Samples are resolved by 
non-denaturing polyacrylamide gel, followed by autoradiography or streptavidin 
treatment and chemiluminescent detection of NF-KB-bound probe. This method 
provides confidence regarding binding specificity as detectable by band 
resolution, but it requires more cellular material than ELISA-based methods, and 
is time consuming and inappropriate for high-throughput screening.
Active Motif offers a high-throughput ELISA assay to quantify NF-kB activation 
by measuring binding of subunits to a consensus promoter sequence. 96-well 
plates contain immobilised oligonucleotide corresponding to the NF-kB consensus 
binding sequence (5 ’ -GGGACTTTCC-3 ’), which the active form of NF-kB 
specifically binds to. Then, primary antibodies that are specific for promoter- 
bound epitopes of NF-kB subunits are used to probe. An HRP-conjugated 
secondary antibody provides a colorimetric readout that is quantified by 
spectrophotometry. Critically—due to the relatively low yields of nuclear protein
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obtained during nuclear purification—this assay is approximately 10-fold more 
sensitive than EMSA according to the manufacturer.
p65 and p50, and c-Rel are the NF-kB isoforms that warrant particular attention in 
CLL (Furman, Asgary et al. 2000, Hewamana, Alghazal et al. 2008). p65
homodimers, and p65/p50 heterodimers are transcriptionally active, whilst p50 
homodimers are transcriptionally inactive, despite the capacity of the latter to bind 
NF-kB promoter sequences.
p65 and p50 NF-kB ELISA (TranAM) was performed, according to the 
manufacturer’s instructions (Active Motif, Belgium), to assess the binding 
capacity of nuclear NF-kB subunits to fixed consensus binding sequence. 
“Complete Lysis Buffer” (hypertonic lysis buffer B), “Washing Buffer” and 
“Complete (antibody) Binding Buffer” were prepared first. 30pl of Complete 
Binding Buffer was added to each well to be used. To demonstrate the specificity 
of NF-kB subunit binding, each batch of samples included control wells that 
contained non-fixed competitive NF-kB consensus binding sequence, or a mutated 
non-competitive version, in excess. For these samples, 30pl of Complete Binding 
Buffer plus 1 Opmol of wild-type or mutated consensus oligonucleotide was used. 
In non-control sample wells, 20pi of sample diluted in Complete Lysis Buffer was 
added, using between 1 and 20pg of nuclear extract, dependent upon antibody 
binding efficiency (0.5pg for p50, and 2pg for p65). Positive control wells 
featured 2.5pg of Jurkat nuclear extract or 5pg of Raji nuclear extract to 
demonstrate assay validity. Blank wells featured Complete Lysis Buffer alone. 
Wells were sealed and incubated for Ih at RT with mild agitation via a rocking
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platform. Following incubation to facilitate protein binding to fixed 
oligonucleotide, wells were washed 3 times with 200|ul Washing Buffer. p65 or 
p50 antibodies were diluted 1:1000 and lOOpl was added to appropriate wells. 
The plate was incubated for a further Ih to allow antibody binding to plate-bound 
NF-kB protein. Wells were then washed x4. Finally, lOOpl “Developing 
Solution” was added to all wells and samples were incubated for between 30s and 
5min at RT and protected from direct light until the samples turned from medium 
to dark blue. lOOjil of “Stop Solution” was added and the yellow signals were 
detected by 450nm spectrophotometry, with a reference wavelength of 655nm. 
Following data collection, blank wells were subtracted from all readings as 
background. Positive control/reference samples were used to standardise multiple 
experiments. The wild-type competitor prevented binding of NF-kB to anchored 
oligonucleotide, and the mutated version did not, as was expected.
Figure 4.2.4 displays reproducibility between the same lysates tested separately 
(A), and between duplicate samples of a single assay (B).
p65 ELISA was performed using 12 nuclear protein sample lysates in two 
separate assays to allow an assessment of assay reproducibility (Figure 4.2.4 A). 
A strong positive correlation (R2=0.887, .P<0.01) was observed between the two 
sets of data, which validates the precision of the assay. The histogram (Figure 
4.2.4 B) shows ELISA measurements for samples assayed in duplicate within one 
experiment, with appropriately low standard deviation (+/-0.64-7.69%; mean +/- 
4.42%).
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1.6
Experiment 1 absorbance Absorbance (Arbitrary)
Figure 4.2.4 p65 NF-kB ELISA provides reproducible data. A. ELISA 
spectrophotometric absorbance for 12 protein samples from two separate assays. 
R =0.887, jP<0.01. B. Mean absorbance for duplicate samples of the same assay 
displaying standard deviation (+/-0.64-7.69%; mean +/-4.42%).
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4.3 Results
4.3.1 NF-kB activity
Mutual antagonism between the GR and NF-kB is well substantiated (De 
Bosscher, Vanden Berghe et al. 2003), and NF-kB is an important mediator of 
CLL cell survival (Cuni, Perez-Aciego et al. 2004, Hewamana, Alghazal et al. 
2008). Furthermore, CLL cells express high constitutive NF-kB activation, and 
Dex can significantly repress NF-kB activation in CLL samples (Furman, Asgary 
et al. 2000). Taken together these reports led to the hypotheses that GC resistance 
in CLL can result from high baseline activation of NF-kB, or from failure of Dex- 
induced repression of NF-kB activity. p65 and p50 are two of the three most 
abundant NF-kB isoforms in CLL cells (Furman, Asgary et al. 2000, Hewamana, 
Alghazal et al. 2008), and the p65/p50 heterodimer is the most common NF-kB 
dimer in B lymphocytes (Sen 2006). Therefore, ELISA was used to quantify 
p65/p50 activation status. It was necessary to perform a preliminary timecourse 
in order to select an appropriate timepoint for comparison of baseline activity and 
Dex-induced repression. It has already been reported that NF-kB activity can be 
significantly repressed by lOOOnM Dex in CLL (Furman, Asgary et al. 2000) 
samples by 12h. Therefore, to identify an appropriate timepoint for this study, 
one sensitive and two resistant samples were cultured for 0, 2, 4, 8, 12, and 16h 
with and without lOOnM Dex, and NF-kB activity was assessed.
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Baseline NF-kB activity either increased slightly or remained fairly constant 
between 0 and 8“12h (Figure 4.3.1). In all samples screened, activity decreased 
between 12h and 16h. . A clear effect of Dex on NF-kB activity was detectable 
between 8h and 16b, in keeping with a previous study (Furman, Asgary et al. 
2000), at which points Dex reduced NF-kB binding to less than one half of the 
value in untreated cells at the same timepoint.
Based on the timecourse (Figure 4.3.1), 8h was selected as an appropriate 
timepoint for further investigation. At this timepoint, the activity of NF-kB in 
untreated CLL cells was relatively high in all samples, thereby allowing detection 
of a suppressive effect. 8 sensitive and 8 resistant samples were subsequently 
cultured for 8h +/- lOOnM Dex, and NF-kB promoter binding measured by the 
ELISA method. The results are shown in Fig 4.3.2.
Consistent with the preliminary results shown in Figure 4.3.1, between Oh and 8h 
of culture p65 and p50 activation status increased in most samples: 7/8 sensitive 
samples for p65, and 7/7 sensitive samples for p50; 5/8 resistant samples for p65, 
and 4/8 resistant samples for p50 (Figure 4.3.2). It is perhaps of note that in vitro 
culture induced NF-kB activation more consistently in the sensitive than resistant 
samples. More importantly, Dex reduced p65 and p50 activation in sensitive 
samples, as expected, but also in all but one resistant sample for which data was 
available (Wilcoxon tests for change: p65 PO.OOO, p50 ^=0.001). Given that 
p50 does not itself interact with the GR, this supports the notion that p50 is 
commonly associated with p65 in CLL cells.
166
To properly assess the hypotheses that constitutive or GC-induced NF-kB activity 
was responsible for GC resistance in this study, the data from Figure 4.3.2 was 
grouped and contrasted (Figure 4.3.3). Upon statistical analysis, there was no 
difference between GC-sensitive and -resistant CLL samples in terms of 
constitutive or Dex-induced p65 activity (Figure 4.3.3 A) (jP>0.05). 
Contrastingly, p50 activation levels were lower in resistant samples both in the 
absence (/M).009) and presence (I>=0.037) of Dex (Figure 4.3.3 A). Given that 
p65 activity was clearly repressed more than p50 activity in both groups of 
samples (4.3.3 B), it is likely that p50 homodimers were detected as well as p65- 
bound p50. Therefore, p50 might positively contribute to Dex-sensitivity by 
virtue of transcriptionally inactive homodimers (Sen 2006). However, the median 
activation levels of p50 in the sensitive group were less than 50% higher than 
those of the resistant group, calling into question the biological significance of 
this observation. Moreover, as was the case regards p65 fold change, there was 
no significant difference in p50 fold change between the two sensitivity groups 
(i^O.05) (Figure 4.3.3 B).
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■ 1875 (S)
■ 2124 (R)
■ 2551 (R)
Figure 4.3.1 NF-kB basal activation status and repression by Dex over a 16h 
timecourse. One sensitive (S) and two resistant (R) samples were cultured for up 
to 16h w/wo lOOnM Dex (UT/T). The resulting samples were used for NF-kB 
activity screening by promoter binding ELISA, which was measured by 
spectrophotometry.
Figure 4.3.2 NF-kB is downregulated by Dex at 8h in both sensitive and 
resistant samples. *2531 Oh p65=0/p50=NO DATA. **2551 T p50=NO 
DATA. Samples from 8 sensitive and 8 resistant samples were incubated w/wo 
lOOnM Dex for 8h. ELISA of p65 and p50 binding was measured by 
spectrophotometry. Wilcoxon paired tests for Dex-induced change for 8h samples 
are as follows: (n=15) p65 /^O.OOO, p50 7^=0.001.
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Figure 4.3.3 Stem and leaf plots representing NF-kB activation status in 
sensitive and resistant samples. A. Stem and leaf plots comparing baseline (UT) 
and final activation level (T) of p65 and p50. Mann-Whitney U tests for group 
difference are as follows: p65 UT P=0.1U (8S/8R), p65 T 7^0.834 (8S/8R); p50 
UT P^O.009 (8S/8R), p50 T /*=0.037 (8S/7R). B. Fold-change in activation level 
of p65 and p50. Mann-Whitney U tests for group difference are as follows: p65 
i*=0.294 (8S/8R), p50 ^=0.908 (8S/7R).
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4.3.2 NF-kB transcriptional activity
There are a number of transcriptional targets of NF-kB the expression of which 
can impact on cell survival (Horie, Watanabe et al. 2006, Vallabhapurapu, Karin 
2009). Bcl-2A1 and Bcl-xl stand out in particular in CLL as having a profound 
role in survival (Vogler, Butterworth et al. 2009). Whilst IkBu can be induced by 
NF-kB5 it can also be induced by GCs in certain cell types (Auphan, DiDonato et 
al. 1995, Scheinman, Cogswell et al. 1995), thus providing a further link between 
GC killing and NF-kB activity. However, GC-mediated induction of IkBoc has not 
been previously reported in CLL. Therefore, in order to gain insight into whether 
differences in NF-kB pro-survival transactivation existed between sensitive and 
resistant samples, it was decided to quantify mRNA expression of these three 
targets. So that the readout was temporally downstream of the NF-kB activation 
assay screen, samples were cultured w/wo Dex overnight. The results are shown 
in Figures 4.3.4 and 4.3.5.
CpG oligodeoxynucleotides are short single-stranded synthetic DNA molecules. 
When these CpG motifs are unmethylated, they act as immunostimulants, which 
stimulate NF-kB signalling in CLL cells via Toll-like receptors (TLRs) (Muzio, 
Ni et al. 1997, Muzio, Natoli et al. 1998)(Yi, Peckham et al. 1999). Therefore, 
CpG stimulated CLL cells can act as positive controls for detection of NF-kB- 
induced factors. CpG treatment clearly induces a band of the appropriate size for 
Bcl-2A1 and also augments the expression of a band that is consistent with Bcl-xl 
(Figure 4.3.4), which validates the PCR conditions for these targets. ACTS 
detection in all samples indicates acceptable sample quality and concentration. 
Bcl-xl was detectable in CLL cells that were cultured overnight as well as in cells
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that were cultured for 4h. However, Bcl-2A1 was not detected in the overnight 
samples at sufficient levels to allow quantitation, and was only faintly detectable 
at 4h without CpG stimulation. Bcl-xl and Ii<Ba alone were therefore used as 
measures of NF-kB activity in order to further explore the hypotheses that GC 
resistance results from either high baseline NF-kB activity or failure of GC- 
induced repression of NF-kB activity.
Neither IkBci nor Bcl-xl mRNA expression was consistently altered by Dex 
(P>0.05) (Figure 4.3.5). Furthermore, expression of both transcripts at baseline 
and Dex-induced fold change was not significantly different between the two 
groups (/*>().05). A difference did exist between the two sensitivity groups in 
Bcl-xl expression of Dex-treated samples, as the sensitive group displayed close to 
double the median expression level of the resistant group. However, this finding 
was counterintuitive, as Bcl-xl is upregulated by NF-kB and is a pro-survival 
member of the Bcl-2 family of proteins. It is plausible that this difference was 
biologically negligible, as there appears to be considerably less Bcl-xl mRNA at 
21,5h than 4h (Figure 4.3.4).
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Bcl-2A1 Bcl-xl Actin
CpG +/-
4h 0/N -cDNA 4h 0/N -cDNA 4h 0/N -cDNA
- + ~ ~ i “ :
Figure 4.3.4 Bcl-xl but not Bcl-2A1 is detectable by qRT-PCR in CLL cells 
cultured overnight. qRT-PCR was perfonned to amplify Bcl-xl (309bp) and Bcl- 
2A1 (539bp) in a CLL sample cultured w/wo CpG treatment for 4h, and in a CLL 
sample cultured w/wo lOOnM Dex for 21.5h. ACTS (Actin) (626bp) was detected 
to estimate sample quantity/quality. Products were separated and visualised by 
AGE.
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IkBq ™
Bcl-xl b
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Figure 4.3.5. IkBo. and Bcl-xl mRNA expression is not associated with 
sensitivity group. 10 sensitive ( black lines) and 10 resistant samples (grey lines) 
were screened for Bcl-xl and IkBo. expression by qRT-PCR after being cultured 
for 21.5h w/wo lOOnM Dex. A. Relative transcript abundance w/wo Dex. IkBo. 
levels do not change in a consistent manner (/*=0.794, Wilcoxon test). Bcl-xl 
levels do not change in a consistent manner CP=0.460, Wilcoxon test). GC- 
sensitive and -resistant samples are not significantly different in terms of (A) IkBo. 
baseline and final expression, or (B) fold-change (7*=0.940 (UT), P= 0.762 (T), 
P=0.545 (FC), Mann-Whitney U test). GC-sensitive and —resistant samples are 
not significantly different in terms of Bcl-xl baseline expression (A) or fold- 
change (B), but are with respect to (A) expression following Dex treatment {P = 
0.247 (UT), 0.021 (T), 0.132 (FC)).
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4.3.3 NF-kB inhibition
The canonical pathway of NF-i<B activation is controlled by IkBcx and upstream 
kinases (Neumann, Naumann 2007). Active, unphosphorylated, IkBcx antagonises 
p65 and p50, which are predominantly activated by the canonical pathway (Sen 
2006). To further test the idea that NF-kB pro-survival activity may have a 
central role in Dex resistance, Bay117082, an inhibitor of IkBcx degradation­
targeting phosphorylation (Pickering, de Mel et al. 2007), was added to 3 resistant 
samples w/wo Dex for overnight culture. A range of concentrations of NF-kB 
inhibitor was used to span the known lethal dose that has been previously used 
within this research group. Similarly, the timepoint for this study was based upon 
the known efficacy of Bay117082. The results are shown in Fig 4.3.6. p-IkBcx 
and, to a lesser extent, IkBcx itself, were downregulated by the higher doses (4 and 
8|iM) of Bayl 17082 in all three resistant samples at 17.5h (Figure 4.3.6 A), as 
expected (Pickering, de Mel et al. 2007). However, whilst Bayl 17082 alone 
displayed dose-dependent cytotoxicity it did not sensitise CLL cells to killing by 
Dex at any concentration (Figure 4.3.6 B). Taken together, the various data 
measuring NF-kB activity does not support a critical role for NF-kB in resistance 
of CLL samples to GC-induced killing.
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Bayll7082 (|iM) 0 2 4 8
kBa 
p-kBa 
Actin
% Viability 76 61 69 59 26 32 2.1 3.0
2124
Bayll7082(pM) 0 2 4 8 Bayll7082 (nM) 0
2174
2 4 8
Dex - +- + - + - +
% Viability 79 65 79 60 56 54 9.5 16.7
Dex - + - + - + - +
kBa 
p-kBa 
Actin
% Viability 55 43 60 46 39 38 0.8 0.8
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Figure 4.3.6. Inhibition of the canonical NF-kB pathway does not facilitate
killing of CLL cells by Dex. Three Dex-resistant CLL samples were incubated 
w/wo lOOnM Dex overnight with a range of concentrations of Bay 117082. 
Viability was determined by DiOC6/PI staining. A. Western blots for iKBa/p- 
IkBo, and Actin. B. Relative viability data as determined by DiOC6/PI.
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4.3.4 Lck and GSK-3P
Unpublished data from this department indicates a prominent role for Lck in BCR 
signalling in CLL cells. Furthermore, a negative correlation between Lck mRNA 
expression and Dex-sensitivity has been reported in CLL samples (Harr, Caimi et 
al. 2010). GSK-3(3 is a BCR/PI3-K-regulated mediator of cell survival. When 
phosphorylated on Serg the kinase possesses prosurvival activity . GSK-3(3 is also 
strongly implicated in GC resistance and inhibition of Bim-induced killing in 
ALL via the PI3-K/Akt survival pathway (Spokoini, Kfir-Erenfeld et al. 2010). In 
light of these considerations, it seemed plausible that Dex-induced killing might 
be influenced by baseline expression of Lck and GSK3-(3 and the Serg 
phosphorylation status of GSK3-(3. Therefore, GC~sensitive and -resistant CLL 
samples were compared for baseline expression of Lck, total GSK3-p and p-GSK- 
3(3 (Serg). The results are shown in Fig 4.3.7.
As T cells highly express Lck, B cells were purified from 6 sensitive and 6 
resistant samples prior to this kinase screen. A Jurkat T-cell line sample and a 
cross-linked CLL sample (BCR-simulated) served as positive controls for Lck, 
and p-GSK-3(3. No difference was observed between the two groups in terms of 
baseline expression of these proteins or GSK-3[3 Ser9 phosphorylation. This 
suggests that baseline Lck expression and baseline GSK-3f3 expression/activation 
do not strongly influence GC sensitivity in CLL cells.
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Figure 4.3.7 Baseline expression of Lck, GSK-3P, and GSK-3P does not 
correlate with GC-sensitivity group. B cells were purified from 6 samples from 
each sensitivity group. A. Expression of Lck (56kDa), GSK-3P (46kDa), and p- 
GSK-3p was measured by Western blot using (lOpg) RIPA lysates. Actin 
(40kDa) was used as a loading control. “S” = sensitive sample; “R” = resistant 
sample; J = Jurkat; XL = a cross-linked CLL sample. B. Densitometry for “A”. 
Horizontal lines represent median expression for each group; S = sensitive 
samples, R = resistant samples. Mann-Whitney U tests for group difference are as 
follows: Lck 7^0.2; GSK-3p 7^0.522; p-GSK-3p P =0.749.
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4.3.5 XIAP and C-IAP2 expression
Despite the evidence that GCs are not absolutely dependent on caspases to kill 
lymphoid cells (Kroemer, Martin 2005), overexpression in resistant samples 
before or after treatment could slow down killing and contribute to a resistant 
phenotype. The lAPs are also reported transcriptional targets of NF-kB (Horie, 
Watanabe et al. 2006) (Section 4.2.1). lAPs have a well-reported role in apoptotic 
suppression (LaCasse, Mahoney et al. 2008) and XIAP has previously been linked 
to GC resistance in T cells (Conte, Liston et al. 2001). Baseline levels of C-IAP2 
and XIAP (c-IAPl proved difficult to quantify) were measured to test the 
hypothesis that GC resistance results from increased expression of these lAPs. 
XIAP levels were measured before and after treatment with Dex in order to test 
the idea that Dex resistance might be related to defective repression of XIAP 
expression. Upon analysis of densitometry data produced by Western blot, 
neither baseline nor induced IAP expression correlated with sensitivity group (All 
jP>0.05) (Figure 4.3.8). Therefore, it would not appear that GC resistsance in this 
investigation is the result of elevated IAP expression.
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Figure 4.3.8. XIAP and C-IAP2 protein expression does not correlate with 
GC-sensitivity group. A. C-IAP2 (68kDa) and XIAP (53kDa) Western blots of 
untreated samples (5pg) from 3 sensitive and 3 resistant samples at 0, 6, 24, and 
48h. Actin (42kDa) was used as a loading control. B. Stem-leaf plots for group 
comparisons of band intensity from “A”. Mann-Whitney U tests for group 
difference are as follows: C-IAP2 P=0.215 (Oh), jP=0.275 (6h), /^0.513 (24h), 
/M).827 (48h); XIAP /M).513 (Oh), ^=0.513 (6h), /M).275 (24h), 7M).275 (48h). 
C. Western blots (lOpg per sample) of XIAP expression at 8h, 12h, and 16h in 
sensitive and resistant samples +/- 1 OOnM Dex. D. Stem and leaf plots of band 
intensity from “C”. Mann-Whitney U tests for group difference are as follows: 
XIAP -Dex P= 0.2 (8h), P= 0.631 (12h), /M).465 (16h); XIAP +Dex 7^0.749 
(8h), P^O.873 (12h),P=0.361 (16h).
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4.4 Discussion
The puipose of this chapter was to identify whether NF-kB signalling—a key 
CLL survival pathway (Cuni, Perez-Aciego et al. 2004) and source of cross-talk 
with GR signalling (De Bosscher, Haegeman 2009)—was an important mediator 
of GC resistance in CLL. Following the rejection of the hypotheses relating to 
this question, the chapter was expanded to include the kinases Lck and GSK-3p, 
as well as IAP proteins.
p65 baseline activation at 8h was found to be similar in both groups. However, 
p50 baseline expression appeared to be elevated in the sensitive samples. 
Nevertheless, the median activation level in the sensitive group was less than 50% 
higher than those of the resistant group, and it is therefore unlikely that this 
feature plays a critical role in GC resistance. Furthermore, there was no observed 
difference in fold-change in NF-kB activity upon Dex treatment.
ELISA of nuclear NF-kB promoter-binding capacity cannot detect all plausible 
alterations in NF-kB activity, as it only measures whether NF-kB is both within 
the nucleus and possesses the ability to bind to a consensus promoter sequence. 
The use of a consensus binding sequence does not take into account promoter 
context, enhancer sequences, and chromatin structure. Furthermore, competition 
between the GR and NF-kB for shared promoters; competition for coactivators; 
inhibitory tethering of NF-kB by the GR, and co-association related post- 
translational modifications of NF-kB have not been addressed within this study. 
Such variables could be assessed by chromatin immunoprecipitation (promoter­
binding competition), standard immunoprecipitation (GR tethering of NF-kB,
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coactivator binding), and Western blotting (NF-kB modifications). Nevertheless, 
nuclear localisation, promoter-binding site blocking of NF-kB by GR, and 
promoter binding related post-translational modification of NF-kB would be 
detected by the type of assay that was used in this study. Most importantly, Dex 
treatment of CLL has already been reported to substantially downregulate NF-kB 
activity as detected by EMSA (Furman, Asgary et al. 2000), which provides 
similar insight to ELISA. Therefore, the assay used here can be deemed relevant 
despite the many models for explaining GR and NF-kB cross talk (De Bosscher, 
Vanden Berghe et al. 2003, Nissen, Yamamoto 2000).
The relatively early timepoint of 8h was used so that high basal activity of NF-kB 
could be contrasted with the activity measured in Dex-treated samples. Though 
this timepoint was given validity by a previous study that focused on 12h 
(Furman, Asgary et al. 2000), it may be worth expanding this study in future to 
include timepoints closer to the 48h timepoint selected for sensitivity group 
designation.
Bcl-xl and IkBcx were used as readouts of NF-kB activity. Whilst Bcl-2A1 proved 
difficult to detect in CLL cells from overnight culture, Bcl-xl and IkBol were 
quantifiable. Neither a consistent change nor a difference between the two groups 
in terms of baseline or fold-change mRNA abundance was detected. 
Counterintuitively, prosurvival Bcl-xl expression following treatment was higher 
in the sensitive group. However, as Bcl-xl expression appeared to be lower at 
baseline at 21.5h—the timepoint used for quantitation—than 4h, the significance 
of changes in expression at the former timepoint is weakened. Whilst many other
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potential transcriptional targets exist that could have been used to measure NF-kB 
prosurvival signalling (Horie, Watanabe et al. 2006, Vallabhapurapu, Karin 2009), 
it was practical to only quantify a small number of targets. Again, timepoints for 
screening could be expanded, but the single overnight timepoint was considered 
reasonable based on its temporal positioning between the NF-kB activity screen 
(8h) and the timepoint selected for sensitivity designation (48h).
The extent of Dex-induced killing was not increased at sublethal or lethal doses of 
Bay117082. Though a single timepoint was used, and this was different from the 
timepoint used for sensitivity designation, the DiOCe/PI killing assay provides 
higher sensitivity than using PI alone. Other NF-kB inhibitors do exist, but given 
the fact that p65 and p50 are controlled predominantly by the canonical pathway 
of NF-kB activation (Sen 2006), Bay117082 seemed sufficient. Taken together, 
the NF-KB-related data, along with the GILZ mRNA expression data from Section 
3.3.3, argue against a critical role for NF-kB in GC resistance in CLL.
Baseline (tO) Lck and GSK-3|3 expression and Sei*9 phosphorylation did not 
correlate with sensitivity group. This pilot study used 6 sensitive and 6 resistant 
samples. Lck phosphorylation was not measured as part of this pilot screen due to 
time constraints, though this variable may be worthy of future characterisation due 
to its importance in Lck-mediated signalling (Harr, Caimi et al. 2010). 
Furthermore, an important role for GSK-3a has been reported in ALL (Spokoini, 
Kfir-Erenfeld et al. 2010), and so it may be worth studying this protein in CLL 
within the context of GC signalling. It may also be worth expanding this initial
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study in the future to identify whether GCs alter Lck or GSK-3 activity in CLL 
cells.
It was decided to identify whether baseline or Dex-induced expression of IAP 
proteins correlated with sensitivity group. Both hypotheses were rejected 
convincingly with respect to XIAP, as samples were from a number of timepoints. 
However, c-IAPl was not included in this screen as it was difficult to detect a 
high resolution band with the available antibody, and the effect of Dex on C-IAP2 
was not investigated. Nonetheless, XIAP is the member of this family with a 
reported link to GC resistance in lymphoid cells (Conte, Liston et al. 2001).
Rather than expand into other areas of GR crosstalk, of which there are many 
(Section 1.6), it was decided to perform studies downstream in the killing pathway 
model to study the machinery of killing (Section 1.7).
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Chapter 5: A central role for Bim 
in GC-induced killing of CLL cells
5.1 Introduction
In the previous chapter it was demonstrated that NF-kB signalling is not 
fundamental to GC resistance in this study. To a lesser extent, Lck, and GSK~3p 
involvement in GC resistance was not supported. Additionally, further 
downstream, a contribution of lAPs to GC resistance in these samples was not 
found. Although an argument could be made to investigate other signalling 
molecules that could impact on GR function (Section 1.6), it was instead decided 
to consider the possibility that GC resistance might result from blockade of the 
mitochondrial death pathway (Section 1.7.1). This approach was supported by the 
observations of Section 2.3 that confirmed the involvement of apoptosis, which 
was clearly more demonstrable in sensitive samples.
Apoptosis plays a critical role in the killing of malignant cells by chemotherapy 
and radiation, particularly in lymphoid cells (Johnstone, Ruefli et al. 2002, Cory, 
Adams 2002) (Section 1.4.3). The primary model of intrinsic apoptosis activation 
depends upon proapoptotic members of the family binding and antagonising 
antiapoptotic members, which leads to indirect activation of the effectors, Bax 
and/or Bak (Danial, Korsmeyer 2004). Alternatively, an indirect activation model 
has been reported, whereby Bax and Bak are bound and activated directly by 
proapoptotic proteins (Kuwana, Bouchier-Hayes et al. 2005). Following Bax/Bak 
activation, pores are formed in the outer mitochondrial membrane resulting in
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mitochondrial depolarisation and release of cytochrome c and Smac/DIABLO, 
which activate caspases (Danial, Korsmeyer 2004).
In CLL cells the expression of the BCL-2 gene family is shifted towards 
protection from apoptosis (Gottardi, Alfarano et al. 1996), and Bcl-2 members are 
frequently overexpressed in leukaemic cells (Ploner, Schmidt et al. 2005) (Section 
1.7.2). Furthermore, induction of proapoptotic BH3 proteins (Wang, Malone et 
al. 2003a, Han, Flemington et al. 2001) and repression of their antiapoptotic 
counterparts (Chauhan, Auclair et al. 2002, Casale, Addeo et al. 2003) has been 
observed in response to GCs (Section 1.7.3).
Studies of a panel of B-ALL cell lines have previously shown Bim protein 
induction to correlate with GC sensitivity, and siRNA knockdown of Bim 
expression was related to increased cell survival (Abrams, Robertson et al. 2004). 
Bim mRNA was upregulated by Dex in both sensitive and resistant samples 
following GC treatment in Section 3.3.3. Given the importance of Bim in the GC- 
induced killing of multiple cell types (Bachmann, Gorman et al. 2005, Lu, 
Quearry et al. 2006, Bouillet, Metcalf et al. 1999, Abrams, Robertson et al. 2004, 
Erlacher, Michalak et al. 2005, Lopez-Royuela, Balsas et al. 2010), and since Bim 
expression can be regulated at the post-transcriptional level, it was decided to 
begin this investigation by comparing Bim protein upregulation in GC-sensitive 
and -resistant CLL samples. As described in Section 1.7.4, the three major 
isoforms—Bim-EL, Bim-L, and Bim-S (Figure 1.6)—are consistently observed in 
haematopoietic cells, including CLL (Kfir-Erenfeld, Sionov et al. 2010).
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5.2 Materials and Methods
5.2.1 CLL cell and PBMC culture
Cells were thawed, and incubated at 2-5x106 cells/ml in RPMI supplemented with 
10% FCS (Sigma), 2mM L-Glutamine (Invitrogen), lOOU/ml penicillin, and 
lOOfig/ml streptomycin (Invitrogen), as described in Section 2.2.4.
5.2.2 Inhibitor studies
In some experiments, CLL cells (2xl06/ml/well) were incubated with the MEK 
inhibitor—U0126 (Calbiochem)—at a final concentration of 10 pM . In other 
experiments, Z-VAD (OMe) FMK Caspase Inhibitor I (Calbiochem) was used at a 
final concentration of 50pM after preincubation of CLL cells (5xl06/ml/well) for 
Ih under standard culture conditions. Both of these inhibitors were diluted in 
DMSO, which was added to untreated control samples at concentrations 
equivalent to those of inhibitor treated samples.
5.2.3 Coculture of CLL cells with CD154 expressing cells
Parental and hCD 154-overexpressing NIH 3T3 mouse fibroblast cell lines were 
provided by Prof. G Cohen at the MRC Toxicological Unit, Leicester. Cells were 
subcultured in high-glucose DMEM with 10% heat-inactivated FCS, 2mML- 
glutamine, and 1% penicillin/streptomycin, and kept in culture until passage 25- 
30. CLL cells were cocultured with the monolayer cells at 3x106 cells in 1ml of 
RPMI, containing IL-4 at a final concentration of lOng/ml.
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5.2.4 Cell lines
Raji cells (human Burkitt Lymphoma cell line) were maintained in RPMI 
supplemented with 10% Fetal Calf Serum (FCS; Biosera, Ringmer, East Sussex, 
UK), 2mM L-Glutamine, lOOU/ml penicillin, and lOOmg/ml streptomycin. The 
cells were cultured at 37°C in the presence of 5% CO2.
Jurkat cells (human acute T-cell Leukaemia cell line) were maintained in RPMI 
supplemented with 10% Fetal Calf Serum (FCS; Biosera, Ringmer, East Sussex, 
UK), 2mM L-Glutamine, lOOU/ml penicillin, and lOOmg/ml streptomycin. They 
were cultured at 37°C, in the presence of 5% CO2.
HeLa cells (human epithelial carcinoma cell line) were maintained in Eagle’s 
medium supplemented with 10% Fetal Calf Serum (FCS; Biosera, Ringmer, East 
Sussex, UK), 2mM L-Glutamine, lOOU/ml penicillin, and lOOmg/ml 
streptomycin. The cells were cultured at 37°C, in the presence of 5% CO2.
5.2.5 Sample preparation and standard Western blotting
Following incubation for 0, 12, and 24h w/wo lOOnM Dex, cells from 6 sensitive 
and 6 resistant samples were washed in PBS, then lysed in 200pL SDS Sample 
Buffer containing 125mM Tris-HCl (pH6.8), 20% glycerol (Sigma), 4% SDS 
(Fisher Scientific, Loughborough, Leicestershire, UK), 10% p-mercaptoethanol 
(Sigma) and 0.006% bromophenol blue (VWR International, Lutterworth, 
Leicestershire, UK). Samples were then sonicated at 30Hz for 4 x 5secs, and 
incubated at 95°C for 5mins.
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Separate aliquots of cells were lysed in the same SDS Sample Buffer except in the 
absence of reducing agent and dye, to allow normalisation of protein 
concentration prior to Western blotting. f3-mercaptoethanol and bromophenol 
blue were subsequently added to samples prior to Western blotting.
Further samples were lysed in RIPA (RadioImmunoPrecipitation Assay) buffer, 
containing 50mM Tris, (pH7.6), 150mM NaCl, 25mM Na-pyrophosphate, 50mM 
Na-glycerophoshpate decahydrate, 2mM EDTA, and 2mM EGTA.
Protein determination was carried out in duplicate using the Biorad DC protein 
assay (Biorad, CA, USA) according to the manufacturer’s instructions. Following 
protein concentration normalisation, remaining components of SDS-sample buffer 
were added to final concentrations of 10% p-mercaptoethanol (Sigma) and 
0.006% bromophenol blue (VWR International, Lutterworth, Leicestershire, UK).
Either 20pl of 200pl of total sample, or between 5pg and 20pg of total protein per 
well were loaded to lanes in Western blotting. Western blotting was performed as 
described in Section 2.2.8, using the conditions described in Table 5.2.1.
5.2.6 Cell viability by PI/FACS
40pl aliquots of resuspended cells were added to 80pi of PI in PBS at 5pg/ml for 
30mins on ice, before analysis as described in Section 2.2.6.
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Table5.2.1 Antibodies used in immunoblotting. Antibody incubations were for 
Ih at R/T or O/N at 4°C.
Primary Antibody Dilution Secondary Antibody Dilution
Bim Rabbit PAb
Cell Signalling
1/2000 5%
BSA TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
Actin Mouse MAb AC-74 
Sigma
1/10,000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
p-ERK 1/2 Mouse MAb E-4 
Santa Cruz
1/2000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
ERK 1/2 Rabbit PAb
Santa Cruz
1/10,000 5%
milk TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
Bcl-2 Rabbit PAb
Santa Cruz
1/1000 5%
milk TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/2000
Tubulin Mouse PAb
Abeam
1/10,000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
Bax Mouse MAb 3
BD Pharmingen
1/2000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
Bak Rabbit PAb
Santa Cruz
1/2000 5%
milk TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
Bcl-2 Mouse MAb 100/D5 
Abeam
1/500 5% milk 
TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/2000
Mcl-1 Mouse MAb 22
BD Pharmingen
1/1000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/2000
PARP Mouse MAb C2-10 
RnD Systems
1/4000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/2000
Bcl-xl Rabbit PAb
BD Pharmingen
1/1000 5%
milk TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/2000
DEC 8 Mouse MAb
EP1660Y
Abeam
1/2000 5%
milk TBS-T
Goat Anti-Mouse HRP 
Santa Cruz
1/5000
Mcl-1 Rabbit PAb
Santa Cruz
1/2000 5%
milk TBS-T
Goat Anti-Rabbit HRP 
Santa Cruz
1/5000
5.2.7 Assessment of cell viability by DiOCc and PI dual staining
Aliquots of 40|ul cells were taken and added to 40|_il DiOCg for 15mins at 
37°C/5% CO2. Then, samples were added to 160pi PI (5pg/ml) in PBS and 
incubated for 30mins on ice before analysing as described in Section 2.2.7.
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5.2.8 Bax/Bak Immunoprecipitation
Bax IP lysis buffer contained lOmM HEPES (pH7.4), 150mM NaCl, 2mM 
EDTA, 1 % 3 - [(3 “Chlolamidopropyl)dimethylammonio] -1 propanesulfonatehydrate 
(CHAPS) (Sigma, UK), and 1/100 protease and phosphatase inhibitor cocktails. 
A buffer of the same composition but with 0.2% CHAPS was used for washing 
steps.
Samples were first washed in ice-cold PBS before adding 200pl of lysis buffer. 
They were then agitated on a rotor mixer at 4°C for l-2h. Sepharose A or G beads 
were pre-rinsed in lysis buffer. Samples were centrifuged at 13,000rcf for 15secs 
at 4°C, and pellets were discarded. 30pl of both Sepharose A and G beads were 
added to each sample, which were then rotor-mixed for Ih at 4°C (preclearing). 
Samples were pulse centrifuged at 10,000rcf, and protein concentration of the pre­
cleared supernatant was measured by DC protein assay (Biorad), as previously 
described. lOOpg of protein/sample was added to 2|ag/lpg of Bax IgGi 6A7 
(Sigma) or Bak IgG2A Ab-1 (Calbiochem) antibody, respectively. Samples were 
incubated with 30pl beads per sample for Ih on a rotor mixer, and then pulse 
centrifuged again. Beads were washed in IP wash buffer and then resuspended to 
a final volume of 30pl total SDS sample buffer.
5.2.9 Bim Immunoprecipitation
300pl RIP A (containing 1/100 phosphatase inhibitor) was added to each sample 
prior to sonication. Protein A beads were prewashed and 50pi slurry was used to 
preclear each sample for Ih at 4°C on a rotor mixer. The beads were discarded
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after the samples had been carefully removed. For IP, lOOpg sample was made up 
to lOOpl, and Ipg Bim Rabbit PAb (Cell Signalling) was added. In the case of 
IgG controls, Ipg IgG-Rabbit antibody was added. Samples were mixed 
overnight on a rotor mixer at 4°C. The following day, Protein-A beads were pre­
rinsed and 30pl slurry was added to each sample. Samples were mixed for 
between 1 and 2h at 4°C on the rotor mixer. The supernatant was very carefully 
removed and stored after high-speed centrifugation. Beads were washed twice in 
400pl RIPA buffer, and were made up to 40 pi prior to addition of 6x Loading 
Buffer. Samples were then briefly vortexed and heated at 95°C for lOmins.
5.2.10 Bim-IP Western blots
Large 15% polyacrylamide gels with 5% stacking layers were used to separate out 
IP protein bands. lOpg of RIPA whole-cell lysate was loaded for each sample 
(10% of protein used for Bim IP), along with the entire IP samples and 10% of 
their equivalent supernatants post-IP. The gels were run over 24h at between 50V 
and 300V until the dye front had migrated to the very edge of the gels. Blots were 
transferred to Immobilon PVDF membrane for 2h at 400mA, and were then 
blocked in 5% Advanced Blocking Reagent for 30m. Exactacruz (Santa Cruz) 
secondary antibodies were used rather than standard antibodies to reduce heavy 
and light-chain background.
5.2.11 Bim Knockdown
To inhibit Bim translation using siRNA, a mixture of 4 different siRNA duplexes 
(Catalog no. M-004383-02, Thermo Scientific Dharmacon, Surrey, UK) targeting 
all three major transcript variants of Bim (Bim-EL, Bim-L and Bim-S) was used.
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As a control, non-targeting siRNA (Catalog no. D-001210-02, Thermo Scientific 
Dharmacon) was also used. For each transfection, 1 x 107 CLL cells were 
resuspended in 100 pi transfection solution from a Human B cell Nucleofector Kit 
(Amaxa AG/Lonza, Cologne, Germany) and mixed with 0.5 mnol of Bim siRNA 
duplexes or 0.5 nmol of non-specific control siRNA before electroporation on the 
Nucleofector (Amaxa AG/Lonza) using program X-03. Cells were then mixed 
with 0.9 ml of pre-warmed medium and cultured overnight at 37°C. The cells 
were subsequently incubated at a density of 5 x 106 cells/ml, with or without Dex, 
for a further 48h.
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5.3 Results
5.3.1 Bim expression and regulation, and activation of downstream 
apoptotic effectors
As Bim mRNA was shown to be upregulated by Dex in both sensitive and 
resistant CLL samples (Figure 3.3.6), it was important to identify whether the 
same was true of Bim protein, given the previously reported importance of Bim 
induction to GC-induced killing (Bachmann, Gorman et al. 2005, Lu, Quearry et 
al. 2006, Bouillet, Metcalf et al. 1999, Abrams, Robertson et al. 2004, Erlacher, 
Michalak et al. 2005, Lopez-Royuela, Balsas et al. 2010). Time points for 
incubation were chosen so as to allow for a delay between gene transcription and 
protein accumulation. Given that Bim transcript levels had been measured at 6h 
and 21.5h, it was decided to measure Bim protein levels at 12 and 24h.
As is shown in Fig 5.3.1, Bim protein upregulation was apparent in the majority 
of CLL samples tested at both 12h and 24h, regardless of sensitivity grouping, 
though it also accumulated in the absence of Dex treatment, as indicated by the 
higher levels observed at 12h and 24h compared with Oh in individual samples 
(Figure 5.3.1 A). Induction of Bim-EL and Bim-S was identifiable in most 
samples [7*=0.002 Bim-EL (12h); P=0.002 Bim-EL (24h); i^0.05 Bim-S (12h), 
TMXOl Bim-S (24h)], whilst Bim-L induction was less consistent across the 12 
samples at both timepoints (#>0.05).
To test the idea that fold-induction of Bim protein might be higher in the sensitive 
group, the two groups were compared (Figure 5.3.2). A statistical difference in 
fold-induction of the three isoforms of Bim between the two sensitivity groups
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was not detectable (P>0.05). This may not be surprising given that mere 
upregulation of Bim is insufficient for apoptosis in certain lymphoma cells (Kfir, 
Sionov et al. 2007). However, some studies have previously suggested that 
failure to induce Bim causes GC resistance (Bachmann, Gorman et al. 2005). 
Despite these observations, at 24h, Bim-EL fold-change did appear to be skewed 
towards the sensitive group, and so extent of Bim-EL induction may contribute to 
Dex response in certain sensitive samples (Figure 5.3.1 B). To strengthen this 
data, separate experiments were performed on 4 samples of each sensitivity group 
after 48h incubation (Figure 5.3.2 D/E). In agreement with the data from earlier 
timepoints, Bim-EL was induced in all samples tested at 48h.
Of the three Bim isoforms measured (Figure 5.3.1), it was apparent that Bim-EL 
was the most consistently upregulated, with a tendency for the sensitive CLL 
samples to show higher fold-induction of this isoform than the resistant samples 
(Figure 5.3.1 C). This trend for Bim-EL to be upregulated less prominently in 
GC-resistant CLL samples may have contributed to GC resistance in these 
samples. ERK, which is associated with pro-survival signalling (Section 1.6.6), 
has been reported to phosphorylate and downregulate Bim-EL (Ley, Ewings et al. 
2005, Fukazawa, Noguchi et al. 2004). Therefore, the impaired GC-induced Bim 
upregulation seen in some GC-resistant CLL samples might have resulted from 
higher constitutive ERK activation, or higher ERK activity post-Dex in these 
samples. To test this idea, ERK1/2 activation in resistant and sensitive samples 
was compared by comparison of the expression of the activated phosphorylated 
version of the kinase with total expression.
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Figure 5.3.1. Bim protein expression is increased by Dex in both sensitive 
and resistant samples. A. 6 sensitive and 6 resistant samples were cultured 
w/wo lOOnM Dex for 0, 12, and 24h. The 3 protein isoforms (EL, L and S) can 
be seen on the Western blots at 23, 15, and 12kDa, respectively. Actin is 
positioned at 42kDa. B. Densitometry for each Bim isoform relative to Actin at 
12 and 24h. Blue lines represent sensitive samples, whilst red lines represent 
resistant samples. P-values of Wilcoxon tests for change are as follows: Bim-EL 
/M).002 (12h), P=0.002 (24h); Bim-L 7^0.060 (12h), 7^0.099 (24h); Bim-S 
7*=0.050 (12h), 7*=0.010 (24h). C. Fold change for each isoform upon Dex 
treatment. P-values for Mann-Whitney U test for group difference are as follows: 
Bim-EL 7M).749 (12h), 7M).423 (24h); Bim-L 7^0.200 (12h), 7^0.873 (24h); 
Bim-S 7^=0.873 (12h), 7^=0.150 (24h). D. Densitometry for independent 
experiments to demonstrate Bim-EL protein induction at 48h in both sensitive and 
resistant samples. E. Representative Western blot from those used in “D”.
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As Figure 5.3.2 B demonstrates, sensitive samples show consistent 
downregulation of p-ERK at both 12h and 24h (P<0.05), whilst p-ERK appears to 
be stable or be induced slightly by Dex in resistant samples at 12h, and is 
downregulated in 4/6 by 24h. In the absence of Dex treatment there seems to be a 
non-significant trend for ERK activation to be higher in sensitive samples, 
whereas in the presence of Dex, ERK activation is higher in resistant samples 
(Figure 5.3.2 C). Combining the two measurements to yield fold-change results in 
a significant difference in ERK activation between the two groups (jP=0.028, 12h; 
i*=0.028, 24h), with median fold change in ERK activation following Dex 
treatment more than two-fold higher in the resistant group at both timepoints. 
However, the difference in fold-change between the two groups appears to be 
mostly attributable to higher baseline ERK activation in sensitive samples. 
Nonetheless, following Dex treatment at 24h, 5/6 sensitive samples display p- 
ERK/ERK ratios below that of all 6 resistant samples (Figure 5.3.2 B), which 
suggests that higher ERK kinase activity post-Dex treatment may contribute to the 
tendency for resistant CLL samples to display less Bim-EL induction at 24h 
(Figure 5.3.1 C).
Since MEK is the kinase responsible for activating ERK by phosphorylation, its 
inhibition leads to ERK deactivation. Furthermore, MEK inhibitors have been 
shown to potentiate Dex lethality in ALL cells via Bim (Rambal, Panaguiton et al. 
2009). Therefore, in order to test the involvement of ERK in GC resistance 
further, the effect of a MEK inhibitor on GC-induced Bim upregulation and 
cytotoxicity was investigated (Figure 5.3.3).
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Figure 5.3.2. p-ERK/ERK ratio is reduced by Dex treatment in sensitive 
samples more so than in those that are resistant. A. Western blots for 6 
samples from each sensitivity group. ERK1 can be seen at 44kDa, whilst ERK2 
at 42kDa. B. Densitometry for p-ERKl/2 normalised to ERKl/2. Blue lines 
represent sensitive samples whilst red lines represent resistant. P-values represent 
Wilcoxon test for only the sensitive samples: jP=0.004 (12h), /*=0.016 (24h). C. 
Grouped data comparisons. P-values represent Mann-Whitney U test: Fold- 
change /*=0.028 (12h), P=0.028 (24h); Untreated P=0.2 (12h). P=0.262 (24h); 
Dex-treated P=0.150(12h), P=0.150 (24h).
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Three samples from each group were cultured with MEK inhibitor and/or Dex to 
identify whether MEK inhibitor could clearly facilitate Dex-induced killing of 
resistant samples, and to identify potential cross-resistance. As expected, both 
sensitive and resistant samples induce Bim-EL in response to Dex (Figure 5.3.3 
B), and this effect was much clearer at 24h than 6h, though induction of Bim-EL 
in sample 2029 was relatively weak. However, a consistent induction of Bim-EL 
by MEK inhibitor was not detected, and only 2499—a sensitive sample— 
appeared to demonstrate this phenomenon. MEK inhibitor did not appear to 
sensitise GC-resistant CLL samples to GC-induced killing (5.3.3 C). This argues 
against the hypothesis that GC resistance in this study resulted from 
downregulation of Bim-EL by high ERK activity. Furthermore, MEK inhibitor 
was selectively cytotoxic to GC-sensitive CLL cells, possibly suggesting that 
sensitivity to GCs and MEK inhibition are mediated by shared mechanisms.
Bim protein has been shown to be induced in both sensitive and resistant samples 
in response to Dex (Figure 5.3.1). Therefore, modification of Bim, its sub-cellular 
localisation, or coassociation with Bim supressors could contribute to a failure of 
Bim to induce apoptosis in resistant samples (Puthalakath, Strasser 2002). 
However, prior to studying GC-resistant CLL samples to identify such regulation, 
it was first important to show that downstream effectors of apoptosis were 
activated by Dex treatment to a greater extent in sensitive than resistant samples. 
This would rule out downstream defects in death signalling as potential resistance 
mechanisms.
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As described in Section 1.7.7, Bax and Bak are cytosolic proteins that undergo 
conformational changes and oligomerisation as a critical activating step of 
apoptosis in CLL (Dewson, Snowden et al. 2003, Vogler, Dinsdale et al. 2008). 
Moreover, a strong correlation has previously been observed between the number 
of Dex-induced apoptotic CLL cells and the percentage of cells stained with 
antibodies that recognise active Bax and Bak conformation (Bellosillo, Villamor 
et al. 2002). Therefore, it would be expected for Bax and Bak to be mediators of 
GC-induced apoptosis in this study.
First of all, a screen of basal tO expression of Bax and Bak proteins was performed 
(Figure 5.3.4). In theory, higher baseline expression of Bax and Bak would 
provide more molecular targets for death inducing Bcl-2 family proteins such as 
Bim, thus making samples more prone to apoptotic stimuli.
As shown in Figure 5.3.4, the abundance of Bax and Bak protein did not differ 
between sensitive and resistant samples (jP>0.5). This observation is consistent 
with a previous study of 39 CLL samples that showed no relationship between 
reduced Bax levels and ex vivo resistance to corticosteroids (P>0.5), despite a 
correlation existing between Bax levels and traditional therapies; anthracyclines, 
alkylating agents and vincristine (all P<0.5) (Bosanquet, Sturm et al. 2002).
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Figure 5.3.3. MEK inhibitor does not sensitise GC-resistant samples to Dex 
but does kill 2/6 samples effectively, both of which are Dex sensitive. A.
Western blots showing Bim-EL, Bim-L and tubulin (normaliser) expression, and 
viability data. B. Densitometry for “A”. C. Viability over 48h. Viability 
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Figure 5.3.4. Basal (tO) expression of Bax and Bak by Western blot (7 
sensitive vs. 8 resistant). Densitometry was normalised to that of Actin 
expression. There was no significant difference in baseline expression of these 
two proteins between sensitivity groups. P=0.817 and 0.643, respectively, by 
Mann-Whitney U test.
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Having established that the quantity of Bax and Bak protein was similar in 
sensitive and resistant samples before treatment, levels of activated Bax and Bak 
were then measured in representative samples incubated with and without Dex. 
Levels of the active isoforms relative to total protein were quantified in order to 
gain insight into activity. Bax and Bak activation was measured by 
immunoprecipitation using an antibody that detected an epitope only present on 
the active form of Bax (Bax IgGi 6A7, Sigma) or Bak (IgG2A Ab-1). Western 
blots were then performed for the immunoprecipitated protein and probed using 
standard polyclonal Bax or Bak antibody.
For clarity, immunoglobulin heavy and light chains are labelled, and 5% input and 
output of the immunoprecipitation are shown (Figure 5.3.5 A-C). Bax was 
detected in the post-IP as well as the pre-IP fraction as the immunoprecipitation 
only removes active Bax from a sample, and because no IP is 100% efficient. 
Both a substantial increase in active Bax levels and cell death was observed when 
sensitive samples were treated with Dex, whilst the effect was much less marked 
when resistant samples were treated with Dex. Therefore, it can be concluded that 
Bax activation does not occur in resistant samples to the same extent that it occurs 
in sensitive samples. A similar trend was observed when Bak activation was 
measured by IP in a sensitive and resistant sample (Figure 5.3.5 D). Hence, the 
failure of Bim to induce killing is the result of events upstream of Bax and Bak 
activation.
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Figure 5.3.5 Bax and Bak activation is skewed towards GC-sensitive samples 
following Dex treatment. Active Bax was immunoprecipitated and then loaded 
onto Western blots alongside 5% IP input and 5% output. Blots were stained with 
an antibody that detects total Bax. A. 3 blots, each of which features 1 sensitive 
(left) and 1 resistant (right) sample. Viability is measured by PI exclusion. B. 
Bak was also determined to be activated in response to Dex in a sensitive but not a 
resistant sample. NS = non-specific band.
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5.3.2 Expression and binding of Bim antagonists 
Figure 5.3.1 A not only showed Bim upregulation in sensitive and resistant 
samples; but it also suggested a difference in baseline expression of Bim protein; 
i.e., Bim appeared to be higher at baseline in resistant than sensitive samples. 
Despite a difference in ERK activation possibly explaining this observation in 
terms of Bim-EL expression, the other isoforms could not be ignored. If a 
difference in expression of all three isoforms was shown to exist between the two 
sensitivity groups then it could be speculated that the post-translational control of 
Bim in resistant samples was skewed towards survival. To clarify this, tO samples 
from the previously screened 6 sensitive and 6 resistant samples were 
immunoblotted on a single gel (Figure 5.3.6 A).
As suspected, there was a higher basal tO expression of Bim in resistant samples 
than sensitive, with median expression in resistant samples more than double that 
of sensitive samples. Group difference in expression was significant (P<0.05) for 
all of the Bim isoforms individually (5.3.6 B) or when grouped (5.3.6 C). Bcl-2 is 
a known attenuator of Bim in CLL cells (Del Gaizo Moore, Brown et al. 2007) 
that is overexpressed in CLL, and is a key element of CLL apoptotic resistance 
(Pepper, Thomas et al. 1999b). Therefore, it was hypothesised that resistant 
samples might possess higher baseline expression of Bcl-2, which may serve to 
protect CLL cells from Dex-induced Bim induction by sequestration. A Western 
blot parallel to Figure 5.3.4 A was performed to indicate whether this might be the 
case (Figure 5.3.4 D). Though the correlation between Bcl-2 and Bim expression 
is too weak to suggest that their levels at tO are directly related (Figure 5.3.4 F), 
there is a tendency for resistant samples to express higher levels of Bcl-2 than
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sensitive samples (Figure 5.3.4 E). This suggests that there is more Bcl-2 
available in these samples that might act as a sink for Bim.
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Figure 5.3.6. Bim expression appears to be higher at tO in GC-resistant than 
GC-sensitive samples, and Bcl-2 also shows a tendency to be more highly 
expressed in resistant samples. A. SDS-lysates were separated by 
electrophoresis and Western blotting was performed to detect Bim-EL (23kDa), 
Bim-L (15kDa), Bim-S (12kDa) and Actin (42kDa). B. Densitometry analysis 
shows that all 3 Bim isoforms were more highly expressed in the sensitive group 
using Mann-Whitney U test (B: Bim-EL /*=0.037, Bim-L /M).004, Bim-S 
/*=().004). C. Total Bim is more highly expressed in resistant samples (P= 0.006 
by Mann-Whitney U test) D. Western blotting shows expression of Bcl-2 
(26kDa) and Actin (42kDa). E. Bcl-2 expression in resistant samples is generally 
higher than that of sensitive samples (P=0.05 by Mann Whitney U test). F. Bcl-2 
and Bim expression appear to loosely correlate (R2=0.161, 7^0.196 by Linear 
Regression).
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To provide further evidence that antiapoptotic proteins were more highly 
expressed in resistant samples, an early timecourse was performed (8, 12, and 
16h) within which Dex treatment was included (Figure 5.3.7). Relatively early 
timepoints were chosen for this study in order to negate the potentially biasing 
effects of culturing sensitive and resistant samples for longer. As well as Bcl-2, 
another critical mediator of CLL cell survival—Mcl-1—was measured, which 
also has been reported to associate with Bim in B cells (Gomez-Bougie, Bataille 
et al. 2005). Furthermore, Mcl-1 expression has been associated with failure to 
achieve complete remission in response to fludarabine and chlorambucil in CLL 
(Kitada, Andersen et al. 1998). CLL samples were cultured w/wo Dex for 8, 12, 
and 16h. As Figure 2.3.4 showed that sensitive samples were undergoing 
apoptosis as early as 4h following Dex treatment, these relatively early timepoints 
were selected to negate the possibility of death-induced bias.
Consistent with Figure 5.3.6, Bcl-2 is overexpressed in resistant samples relative 
to sensitive samples, though statistical validity is imperfect over time (Figure 
5.3.7 C). Furthermore, Dex does not appear to alter Bcl-2 expression (Figure 
5.3.7 B). Therefore, overexpression of Bcl-2 may play a role in preventing GC- 
induced killing. This opposes previous observations of 39 CLL samples in vitro, 
which showed that Bcl-2 did not associate with drug sensitivity at all (Bosanquet, 
Sturm et al. 2002). Mcl-1 levels before and after treatment are of a similar range 
regardless of sensitivity group (Figure 5.3.7 B). Therefore, neither baseline 
expression level nor failure of downregulation of Mcl-1 expression (Figure 5.3.7 
C) appears to block GC action in resistant samples. However, the observed 
consistent downregulation of Mcl-1 in response to Dex is interesting.
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Figure 5.3.7. Bcl-2 expression is higher in GC-resistant than GC-sensitive 
samples, whilst Mcl-1 levels are similar in both sensitivity groups. A.
Western blots for Mcl-1 (rabbit PAb,42kDa), Bcl-2 (mouse MAb, 29kDa), and 
Actin (40kDa) in 6 sensitive and 6 resistant samples at 8h, 12h, and 16h. Viability 
was determined by DiOCe/PI. B. Histograms representing mean expression of 
Bcl-2 and Mcl-1 relative to Actin by densitometry. C. Grouped data stem and 
leaf plots. Mann-Whitney U test P-values for sensitive versus resistant are as
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follows: Bcl-2 UT 0.055 (8h), 0.006 (12h), 0.201 (16h); Mcl-1 UT 0.749 (8h), 
0.423 (UT), 0.465 (UT); Mcl-1 T: 0.522 (8h), 0.749 (12h), 0.855 (16h).
Mcl-1 expression is rapidly altered by transcription and protein stability by 
various environmental cues. It has a rapid turnover and can be targeted by 
ubiquitination for proteasomal degradation. During apoptosis, Mcl-1 is an 
efficient caspase substrate (Clohessy, Zhuang et al. 2004). However, Figure 5.3.7 
B displays ~50% reduction in Mcl-1 as early as 8h post-Dex culture, whilst death 
induction in the sensitive samples as measured by DiOCe/PI was measured at only 
18%. Taken together, these two points suggest it is unlikely that the Dex-induced 
reduction of Mcl-1 in both groups was simply a result of caspase-mediated 
cleavage. To explore this issue further, 4 sensitive samples were cultured for 8h 
in the absence or presence of both Dex and a pan-caspase inhibitor, Z-vad.fmk 
(Figure 5.3.8).
In all samples, Mcl-1 was downregulated by Dex, but caspase inhibitor did not 
rescue CLL cells from this effect, despite its effectiveness in preventing PARP 
cleavage in 4/4 samples (Figure 5.3.8 A/B) and apoptosis in 3/4 samples (Figure 
5.3.8 C). Therefore, Mcl-1 downregulation results from a non-caspase dependent 
mechanism following CLL treatment with Dex, at least in the early phase of GC 
action. Furthermore, as Mcl-1 downregulation occurs in the absence of killing, it 
is not likely that Mcl-1 is important to Dex-induced killing of CLL cells, at least 
at early timepoints.
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Figure 5.3.8 At 8h Z-vad.fmk confers resistance to Dex upon 3/4 sensitive 
samples despite evidence of Mcl-1 downregulation. Samples were incubated in 
the presence or absence of lOOnM Dex and z-vad.fmk (Ih pre-incubation) for 8h. 
A. Western blots (lOpg per sample) showing Mcl-1 (rabbit PAb) and Actin 
(loading control) expression, and PARP/cleaved-PARP as a positive control for 
caspase activation. Viability was measured using DiOCc/PI. B. Densitometry for 
“A”. C. Dex-induced killing data for each sample (/*=0.61, paired / test).
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Though Mcl-1 downregulation by Dex could warrant further exploration, the 
overall purpose of this thesis is to identify signalling events that differ between 
samples that respond well and those that do not to treatment with Dex. Therefore, 
this avenue of investigation was not further developed. In contrast, Bim appeared 
to be expressed at a higher level in resistant than sensitive samples, and this 
coincided with Bcl-2 expression (Figure 5.3.6/Figure 5.3.7). Because Bax 
activation is more marked in sensitive samples (Figure 5.3.5) a failure of indirect 
or direct Bim activation of Bax could be envisaged in resistant samples. 
However, the importance of Bim in Dex-induced killing had not been assessed, 
nor had any coassociation with Bim antagonists. Therefore, siRNA knockdown, 
which had previously been shown to protect GC-sensitive B-ALL cells from GCs 
(Abrams, Robertson et al. 2004), was performed to reduce Bim expression in 
sensitive samples (Figure 5.3.9). If a resistant phenotype could be induced, this 
would demonstrate a critical role for Bim in Dex-induced killing in CLL. Indeed, 
Bim-EL was induced by Dex, as expected, in Dex-sensitive CLL samples (Figure 
5.3.9 A). Control siRNA had no effect on this induction. However, Bim siRNA 
clearly reduced the expression of Bim. Concomitantly, killing induced by Dex 
was reduced to 50% when cells were pretreated with Bim siRNA (Figure 5.3.9 B). 
Therefore, it can be concluded that Bim-EL is a critical molecule in Dex-induced 
apoptosis in this experimental system.
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Figure 5.3.9 Knockdown of Bim rescues Dex-sensitive CLL samples from 
Dex-induced killing. 3 Sensitive samples (1927, 2273, 2422) were pre-treated 
with Bim siRNA and 24h later were cultured with 1 OOnM Dex for a further 48h. 
A. A representative Western blot and mean Bim-EL expression for various 
controls and experimental samples (error bars = standard deviation). B. The 
effect of control and Bim siRNA on Dex-induced killing (measured by PI 
exclusion).
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Release of Bim-EL and Bim-L from cytoskeletal sequestration can facilitate Bim 
activation (Puthalakath, Huang et al. 1999, Ley, Balmamio et al. 2003), which has 
been reported to involve phosphorylation by JNK and p38 (Ley, Ewings et al. 
2005)(Chen, Zhou 2004, Cai, Chang et al. 2006). More recently, GSK3 has been 
reported to activate Bim through a direct interaction (Spokoini, Kftr-Erenfeld et 
al. 2010). Contrastingly, Bim-EL is predominantly serine phosphorylated in 
murine lymphoma lymphocytes and thymocytes, which has been reported to 
prevent, rather than induce, Bim-induced apoptosis (Seward, von Haller et al. 
2003). Thus, Bim activation may be regulated both positively and negatively by 
phosphorylation. Due to a lack of clarity in the literature regarding the nature of 
Bim phosphorylation and molecular activation, it was decided to focus on Bim 
binding partners as potentially hindering Dex-upregulated Bim.
Bim has been shown to bind a number of different proteins in B-cells (Gomez- 
Bougie, Bataille et al. 2005). In normal tonsil B cells Bim was shown to associate 
with Bcl-2, Mcl-1, and Bcl-xl. The Mcl-l/Bim complex was the most abundant of 
the three dominant complexes. Additionally, a weak association between Bim-EL 
and Bim-L with DLC8 was found. As Bim is shown to be upregulated in both 
sensitive and resistant samples consistently within this investigation it is plausible 
that one or a combination of antiapoptotic proteins is able to block the 
proapoptotic function of Bim in resistant samples by physical antagonism and/or 
sub-cellular sequestration. To test this hypothesis Bim was immunoprecipitated 
from 3 sensitive and 3 resistant samples at 48h to identify whether the protein 
coassociated with previously reported antagonists in CLL cells. If association
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were detected, the effect of Dex treatment could be determined, and sensitive and 
resistant samples could be compared.
Before attempting to detect Bim-binding partners in immunoprecipitated samples 
it was necessary to ensure their presence in the CLL lysates to be used in 
immunoprecipitation. Bcl-xl was barely detectable in RIPA-soluble and - 
insoluble fractions by Western blotting relative to CD154-stimulated cells (5.3.10 
A), as expected. Contrastingly, DLC8 expression was difficult to detect in RIPA 
lysates but less so in SDS-lysed RIPA-insoluble pellets (5.3.10 B). This 
highlights a flaw in using the gentler lysis buffers required for applications such 
as immunoprecipitation. Moreover, as Bim was clearly detected in the RIPA- 
insoluble pellet (Figure 5.3.10 A), this fraction of the total Bim was not included 
in the binding partner assay. Nevertheless, the insoluble pellets consistently 
contained less protein than the RIPA lysates. DLC8, as well as Bcl-xl were thus 
excluded from the Bim IP.
Following Bim immunoprecipitation, Mcl-1 was not detectable in the IP fraction, 
but was apparent in the pre-IP and post-IP fractions (Figure 5.3.10 C), indicating a 
lack of association between Bim and Mcl-1 in CLL cells. Contrastingly, Bcl-2 
clearly co-associated with Bim, and this binding was specific as confirmed by a 
lack of association with the IP isotype control. Bax was not associated with Bim 
as indicated by the lack of detection in the IP fraction relative to the lysate and IP 
supernatant. Together these data support an indirect model of Bax/Bak activation 
by Bim, and highlight Bcl-2 as a critical binding partner of Bim in CLL cells.
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Figure 5.3.10 Screen for Bim-binding partners. 3 sensitive and 3 resistant 
samples were cultured w/wo Dex for 48h. A. Bcl-xl (26kDa) is neither readily 
detected by immunoblot in CLL or non-CD 154 expressing fibroblasts (P), whilst 
CLL cells co-cultured with CD-154 expressing fibroblasts (154) do express 
readily detectable Bcl-xl. Bim is detected in RIPA lysate as well as SDS-lysed 
RIPA-insoluble pellet (2533=sensitive, 2254=resistant). B. DLC8 (lOkDa) is 
detectable in CLL cells, though RIPA lysis buffer yields only a fraction of the 
DLC8 that is detected in the RIPA-insoluble pellet (2064=sensitive, 
2551=resistant). C. Bim IP of 3 sensitive and 3 resistant samples shows that Bcl- 
2 (25kDa) appears to co-associate with Bim, whilst Mcl-1 (40kDa) and Bax 
(21 kDa) do not.
214
Further immunoprecipitation experiments confirmed a lack of association between 
Bim and Bax, and also Bak (Figure 5.3.11 A/B/C). Once again, Bim-bound Mcl- 
1 was difficult to detect, whilst Bcl-2 was clearly associated with Bim (Figure 
5.3.11 B). A reciprocal IP using Bcl-2 antibody further confirmed the Bim:Bcl-2 
interaction (Figure 5.3.11 E).
As the study of the potential Bim antagonists had uncovered only Bcl-2 as a 
candidate for Bim suppression, and given the apparent overexpression of Bcl-2 in 
resistant samples, it was clear that resensitisation of resistant samples to Dex 
should be attempted via inhibition of Bcl-2. ABT-737, a BH3-only mimetic, is a 
potent killer of CLL cells, and can displace proapoptotic proteins from Bcl-2, Bcl- 
xl, and Bcl-w (Certo, Del Gaizo Moore et al. 2006), but not from Mcl-1 or Bel- 
2A1 (Oltersdorf, Elmore et al. 2005, van Delft, Wei et al. 2006). As this 
compound has been previously shown to synergise with Dex in CLL cells 
(Mason, Kliaw et al. 2009), it was decided to test for synergy in Dex resistant 
samples (Figure 5.3.12).
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Figure 5.3.11. Bim does not interact directly with Bax or Bak, but is 
sequestered by Bcl-2 in CLL samples. A/B/C. Western blots to identify 
coassociation between Bim and Bax/Bak following immunoprecipitation of CLL 
samples cultured w/wo lOOnM Dex for 48h. D/E. Western blots to identify 
coassociation between Bim and Bcl-2/Mcl-l following immunoprecipitation of 
CLL samples cultured w/wo lOOnM Dex for 48h.
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Figure 5.3.12 ABT-737 increases Dex-induced killing beyond that induced by 
the isolated treatments alone. A. Killing of 6 resistant and 3 sensitive samples 
by ABT-737 and enantiomer w/wo Dex. B. A comparison of combined killing 
and mutual killing by Dex and InM ABT-737. C. A statistical comparison of the 
data from “B” (i^Mann-Whitney U test). D. Dex killing versus InM ABT0737 
killing (R2=0.865, P=0.000278).
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Figure 5.3.12 suggests that ABT-737 enhances the killing of CLL cells by Dex. 6 
resistant and 3 sensitive samples were treated with a range of concentrations of 
ABT-737 or enantiomer, and were cultured for 48h in the absence or presence of 
lOOnM Dex (Figure 5.3.12 A). All CLL samples were killed effectively by 
lOOnM ABT-737, but sensitivity to this agent correlated with sensitivity to lOOnM 
Dex (Figure 5.3.12 D), possibly implying a shared mechanism of killing. At InM 
ABT-737, resistant samples display some reduction in viability, but still show 
relative viabilities that are consistently over 70% (Figure 5.3.12 A). Therefore, it 
was decided to use this concentration of ABT-737 to contrast additive and 
combined killing of resistant samples by the two agents (Figure 5.3.12 B). The 
median increase in killing was over 10% when the two agents were combined 
relative to that achieved by the summation of killing by the two agents in isolation 
(1M).046) (Figure 5.3.12 C). Therefore, ABT-737 may have been acting in 
synergy with Dex. This highlights an important role for Bcl-2 in sequestering 
Bim as a mechanism of GC resistance in CLL. This is perhaps not a surprising 
observation given that Bcl-2 sequestration of Bim has been strongly suggested to 
have importance for CLL cell survival (Del Gaizo Moore, Brown et al. 2007). 
Moreover, a further previous study has shown that co-incubation of CLL samples 
with Dex and ABT-737 sensitises CLL samples to the BH-3 only mimetic 
(Mason, Khaw et al. 2009). However, in conflict with Figure 5.3.12 D, this effect 
could not be predicted by responses to either agent alone. Notwithstanding these 
observations, the identification of a role for ABT-737 in sensitising resistant CLL 
samples to treatment with Dex is novel.
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5.4 Discussion
The aim of this chapter was to explore the regulation of downstream effectors of 
GC-induced killing in CLL. This centred upon the regulation of Bim due to its 
well-reported role in multiple models of GC-induced killing (Bachmann, Gorman 
et al. 2005, Lu, Quearry et al. 2006, Bouillet, Metcalf et al. 1999, Abrams, 
Robertson et al. 2004, Erlacher, Michalak et al. 2005, Lopez-Royuela, Balsas et 
al. 2010). Bim protein induction was detected in both sensitive and resistant 
samples, thus GC resistance in this study was not caused by a failure to induce 
Bim protein. However, subtle differences in Bim expression between sensitive 
and resistant samples led to an exploration of upstream ERK signalling by virtue 
of the reported relationship between the two proteins (Ewings, Wiggins et al. 
2007). This data did not support a major role for ERK or regulation of Bim-EL 
expression as a cause of GC resistance. In contrast with some previous studies of 
T cells and lymphoma cell lines (Rathmell, Lindsten et al. 2002, Salomons, Brady 
et al. 1997), a difference in the baseline expression of Bax and Bak was not found, 
though in this investigation the activation of these proteins was clearly related to 
the induction of killing by GCs. However, it should be noted that the 
demonstration of Bax and Bak activation in resistant samples by non-GC agents 
would provide this observation with further substance. The observation of higher 
expression of Bcl-2 (though only approximately double, with high standard 
deviation) but not Mcl-1 in resistant samples led to the hypothesis that Bcl-2 
sequestration of Bim might be responsible for the failure of Dex-induced Bim to 
kill resistant samples. Whilst Bcl-2 overexpression has been linked with 
apoptosis resistance and drug resistance in CLL (Pepper, Thomas et al. 1999b, 
Pepper, Thomas et al. 1999a), it has not been previously associated with GC
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resistance. The importance of Bim was confirmed by the cytoprotective effect of 
siRNA knockdown in GC-sensitive samples. Although knockout mice of Bim 
had demonstrated a role for Bim in the GC-induced killing of lymphocytes 
(Bouillet, Metcalf et al. 1999), this is the first demonstration by gene silencing 
(siRNA) of the involvement of Bim in CLL GC-induced death. The most 
interesting aspect of this chapter is the analysis of the role played by Bcl-2 in 
buffering Bim and making CLL cells with high Bcl-2 levels resistant to Dex- 
induced apoptosis. A clear association of Bim with Bcl-2, but not other potential 
Bim-binding partners, was demonstrated. To provide further confidence in the 
negative results of this particular study reciprocal IPs should be performed. ABT- 
737 has been previously been shown to facilitate the killing of CLL cells by GCs 
(Mason, Khaw et al. 2009). In this investigation, co-treatment with Dex and the 
Bcl-2 inhibitor actually appeared to sensitise resistant samples to GC-induced 
killing, though formal tests for synergy are yet to be performed. It can therefore 
be concluded that sequestration of Bim by Bcl-2 is a mechanism that contributes 
significantly to GC resistance in CLL.
Further experiments would certainly solidify the main conclusions of this chapter. 
For instance, the effect of overexpression of Bcl-2 in sensitive samples would be 
highly informative, as would Bcl-2 knockdown. Furthermore, the effect of Bim 
overexpression on sensitivity could further emphasise the importance of this 
mechanism in GC resistance in CLL. Despite the observation that Bim 
predominantly appeared to be bound to Bcl-2 in CLL cells, this observation 
applied to both sensitive and resistant samples. Furthermore the Bim knockdown 
negated killing at 48h in sensitive samples, but it remains to be seen whether this
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merely corresponded to a delay in death kinetics rather than bona fide 
desensitisation. Thus, it would be informative to follow sample viability beyond 
48h post-Dex in sensitive samples that had been pretreated with Bim siRNA. 
However, this may prove difficult as viability is considerably reduced by the 
electroporation procedure alone at 72h. Further, whilst Bim silencing may 
densensitise sensitive samples, this observation does not explain why Bim 
upregulation in resistant samples was not sufficient to induce cell death. As yet, 
direct evidence is not available that proves that excess Bcl-2 acts as a sink for 
upregulated Bim in resistant samples. Rather, the Bim binding partner data and 
ABT-737 Dex-sensitisation data combine to imply an important role for the 
relationship between Bim and Bcl-2 in GC activity within CLL cells.
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Chapter 6: General Discussion
6.1 Discussion
Little was known about GC resistance in CLL prior to this investigation, and there 
are many unanswered questions in this field. In this study, molecular mechanisms 
that might contribute to GC resistance in CLL samples were explored by 
comparison of the most sensitive and resistant samples of a group of 46 primary 
CLL samples. In keeping with previous studies (Tiwari, Dong et al. 2005, 
Chandra, Gilbreath et al. 1997, McConkey, Chandra 1999), markers of apoptosis 
were elevated in CLL samples treated with Dex. These included PS exposure, 
PARP cleavage, and the previously reported activation of Bax and Bak 
(Bellosillo, Villamor et al. 2002). Signs of apoptosis were detectable as early as 
4h following incubation with Dex, though killing was much more marked at 48h. 
Though caspase inhibition protected CLL samples from Dex-induced killing at 
8h, at later timepoints this effect was not demonstrable. This confirms previous 
reports that caspases are not essential to cell death following initiation of 
apoptosis (Kroemer, Martin 2005). Consistent with the idea that GC resistance is 
not simply an extension of multi-drug resistance, fludarabine sensitivity did not 
appear to correlate with GC sensitivity. The observation that spontaneous 
apoptosis did not correlate with Dex sensitivity provided compelling evidence that 
GC sensitivity is not simply dependent upon constitutive survival signalling.
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Intriguing!y, samples from UM-ZGi/F patients were more prone to GC-induced 
killing than those from M-/GZ/F patients. Although similar findings were 
reported by others before and during this investigation (Aleskog, Tobin et al. 
2004, Lindhagen, Norberg et al. 2009), this observation confirms that IGHV 
mutation status is relevant to GC resistance in CLL. The mechanisms by which 
IGHV mutational status might impact upon GC sensitivity are unclear and are not 
within the scope of this investigation. However, it has previously been suggested 
that UM-/GZ/K cases are more responsive to BCR stimulation than their WL-IGHV 
counterparts, and it has been postulated that GM-IGHV cases may be chronically 
BCR activated (Zenz, Mertens et al. 2010). It is plausible that such cases are 
addicted to BCR-associated survival signals that can be disrupted by GC 
treatment. Thus, signalling pathways that are both activated by BCR stimulation 
and also implicated in GC signalling warrant further exploration in the setting of 
GC resistance. In support of this idea, whilst fludarabine sensitivity did not 
correlate with GC sensitivity, sensitivity to pro-survival factor inhibitors (MEK 
inhibitor and Bcl-2 inhibitor, Section 5.3) did appear to positively correlate with 
GC sensitivity, which suggests that GC-sensitive samples may have been more 
dependent upon pro-survival signalling than GC-resistant samples for their 
survival. As well as displaying higher levels of ZAP-70 and CD38, UM-/G//F 
samples have been shown to express higher levels of various genes relative to M- 
IGHV samples (Zenz, Mertens et al. 2010). These include the genes 
corresponding to targets of the kinase PKC, cell cycle regulators such as Cyclin- 
Dl, and proteins involved in cellular metabolism (Rosenwald, Alizadeh et al. 
2001). As described in Section 1.6.6, PKC, and various cell cycle regulating 
proteins have been implicated in GC sensitivity of certain haematopoietic cell
223
types, and so the activity of these proteins may contribute to the tendency for UM- 
IGHV samples to respond better to GC treatment than their M-IGHV counterparts.
Baseline expression of GRa and GR(3 did not separate the two sensitivity groups, 
though GR5 mRNA level appeared to be higher in GC-sensitive samples. 
However, this difference could not be corroborated by protein levels due to the 
lack of an available antibody. This avenue warrants further exploration. 
Consistent with a previous study in CLL (Furman, Asgary et al. 2000), NF-kB 
was downregulated by Dex in sensitive samples. However, NF-kB was also 
downregulated in resistant samples. This provides novel insight and suggests that 
NF-kB is not a critical mediator of GC resistance in CLL cells. Consistent with 
these findings, pro-survival transcriptional targets of NF-kB were not 
preferentially downregulated in either sensitivity group, and an NF-kB inhibitor 
did not sensitise resistant samples to GC-induced killing. Pilot studies of Lck 
expression and GSK-3p expression and activation did not support a role for either 
kinase in GC sensitivity of CLL cells. Whilst Lck has previously been reported to 
be important in GC resistance in CLL cells (Harr, Caimi et al. 2010), the GSK-3|3 
comparison was based on recent studies in ALL (Galliher-Beckley, Williams et al. 
2008, Nuutinen, Ropponen et al. 2009). Furthermore, XIAP and C-IAP2 
expression did not appear to segregate the two sensitivity groups, contrary to 
previous observations of the former in T cells (Conte, Liston et al. 2001).
Despite a clear difference in baseline ERK activation between the two sensitivity 
groups, MEK inhibitor did not sensitise resistant samples to GC-induced killing. 
Interestingly, Bim—a target of ERK, and apoptotic activator that is induced by
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GCs in CLL (Iglesias-Serret, de Frias et al. 2007)—was induced in both groups of 
samples at the mRNA and protein levels. Bax and Bak baseline expression did 
not correlate with sensitivity to GC in this study, concordant with a previous study 
in CLL (Bosanquet, Sturm et al. 2002), but Bim and Bcl-2 did appear to be 
overexpressed in resistant samples. Mcl-1 levels were similar between the two 
groups with and without Dex treatment. However, Mcl-1 was not protected by a 
pan-caspase inhibitor despite observed protection from both apoptosis and PARP 
cleavage. This indicates that Mcl-1 is not essential for CLL cell survival at early 
timepoints and that Dex may downregulate Mcl-1 by a non-caspase dependent 
mechanism. This observation may be worth pursuing from a mechanistic 
perspective.
This study was the first to show the effect of Bim siRNA knockdown on GC- 
induced killing in CLL cells. As has been demonstrated in B-ALL cell lines 
(Abrams, Robertson et al. 2004), Bim inhibition protected sensitive samples from 
GCs. The predominant binding partner for Bim appeared to be Bcl-2, despite the 
fact that Bim can be bound/sequestered by various cellular proteins (Gomez- 
Bougie, Bataille et al. 2005). Thus, ABT-737—a mimetic of the BH3 domain that 
binds with high affinity to Bcl-2, Bcl-xl and Bcl-w (Certo, Del Gaizo Moore et al. 
2006)—appeared to sensitise resistant samples to treatment with GC. Whilst 
synergy between these two agents has been suggested previously in CLL samples 
(Mason, Khaw et al. 2009), ABT-737 attenuation of Bcl-2 has not previously been 
linked to alleviation of GC resistance in CLL. A summary of the findings of this 
investigation is shown in Figure 6.1.
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Figure 6.1. Model of GC-induced killing and resistance in CLL cells. Red
entities predominantly possess proapoptotic function when activated, whilst green 
entities predominantly possess prosurvival function when activated. Red crosses 
highlight signalling entitities that do not appear to be imporant for GC resistance 
according to this investigation, whilst green ovals highlight points of interest. 
Clear differences between GC-sensitive and GC-resistant CLL samples were not 
observed with respect to GR expression and transactivation, NF-kB activity, 
kinase expression, or IAP expression. Sensitive samples did show a greater 
degree of apoptotic activation than resistant samples, as far upstream in the killing 
mechanism as Bax and Bak activation. Resistant samples showed higher 
expression of anti-apoptotic Bcl-2, but not Mcl-1, and Bcl-2 was found to 
coimmunoprecipitate with the GC-induced proapoptotic Bim. The Bcl-2 inhibitor 
ABT-737 increased GC-induced killing in resistant samples, and thus Bcl-2 
sequestration of Bim is likely to contribute to GC resistance in CLL.
6.2 Strategic limitations
To define GC resistance in CLL patients refractory to GC treatment might be 
more informative than to screen samples for sensitivity in vitro and to then probe 
potential killing mechanisms. One of the reasons for this is that the in vitro test 
that this investigation was based on did not mimic the potential in vivo 
microenvironmental protection of CLL cells via localisation of cells within 
protective physiological compartments. Therefore, it might be more informative 
to purify CLL cells from the various lymphoid compartments of GC-resistant 
patients, for comparison to CLL cells from GC~responsive patients. This type of 
investigation was beyond the scope of this thesis, but is certainly worthy of 
consideration, in order to provide increased clinical relevance.
Regardless of whether samples from patients displaying GC resistance at the 
clinical level were used, without a clear mechanism of killing to probe, the 
detection of defects in resistant samples was likely to prove difficult in this study 
without a large cohort of samples to increase the power of statistical analyses. To 
screen the entire cohort at each stage of this investigation would certainly have 
been more informative. However, this would have been impractical, particularly 
with respect to the more time consuming assays.
Perhaps the most significant confounding factor in this study was the lack of 
correlation between GC sensitivity at 24 and 48h. This suggests that GC-induced 
killing is a dynamic process, and thus the experiments that use timepoints of 24h 
or less may not have provided a fair reflection of events at 48h. Perhaps a better
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approach would to be contrast early events in sensitive samples with later events 
in resistant samples.
A broader approach to the question of whether GR-mediated alterations to the 
transcriptome contribute to GC resistance in CLL could be taken by conducting 
microarray experiments and to then validate interesting targets by further 
screening using multiple timepoints. However, such assays are complex, as is the 
analysis of the data produced, which may explain why no such analyses have been 
performed in CLL as yet. Furthermore, as Chapter 1 explains, there is increasing 
evidence that GCs are not entirely dependent upon changes in the transcriptome to 
induce cell death.
6.3 Future work
Along with the potential avenues of further investigation outlined in Sections 6.1 
and 6.2, more pressing questions remain regarding the nature of Bcl-2 mediated 
GC resistance in CLL. Ideally, the experiments alluded to in Section 5.4 would 
be completed. To summarise, it would be helpful to:
• Increase n for Bcl-2 expression versus Dex response
• Show the effects of Bcl-2 and Bim overexpression on GC-induced killing
• Perform sub-cellular fractionation and confocal microscopy to localise 
Bim in CLL samples w/wo Dex treatment
• Identify the phosphorylation status of Bim in samples w/wo Dex treatment
• Perform reciprocal IPs for proteins not found to associate with Bim 
following Bim IP
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• Show that Bax and Bak of GC-resistant samples can be activated by non- 
GC cytotoxic agents
• Perform formal tests for synergy with Dex and ABT-737
229
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